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PREAMBLE
The medical profession should play a central role in
evaluating the evidence related to drugs, devices, and
procedures for the detection, management, and pre-
vention of disease. When properly applied, expert
analysis of available data on the beneﬁts and risks of
these therapies and procedures can improve the quality
of care, optimize patient outcomes, and favorably affect
costs by focusing resources on the most effectivestrategies. An organized and directed approach to a
thorough review of evidence has resulted in the pro-
duction of clinical practice guidelines that assist clini-
cians in selecting the best management strategy for an
individual patient. Moreover, clinical practice guidelines
can provide a foundation for other applications, such as
performance measures, appropriate use criteria, and
both quality improvement and clinical decision support
tools.
The American College of Cardiology (ACC) and
the American Heart Association (AHA) have jointly
engaged in the production of guidelines in the area
of cardiovascular disease since 1980. The ACC/AHA
Task Force on Practice Guidelines (Task Force), whose
charge is to develop, update, or revise practice guidelines
for cardiovascular diseases and procedures, directs
this effort. Writing committees are charged with the
task of performing an assessment of the evidence and
acting as an independent group of authors to develop,
update, or revise written recommendations for clinical
practice.
Experts in the subject under consideration are
selected from both organizations to examine subject-
speciﬁc data and write guidelines. Writing committees
are speciﬁcally charged to perform a literature review;
weigh the strength of evidence for or against particular
tests, treatments, or procedures; and include estimates
of expected health outcomes where such data exist.
Patient-speciﬁc modiﬁers, comorbidities, and issues of
patient preference that may inﬂuence the choice of
tests or therapies are considered, as well as frequency
of follow-up and cost-effectiveness. When available,
information from studies on cost is considered; how-
ever, review of data on efﬁcacy and outcomes consti-
tutes the primary basis for preparing recommendations
in this guideline.
In analyzing the data, and developing recommenda-
tions and supporting text, the writing committee uses
evidence-based methodologies developed by the Task
Force (1). The Classiﬁcation of Recommendation (COR)
is an estimate of the size of the treatment effect, with
consideration given to risks versus beneﬁts, as well as
evidence and/or agreement that a given treatment or
procedure is or is not useful/effective or in some situ-
ations may cause harm; this is deﬁned in Table 1. The
Level of Evidence (LOE) is an estimate of the certainty
or precision of the treatment effect. The writing com-
mittee reviews and ranks evidence supporting each
recommendation, with the weight of evidence ranked
as LOE A, B, or C, according to speciﬁc deﬁnitions that
are included in Table 1. Studies are identiﬁed as
observational, retrospective, prospective, or random-
ized, as appropriate. For certain conditions for which
inadequate data are available, recommendations are
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons
of the treatments or strategies being evaluated.
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e4based on expert consensus and clinical experience and
are ranked as LOE C. When recommendations at LOE C
are supported by historical clinical data, appropriate
references (including clinical reviews) are cited if
available.
For issues with sparse available data, a survey of cur-
rent practice among the clinician members of the writing
committee is the basis for LOE C recommendations and no
references are cited.
The schema for COR and LOE is summarized in Table 1,
which also provides suggested phrases for writing rec-
ommendations within each COR.A new addition to this methodology is the separa-
tion of the Class III recommendations to delineate
whether the recommendation is determined to be of
“no beneﬁt” or is associated with “harm” to the pa-
tient. In addition, in view of the increasing number of
comparative effectiveness studies, comparator verbs
and suggested phrases for writing recommendations
for the comparative effectiveness of one treatment or
strategy versus another are included for COR I and IIa,
LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 January et al.
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e5designated the term guideline-directed medical therapy to
represent optimal medical therapy as deﬁned by ACC/AHA
guideline (primarily Class I)–recommended therapies. This
new term, guideline-directed medical therapy, is used herein
and throughout subsequent guidelines.
Therapies not available in the United States are
discussed in the text without a speciﬁc COR. For
studies performed in large numbers of subjects outside
North America, each writing committee reviews the
potential impact of different practice patterns and
patient populations on the treatment effect and
relevance to the ACC/AHA target population to deter-
mine whether the ﬁndings should inform a speciﬁc
recommendation.
The ACC/AHA practice guidelines are intended to assist
clinicians in clinical decision making by describing a
range of generally acceptable approaches to the diagnosis,
management, and prevention of speciﬁc diseases or con-
ditions. The guidelines attempt to deﬁne practices that
meet the needs of most patients in most circumstances.
The ultimate judgment about care of a particular patient
must be made by the clinician and patient in light of
all the circumstances presented by that patient. As a
result, situations may arise in which deviations from
these guidelines may be appropriate. Clinical decision
making should involve consideration of the quality and
availability of expertise in the area where care is
provided. When these guidelines are used as the basis for
regulatory or payer decisions, the goal should be
improvement in quality of care. The Task Force recog-
nizes that situations arise in which additional data are
needed to inform patient care more effectively; these
areas are identiﬁed within each respective guideline
when appropriate.
Prescribed courses of treatment in accordance with
these recommendations are effective only if followed.
Because lack of patient understanding and adherence
may adversely affect outcomes, clinicians should make
every effort to engage the patient’s active participation in
prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, beneﬁts, and
alternatives to a particular treatment and should be
involved in shared decision making whenever feasible,
particularly for COR IIa and IIb, for which the beneﬁt-
to-risk ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conﬂicts of interest that may
arise as a result of relationships with industry and other
entities (RWI) among the members of the writing com-
mittee. All writing committee members and peer
reviewers of the guideline are required to disclose all
current healthcare-related relationships, including
those existing 12 months before initiation of the writing
effort.In December 2009, the ACC and AHA implemented a
new RWI policy that requires the writing committee
chair plus a minimum of 50% of the writing committee
to have no relevant RWI (Appendix 1 includes the ACC/
AHA deﬁnition of relevance). The Task Force and all
writing committee members review their respective RWI
disclosures during each conference call and/or meeting
of the writing committee, and members provide updates
to their RWI as changes occur. All guideline recom-
mendations require a conﬁdential vote by the writing
committee and require approval by a consensus of the
voting members. Members may not draft or vote on any
recommendations pertaining to their RWI. Members who
recused themselves from voting are indicated in the list
of writing committee members, and speciﬁc section re-
cusals are noted in Appendix 1. Authors’ and peer re-
viewers’ RWI pertinent to this guideline are disclosed in
Appendices 1 and 2. In addition, to ensure complete
transparency, writing committee members’ comprehen-
sive disclosure information—including RWI not pertinent
to this document—is available as an online supplement.
Comprehensive disclosure information for the Task
Force is also available as an online supplement. The
ACC and AHA exclusively sponsor the work of
the writing committee, without commercial support.
Writing committee members volunteered their time for
this activity. Guidelines are ofﬁcial policy of both the
ACC and AHA.
In an effort to maintain relevance at the point of care
for clinicians, the Task Force continues to oversee an
ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to this
guideline will be apparent, including limited narrative
text, a focus on summary and evidence tables (with
references linked to abstracts in PubMed), and more
liberal use of summary recommendation tables (with
references that support the LOE) to serve as a quick
reference.
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We
Can Trust (2,3). It is noteworthy that the Institute of
Medicine cited ACC/AHA practice guidelines as being
compliant with many of the proposed standards. A
thorough review of these reports and of our current
methodology is under way, with further enhancements
anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update,
the full-text guideline is revised, or until a published
addendum declares it out of date and no longer ofﬁcial
ACC/AHA policy.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
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e61. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this document are,
whenever possible, evidence based. An extensive evi-
dence review was conducted, focusing on 2006 through
October 2012 and selected other references through
March 2014. The relevant data are included in evidence
tables in the Online Data Supplement. Searches were
extended to studies, reviews, and other evidence
conducted in human subjects, published in English, and
accessible through PubMed, EMBASE, Cochrane,
Agency for Healthcare Research and Quality Reports,
and other selected databases relevant to this
guideline. Key search words included but were not
limited to the following: age, antiarrhythmic, atrial
ﬁbrillation, atrial remodeling, atrioventricular conduc-
tion, atrioventricular node, cardioversion, classiﬁcation,
clinical trial, complications, concealed conduction,
cost-effectiveness, deﬁbrillator, demographics, epidemi-
ology, experimental, heart failure, hemodynamics, hu-
man, hyperthyroidism, hypothyroidism, meta-analysis,
myocardial infarction, pharmacology, postopera-
tive, pregnancy, pulmonary disease, quality of life,
rate control, rhythm control, risks, sinus rhythm, symp-
toms, and tachycardia-mediated cardiomyopathy.
Additionally, the writing committee reviewed docu-
ments related to atrial ﬁbrillation (AF) previously pub-
lished by the ACC and AHA. References selected and
published in this document are representative and not
all-inclusive.
To provide clinicians with a comprehensive set of data,
whenever deemed appropriate or when published, the
absolute risk difference and number needed to treat or
harm are provided in the guideline or data supplement,
along with conﬁdence intervals (CI) and data related to
the relative treatment effects such as the odds ratio (OR),
relative risk (RR), hazard ratio, or incidence rate ratio.1.2. Organization of the Writing Committee
The 2014 AF writing committee was composed of clini-
cians with broad expertise related to AF and its treat-
ment, including adult cardiology, electrophysiology,
cardiothoracic surgery, and heart failure (HF). The
writing committee was assisted by staff from the ACC
and AHA. Under the guidance of the Task Force, the
Heart Rhythm Society was invited to be a partner orga-
nization and provided representation. The writing com-
mittee also included a representative from the Society of
Thoracic Surgeons. The rigorous methodological policies
and procedures noted in the Preamble differentiate ACC/
AHA guidelines from other published guidelines and
statements.1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by the ACC, AHA, and Heart Rhythm Society,
as well as 1 reviewer from the Society of Thoracic Sur-
geons and 43 individual content reviewers (from the ACC
Electrophysiology Section Leadership Council, ACC Adult
Congenital and Pediatric Cardiology Section Leadership
Council, ACC Association of International Governors, ACC
Heart Failure and Transplant Section Leadership Council,
ACC Imaging Section Leadership Council, ACC Interven-
tional Section Leadership Council, ACC Surgeons’ Coun-
cil, and the Heart Rhythm Society Scientiﬁc Documents
Committee). All information on reviewers’ RWI was
distributed to the writing committee and is published in
this document (Appendix 2).
This document was approved for publication by
the governing bodies of the ACC, AHA, and Heart
Rhythm Society and endorsed by the Society of Thoracic
Surgeons.
1.4. Scope of the Guideline
The task of the 2014 writing committee was to establish
revised guidelines for optimum management of AF. The
new guideline incorporates new and existing knowledge
derived from published clinical trials, basic science, and
comprehensive review articles, along with evolving
treatment strategies and new drugs. This guideline
supersedes the “ACC/AHA/ESC 2006 Guidelines for the
Management of Patients With Atrial Fibrillation” (4) and
the 2 subsequent focused updates from 2011 (5,6). In
addition, the ACC, AHA, American College of Physicians,
and American Academy of Family Physicians submitted a
proposal to the Agency for Healthcare Research and
Quality to perform a systematic review on speciﬁc ques-
tions related to the treatment of AF. The data from that
report were reviewed by the writing committee and
incorporated where appropriate (7a,7b).
The 2014 AF guideline is organized thematically,
with recommendations, where appropriate, provided
with each section. Some recommendations from earlier
guidelines have been eliminated or updated as warranted
by new evidence or a better understanding of earlier
evidence. In developing the 2014 AF guideline, the
writing committee reviewed prior published guidelines
and related statements. Table 2 lists these publications
and statements deemed pertinent to this effort and is
intended for use as a resource.
2. BACKGROUND AND PATHOPHYSIOLOGY
AF is a common cardiac rhythm disturbance that increases
in prevalence with advancing age. Approximately 1% of
patients with AF are <60 years of age, whereas up to 12%
of patients with AF are 75 to 84 years of age (29). More
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 January et al.
D E C E M B E R 2 , 2 0 1 4 : e 1 – 7 6 AHA/ACC/HRS Practice Guideline
e7than one third of patients with AF are $80 years of age
(30,31). In the United States, the percentage of Medicare
fee-for-service beneﬁciaries with AF in 2010 was reported
as 2% for those <65 years of age and 9% for those $65
years of age (32). For individuals of European descent, the
lifetime risk of developing AF after 40 years of age is 26%
for men and 23% for women (33). In African Americans,
although risk factors for AF are more prevalent, incidence
of AF appears to be lower (34). AF is often associated
with structural heart disease and other co-occurring
chronic conditions (Table 3; see also http://www.cms.gov/
Research-Statistics-Data-and-Systems/Statistics-Trends-and-
Reports/Chronic-Conditions/Downloads/2012Chartbook.pdf).TABLE 2 Associated Guidelines and Statements
Title
Guidelines
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluat
and Treatment of High Blood Pressure (JNC 7)
Assessment of Cardiovascular Risk in Asymptomatic Adults
Coronary Artery Bypass Graft Surgery
Hypertrophic Cardiomyopathy
Percutaneous Coronary Intervention
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and
Atherosclerotic Vascular Disease
Atrial Fibrillation*
Atrial Fibrillation
Stable Ischemic Heart Disease
Antithrombotic Therapy
Device-Based Therapy
Heart Failure
ST-Elevation Myocardial Infarction
Unstable Angina/Non-ST-Elevation Myocardial Infarction
Valvular Heart Disease
Assessment of Cardiovascular Risk
Lifestyle Management to Reduce Cardiovascular Risk
Management of Overweight and Obesity in Adults
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in A
Statements
Treatment of Atrial Fibrillation
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibri
A Science Advisory for Healthcare Professionals
Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation
Recommendations for Patient Selection, Procedural Techniques, Patient Mana
and Follow-Up, Deﬁnitions, Endpoints, and Research Trial Design
*Includes the following sections: Catheter Ablation for AF/Atrial Flutter; Prevention and Tre
Stroke and Systemic Thromboembolism in AF and Flutter; Management of Recent-Onset AF
Therapy in the Outpatient Setting; and Focused 2012 Update of the CCS AF Guidelines: Reco
AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardio
AF, atrial ﬁbrillation; AHA, American Heart Association; AHRQ, Agency for Healthcare Research
European Cardiac Arrhythmia Society; EHRA, European Heart Rhythm Association; ESC, Europ
NHLBI, National Heart, Lung, and Blood Institute; PCNA, Preventive Cardiovascular Nurses Ass
Thoracic Surgeons; and TOS, The Obesity Society.The mechanisms causing and sustaining AF are multi-
factorial; AF can be complex and difﬁcult for clinicians
to manage. Symptoms of AF range from nonexistent to
severe. Frequent hospitalizations, hemodynamic abnor-
malities, and thromboembolic events related to AF result
in signiﬁcant morbidity and mortality. AF is associated
with a 5-fold increased risk of stroke (35), and stroke risk
increases with age (36). AF-related stroke is likely to be
more severe than non–AF-related stroke (37). AF is also
associated with a 3-fold risk of HF (38–40) and a 2-fold
increased risk of both dementia (41) and mortality (35).
In the United States, hospitalizations with AF as the pri-
mary diagnosis total >467 000 annually, and AF isOrganization
Publication Year/
Reference
ion, NHLBI 2003 (8)
ACC/AHA 2010 (9)
ACC/AHA 2011 (10)
ACC/AHA 2011 (11)
ACC/AHA/SCAI 2011 (12)
Other AHA/ACC 2011 (13)
CCS 2012 (14)
ESC 2012 (15)
ACC/AHA/ACP/AATS/PCNA/SCAI/STS 2012 (16)
ACCP 2012 (17)
ACC/AHA/HRS 2012 (18)
ACC/AHA 2013 (19)
ACC/AHA 2013 (20)
ACC/AHA 2014 (21)
AHA/ACC 2014 (22)
ACC/AHA 2013 (23)
AHA/ACC 2013 (24)
AHA/ACC/TOS 2013 (25)
dults ACC/AHA 2013 (26)
AHRQ 2013 (7a,7b)
llation: AHA/ASA 2012 (27)
:
gement
HRS/EHRA/ECAS 2012 (28)
atment of AF Following Cardiac Surgery; Rate and Rhythm Management; Prevention of
and Flutter in the Emergency Department; Surgical Therapy; The Use of Antiplatelet
mmendations for Stroke Prevention and Rate/Rhythm Control.
logy; ACCP, American College of Chest Physicians; ACP, American College of Physicians;
and Quality; ASA, American Stroke Association; CCS, Canadian Cardiology Society; ECAS,
ean Society of Cardiology; HRS, Heart Rhythm Society; JNC, Joint National Committee;
ociation; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of
TABLE 3 10 Most Common Comorbid Chronic Conditions Among Medicare Beneﬁciaries With AF
Beneﬁciaries $65 y of Age (N¼2 426 865)
(Mean Number of Conditions¼5.8; Median¼6)
Beneﬁciaries <65 y of Age (N¼105 878)
(Mean Number of Conditions¼5.8; Median¼6)
N % N %
Hypertension 2015 235 83.0 Hypertension 85908 81.1
Ischemic heart disease 1 549 125 63.8 Ischemic heart disease 68 289 64.5
Hyperlipidemia 1 507 395 62.1 Hyperlipidemia 64 153 60.6
HF 1 247 748 51.4 HF 62 764 59.3
Anemia 1027 135 42.3 Diabetes mellitus 56246 53.1
Arthritis 965472 39.8 Anemia 48252 45.6
Diabetes mellitus 885443 36.5 CKD 42637 40.3
CKD 784631 32.3 Arthritis 34949 33.0
COPD 561826 23.2 Depression 34900 33.0
Cataracts 546421 22.5 COPD 33218 31.4
AF indicates atrial ﬁbrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; and HF, heart failure.
Reproduced with permission from the Centers for Medicare & Medicaid Services (44).
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tients with AF are hospitalized twice as often as patients
without AF and are 3 times more likely to have multiple
admissions; 2.1% of patients with AF died in the hospital,
compared with 0.1% without it (42,43). AF is also expen-
sive, adding approximately $8700 per year (estimate
from 2004 to 2006) for a patient with AF compared with
a patient without AF. It is estimated that treating
patients with AF adds $26 billion to the US healthcare bill
annually. AF affects between 2.7 million and 6.1 million
American adults, and that number is expected to double
over the next 25 years, adding further to the cost
burden (42,43).
AF Web-based tools are available, including several
risk calculators and clinical decision aids; however, these
tools must be used with caution because validation across
the broad range of patients with AF encountered in clinical
practice is incomplete.
2.1. Deﬁnitions and Pathophysiology of AF
AF is a supraventricular tachyarrhythmia with uncoordi-
nated atrial activation and consequently ineffective
atrial contraction (4,28,30). Characteristics on an elec-
trocardiogram (ECG) include 1) irregular R-R intervals
(when atrioventricular [AV] conduction is present),
2) absence of distinct repeating P waves, and 3) irregular
atrial activity.
Hemodynamic consequences of AF can result from a
variable combination of suboptimal ventricular rate
control (either too rapid or too slow), loss of coordi-
nated atrial contraction, beat-to-beat variability in ven-
tricular ﬁlling, and sympathetic activation (45–47).
Consequences for individual patients vary, ranging from
no symptoms to fatigue, palpitations, dyspnea, hypo-
tension, syncope, or HF (48). The most commonsymptom of AF is fatigue. The appearance of AF is often
associated with exacerbation of underlying heart dis-
ease, either because AF is a cause or consequence of
deterioration or because it contributes directly to dete-
rioration (49,50). For example, initially asymptomatic
patients may develop tachycardia-induced ventricular
dysfunction and HF (tachycardia-induced cardiomyo-
pathy) when the ventricular rate is not adequately
controlled (51,52). AF also confers an increased risk of
stroke and/or peripheral thromboembolism owing to the
formation of atrial thrombi, usually in the left atrial
appendage (LAA).
In the absence of an accessory AV pathway, the ven-
tricular rate is determined by the conduction and
refractory properties of the AV node and the sequence of
wave fronts entering the AV node (53–55). L-type calcium
channels are responsible for the major depolarizing
current in AV nodal cells. Beta-adrenergic receptor
stimulation enhances AV nodal conduction, whereas
vagal stimulation (muscarinic receptor activation by
acetylcholine) impedes AV nodal conduction (55). Sym-
pathetic activation and vagal withdrawal such as that
with exertion or illness accelerates the ventricular
rate. Each atrial excitation wave front that depolarizes
AV nodal tissue renders those cells refractory for a period
of time, preventing successive impulses from propagating
in the node, an effect called concealed conduction (55).
This effect of concealed conduction into the AV node
explains why the ventricular rate can be faster and more
difﬁcult to slow when fewer atrial wave fronts are
entering the AV node, as in atrial ﬂutter, compared with
AF (53).
Loss of atrial contraction may markedly decrease car-
diac output, particularly when diastolic ventricular
ﬁlling is impaired by mitral stenosis, hypertension,
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diomyopathy (50,56,57). After restoration of sinus
rhythm, atrial mechanical function fails to recover in
some patients, likely as a consequence of remodeling or
underlying atrial disease and duration of AF (58). Ven-
tricular contractility is not constant during AF because of
variable diastolic ﬁlling time and changes in the force-
interval relationship (59,60). Overall, cardiac output
may decrease and ﬁlling pressures may increase
compared with a regular rhythm at the same mean rate.
In patients undergoing AV nodal ablation, irregular right
ventricular (RV) pacing at the same rate as regular ven-
tricular pacing resulted in a 15% reduction in cardiac
output (60). Irregular R-R intervals also promote sym-
pathetic activation (45,46).
2.1.1. AF Classiﬁcation
AF may be described in terms of the duration of episodes
using a simpliﬁed scheme shown in Table 4 (4,28,30).
Implanted loop recorders, pacemakers, and deﬁbrillators
offer the possibility of reporting frequency, rate, and dura-
tion of abnormal atrial rhythms, including AF (61,62).
Episodes often increase in frequency and duration over time.
Characterization of patients with AF by duration of
their AF episodes (Table 4) has clinical relevance in that
outcomes of therapy such as catheter ablation are better
for paroxysmal AF than for persistent AF (28). When sinus
rhythm is restored by cardioversion, however, the ulti-
mate duration of the AF episode(s) is not known.
Furthermore, both paroxysmal and persistent AF may
occur in a single individual.
“Lone AF” is a historical descriptor that has been var-
iably applied to younger persons without clinical orTABLE 4 Deﬁnitions of AF: A Simpliﬁed Scheme
Term Deﬁnition
Paroxysmal AF  AF that terminates spontaneously or with interven-
tion within 7 d of onset.
 Episodes may recur with variable frequency.
Persistent AF  Continuous AF that is sustained >7 d.
Long-standing
persistent AF
 Continuous AF >12 mo in duration.
Permanent AF  The term “permanent AF” is used when the patient
and clinician make a joint decision to stop further
attempts to restore and/or maintain sinus rhythm.
 Acceptance of AF represents a therapeutic attitude
on the part of the patient and clinician rather than
an inherent pathophysiological attribute of AF.
 Acceptance of AF may change as symptoms, efﬁcacy
of therapeutic interventions, and patient and clini-
cian preferences evolve.
Nonvalvular AF  AF in the absence of rheumatic mitral stenosis, a
mechanical or bioprosthetic heart valve, or mitral
valve repair.
AF indicates atrial ﬁbrillation.echocardiographic evidence of cardiopulmonary disease,
hypertension, or diabetes mellitus (63). Because the def-
initions are variable, the term lone AF is potentially
confusing and should not be used to guide therapeutic
decisions.
2.1.1.1. Associated Arrhythmias
Other atrial arrhythmias are often encountered in patients
with AF. Atrial tachycardias are characterized by an atrial
rate of $100 beats per minute (bpm) with discrete P waves
and atrial activation sequences. Atrial activation is most
commonly the same from beat to beat.
Focal atrial tachycardia is characterized by regular,
organized atrial activity with discrete P waves, typically
with an isoelectric segment between P waves (Figure 1)
(64,65). Electrophysiological mapping reveals a focal
point of origin. The mechanism can be automaticity or a
microreentry circuit (66,67). In multifocal atrial tachy-
cardia, the atrial activation sequence and P-wave
morphology vary (64).
2.1.1.2. Atrial Flutter and Macroreentrant Atrial Tachycardia
Early studies designated atrial ﬂutter with a rate of 240
bpm to 340 bpm as “type I ﬂutter,” and this term has
commonly been applied to typical atrial ﬂutter (65,68). An
electrocardiographic appearance of atrial ﬂutter with a
rate faster than 340 bpm was designated as “type II
ﬂutter”; the mechanism for type II ﬂutter remains unde-
ﬁned (69). It is now recognized that tachycardias satis-
fying either of these descriptions can be due to reentrant
circuits or rapid focal atrial tachycardia.
Typical atrial ﬂutter is a macroreentrant atrial tachy-
cardia that usually proceeds up the atrial septum, down
the lateral atrial wall, and through the cavotricuspid
(subeustachian) isthmus between the tricuspid valve
annulus and inferior vena cava, where it is commonly
targeted for ablation. It is also known as “common atrial
ﬂutter” or “cavotricuspid isthmus–dependent atrial
ﬂutter” (64). This sequence of activation (also referred
to as “counterclockwise atrial ﬂutter”) produces pre-
dominantly negative “sawtooth” ﬂutter waves in ECG
leads II, III, and aVF, and a positive deﬂection in V1
(Figure 1). The atrial rate is typically 240 bpm to 300 bpm,
but conduction delays in the atrial circuit due to scars
from prior ablation, surgery, or antiarrhythmic drugs
can slow the rate to <150 bpm in some patients (65).
When the circuit revolves in the opposite direction,
ﬂutter waves typically appear positive in the inferior ECG
leads and negative in V1 (reverse typical atrial ﬂutter,
also referred to as clockwise typical atrial ﬂutter)
(65). Unusual ﬂutter wave morphologies occur in the
presence of substantial atrial disease, prior surgery, or
radiofrequency catheter ablation; the P-wave mor-
phology is not a reliable indicator of the type of
FIGURE 1 Atrial Tachycardias
Diagram summarizing types of atrial tachycardias often encountered in patients with a history of AF, including those seen after catheter or surgical ablation
procedures. P-wave morphologies are shown for common types of atrial ﬂutter; however, the P-wave morphology is not always a reliable guide to the
reentry circuit location or the distinction between common atrial ﬂutter and other macroreentrant atrial tachycardias.
*Exceptions to P-wave morphology and rate are common in scarred atria.
AF indicates atrial ﬁbrillation; bpm, beats per minute; and ECG, electrocardiogram (72,80).
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(70–72). Atrial ﬂutter is often a persistent rhythm
that requires electrical cardioversion or radiofrequency
catheter ablation for termination. It is often initiated
by a brief episode of atrial tachycardia or by AF (69,73).
This relationship between AF and atrial ﬂutter may
explain why $80% of patients who undergo radiofre-
quency catheter ablation of typical atrial ﬂutter will
have AF within the following 5 years (74).
AF may be misdiagnosed as atrial ﬂutter when AF
activity is prominent on the ECG (75,76). Atrial ﬂutter
may also arise during treatment with antiarrhythmic
agents prescribed to prevent recurrent AF (77), particu-
larly sodium channel–blocking antiarrhythmic drugs
such as ﬂecainide or propafenone. Catheter ablation of
the cavotricuspid isthmus is effective for prevention of
recurrent atrial ﬂutter in these patients while allowingcontinued antiarrhythmic treatment to prevent recurrent
AF (78).
Atypical ﬂutter, or “non–cavotricuspid isthmus–
dependent macroreentrant atrial tachycardia,” describes
macroreentrant atrial tachycardias that are not one of the
typical forms of atrial ﬂutter that use the cavotricuspid
isthmus (64). A variety of reentrant circuits have been
described, including “perimitral ﬂutter” reentry involving
the roof of the left atrium (LA), and reentry around scars
in the left or right atrium, often from prior surgery or
ablation (65,67,79). Complex reentry circuits with >1
reentry loop or circuit can occur and often coexist with
common atrial ﬂutter. These arrhythmias are not abol-
ished by ablation of the cavotricuspid isthmus, but
recognition and distinction of these arrhythmias from
common atrial ﬂutter usually requires electrophysiolog-
ical study with atrial mapping (65). A variety of terms
FIGURE 2 Mechanisms of AF
AF indicates atrial ﬁbrillation; Caþþ, ionized calcium; and RAAS, renin-angiotensin-aldosterone system.
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reentry circuit location, including LA ﬂutter and LA
macroreentrant tachycardia (65,67,79,80).
2.2. Mechanisms of AF and Pathophysiology
AF occurs when structural and/or electrophysiological
abnormalities alter atrial tissue to promote abnormal
impulse formation and/or propagation (Figure 2). These
abnormalities are caused by diverse pathophysiological
mechanisms (28,81,82), such that AF represents a ﬁnal
common phenotype for multiple disease pathways and
mechanisms that are incompletely understood.
2.2.1. Atrial Structural Abnormalities
Any disturbance of atrial architecture potentially increases
susceptibility to AF (83). Such changes (e.g., inﬂammation,
ﬁbrosis, hypertrophy) occur most commonly in the setting
of underlying heart disease associated with hypertension,
coronary artery disease (CAD), valvular heart disease, car-
diomyopathies, and HF, which tend to increase LA pres-
sure, cause atrial dilation, and alter wall stress. Similarly,
atrial ischemia from CAD and inﬁltrative diseases such as
amyloidosis, hemochromatosis, and sarcoidosis can also
promote AF. Extracardiac factors that promote AF include
hypertension, sleep apnea, obesity, use of alcohol/drugs,and hyperthyroidism, all of which have pathophysiological
effects on atrial cellular structure and/or function. Even in
patients with paroxysmal AF without recognized structural
heart disease, atrial biopsies have revealed inﬂammatory
inﬁltrates consistent with myocarditis and ﬁbrosis (84).
In addition, prolonged rapid atrial pacing increases
arrhythmia susceptibility and forms the basis for a well-
studied model of AF. In the atria of patients with estab-
lished AF and of animals subjected to rapid atrial pacing,
there is evidence of myocyte loss from glycogen deposits
and of mitochondrial disturbances and gap-junction
abnormalities that cause cell necrosis and apoptosis
(85–87). These structural abnormalities can heteroge-
neously alter impulse conduction and/or refractoriness,
generating an arrhythmogenic substrate.
Myocardial ﬁbrosis is a common feature of both
experimental and human AF (88). The atria are more
sensitive to proﬁbrotic signaling and harbor a greater
number of ﬁbroblasts than the ventricles. Atrial stretch
activates the renin-angiotensin-aldosterone system,
which generates multiple downstream proﬁbrotic factors,
including transforming growth factor-beta1. Additional
mechanisms, including inﬂammation and genetic factors,
can also promote atrial ﬁbrosis. The canine rapid
ventricular pacing model of HF causes extensive atrial
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occurs in the rapid atrial pacing model of AF. Late
gadolinium-enhancement magnetic resonance imaging is
used to image and quantitate atrial ﬁbrosis noninvasively
(90–95). Human studies show a strong correlation be-
tween regions of low voltage on electroanatomic mapping
and areas of late enhancement on magnetic resonance
imaging. Preliminary results suggest that the severity of
atrial ﬁbrosis correlates with the risk of stroke (91) and
decreased response to catheter ablation (90).
2.2.2. Electrophysiological Mechanisms
AF requires both a trigger for initiation and an appropriate
anatomic substrate for maintenance, both of which are
potential targets for therapy. Several hypotheses have
been proposed to explain the electrophysiological mech-
anisms that initiate and maintain AF (28). In humans, the
situation is complex, and it is likely that multiple mech-
anisms coexist in an individual patient.
2.2.2.1. Triggers of AF
Ectopic focal discharges often initiate AF (96–98). Rapidly
ﬁring foci initiating paroxysmal AF arise most commonly
from LA myocardial sleeves that extend into the pulmo-
nary veins. These observations led to the development
of pulmonary vein isolation as the cornerstone for
radiofrequency catheter ablation strategies (28). Unique
anatomic and electrophysiological features of the pulmo-
nary veins and atriopulmonary vein junctions may account
for their arrhythmogenic nature. Atrial myocardial ﬁbers
are oriented in disparate directions around the pulmonary
veins and the posterior LA, with considerable anatomic
variability among individuals. Conduction abnormalities
that promote reentry are likely due to relatively depolar-
ized resting potentials in pulmonary vein myocytes that
promote sodium channel inactivation and to the abrupt
changes in ﬁber orientation. Reentry is further favored by
abbreviated action potentials and refractoriness in pul-
monary vein myocytes (99). Isolated pulmonary vein
myocytes also demonstrate abnormal automaticity and
triggered activity that could promote rapid focal ﬁring.
Additional potential sources for abnormal activity include
interstitial cells (similar to pacemaker cells in the gastro-
intestinal tract) (100) and melanocytes (101), both of which
have been identiﬁed in pulmonary veins. Although the
pulmonary veins are the most common sites for ectopic
focal triggers, triggers can also arise elsewhere, including
the posterior LA, ligament of Marshall, coronary sinus,
venae cavae, septum, and appendages.
Abnormal intracellular calcium handling may also play
a role in AF owing to diastolic calcium leak from the
sarcoplasmic reticulum, which can trigger delayed after-
depolarizations (102–106).2.2.2.2. Maintenance of AF
Theories proposed to explain the perpetuation and
maintenance of AF include 1) multiple independent
reentrant wavelets associated with heterogeneous con-
duction and refractoriness; 2) $1 rapidly ﬁring foci, which
may be responsive to activity from cardiac ganglion plexi;
and 3) $1 rotors, or spiral wave reentrant circuits
(28,82,88,107–113). With a single rapid focus or rotor
excitation, wave fronts may encounter refractory tissue
and break up during propagation, resulting in irregular or
ﬁbrillatory conduction (28,107,110). Both rapid focal ﬁring
and reentry may be operative during AF.
These presumed mechanisms have driven the devel-
opment of therapies. The atrial maze procedure and
ablation lines may interrupt paths for multiple wavelets
and spiral reentry. When a biatrial phase mapping
approach was used, a limited number of localized, rapid
drivers (mean of approximately 2 per patient) were
identiﬁed in a small group of patients with various types
of AF (112). In most cases, these localized sources
appeared to be reentrant, whereas in others they were
consistent with focal triggers, and radiofrequency cath-
eter ablation targeting of these sites often terminated or
slowed AF. Other investigators, using a noninvasive
continuous biatrial mapping system, report contrasting
results, observing mostly evidence for multiple wavelets
and focal sites rather than rotor activity (114).
Some investigators targeted regions in which electro-
gram recordings show rapid complex atrial fractionated
electrograms, which are thought to be indicative of the
substrate for AF or markers for ganglion plexi (see
Section 2.2.2.3 for ablation of AF) (109). The relation of
complex atrial fractionated electrograms to AF remains
controversial.
2.2.2.3. Role of the Autonomic Nervous System
Autonomic stimulation can provoke AF (28,98,115). Acti-
vation of the parasympathetic and/or sympathetic limbs
can provoke atrial arrhythmias (108,116). Acetylcholine
activates a speciﬁc potassium current, IK,ACh, which
heterogeneously shortens atrial action potential duration
and refractoriness, increasing susceptibility to reentry.
Sympathetic stimulation increases intracellular calcium,
which promotes automaticity and triggered activity.
Increased parasympathetic and/or sympathetic activity
before onset of AF has been observed in some animal
models and humans (117,118).
Plexi of autonomic ganglia that constitute the intrinsic
cardiac autonomic nervous system are located in epicar-
dial fat near the pulmonary vein-LA junctions and
the ligament of Marshall. Stimulation of the ganglia in
animals elicits repetitive bursts of rapid atrial activity.
These plexi are often located proximal to atrial sites
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recorded. Ablation targeting these regions improved
outcomes over pulmonary vein isolation alone in some
but not all studies (119–121).
In some patients with structurally normal hearts, AF is
precipitated during conditions of high-parasympathetic
tone, such as during sleep and following meals, and is
referred to as “vagally mediated AF.” (122). Avoidance of
drugs, such as digoxin, that enhance parasympathetic
tone has been suggested in these patients, but this re-
mains an unproven hypothesis. Catheter ablation target-
ing ganglion plexi involved in vagal responses abolished
AF in only 2 of 7 patients in 1 small series (120). Adrenergic
stimulation, such as that during exercise, can also pro-
voke AF in some patients (123).
2.2.3. Pathophysiological Mechanisms
2.2.3.1. Atrial Tachycardia Remodeling
AF often progresses from paroxysmal to persistent over a
variable period of time. Cardioversion of AF and subse-
quent maintenance of sinus rhythm are more likely to be
successful when AF duration is <6 months (124). The
progressive nature of AF is consistent with studies
demonstrating that AF causes electrical and structural
remodeling such that “AF begets AF.” (125,126).
2.2.3.2. Inﬂammation and Oxidative Stress
Inﬂammation (e.g., associated with pericarditis and car-
diac surgery) may be linked to AF and can be correlated
with a rise in plasma concentrations of C-reactive protein
(81). Inﬂammatory inﬁltrates consistent with myocarditis
are often present in the atria of patients with AF and in
animals with atrial dilation. Plasma concentrations of
C-reactive protein and interleukin-6 are elevated in AF;
increased C-reactive protein predicts the development of
AF and relapse after cardioversion; and genetic variants
in the interleukin-6 promoter region may inﬂuence the
development of postoperative AF. In the canine peri-
carditis and atrial tachypacing models, prednisone
suppresses AF susceptibility and reduces plasma con-
centrations of C-reactive protein (127).
Aging, environmental stress, inﬂammation, and acti-
vation of the renin-angiotensin-aldosterone system can
cause oxidative damage in the atrium. Oxidative changes
are present in the atrial tissue of patients with AF and are
associated with upregulation of genes involved in the
production of reactive oxygen species. In human AF and a
porcine model of atrial tachypacing, atrial superoxide
production increased, with an apparent contribution of
NAD(P)H oxidase (128). The antioxidant ascorbate atten-
uated electrical remodeling in the canine atrial tachy-
pacing model and reduced postoperative AF in a small
study in humans (129).2.2.3.3. The Renin-Angiotensin-Aldosterone System
Stimulation of the renin-angiotensin-aldosterone system
promotes structural and likely electrophysiological ef-
fects in the atrium and ventricle that increase arrhythmia
susceptibility (130–133). In addition to adverse hemody-
namic effects, activation of multiple cell signaling
cascades promotes increased intracellular calcium, hy-
pertrophy, apoptosis, cytokine release and inﬂamma-
tion, oxidative stress, and production of growth-related
factors that also stimulate ﬁbrosis, as well as possible
modulation of ion channel and gap-junction dynamics.
Components of the renin-angiotensin-aldosterone sys-
tem (including angiotensin II, angiotensin-converting
enzyme [ACE], and aldosterone) are synthesized lo-
cally in the atrial myocardium and are increased during
atrial tachypacing and AF. Variants in the ACE gene
that increase angiotensin II plasma concentrations can
elevate risk of AF, whereas selective cardiac over-
expression of ACE causes atrial dilation, ﬁbrosis, and
increased susceptibility of AF. Therapy with these
agents can reduce the occurrence of AF in patients
with hypertension or left ventricular (LV) dysfunction
but does not help prevent recurrence of AF in the
absence of these other indications for these drugs
(Section 6.2.1).
Aldosterone plays an important role in angiotensin
II–mediated inﬂammation and ﬁbrosis; in patients with
primary hyperaldosteronism, the incidence of AF is
increased. In experimental models of HF, spironolactone
and eplerenone decreased atrial ﬁbrosis and/or suscepti-
bility of AF. Eplerenone therapy is associated with
decreased AF in patients with HF (134).
2.2.3.4. Risk Factors and Associated Heart Disease
Multiple clinical risk factors, electrocardiographic and
echocardiographic features, and biochemical markers
are associated with an increased risk of AF (Table 5).
One epidemiological analysis found that 56% of the
population-attributable risk of AF could be explained
by $1 common risk factor (135). Thus, it may be possible to
prevent some cases of AF through risk factor modiﬁcation
such as blood pressure control or weight loss.
Many potentially “reversible” causes of AF have been
reported, including binge drinking, cardiothoracic and
noncardiac surgery, myocardial infarction (MI), pericar-
ditis, myocarditis, hyperthyroidism, electrocution, pneu-
monia, and pulmonary embolism (10,49,136–138). AF that
occurs in the setting of Wolff-Parkinson-White (WPW)
syndrome, AV nodal reentrant tachycardia, or atrial
ectopic tachycardia may resolve after catheter ablation for
these arrhythmias (69). It is important to recognize that
sparse data support the notion that patients with AF that
occurs in the setting of 1 of these potentially “reversible”
TABLE 5 Selected Risk Factors and Biomarkers for AF
Clinical Risk Factors References
Increasing age (139)
Hypertension (139)
Diabetes mellitus (139)
MI (139)
VHD (139)
HF (38,139)
Obesity (140–142)
Obstructive sleep apnea (142)
Cardiothoracic surgery (137)
Smoking (143)
Exercise (144–146)
Alcohol use (147–149)
Hyperthyroidism (150–152)
Increased pulse pressure (153)
European ancestry (154)
Family history (155)
Genetic variants (156–159)
ECG
LVH (35)
Echocardiographic
LA enlargement (35,160)
Decreased LV fractional shortening (35)
Increased LV wall thickness (35)
Biomarkers
Increased CRP (86,161)
Increased BNP (162,163)
AF indicates atrial ﬁbrillation; BNP, B-type natriuretic peptide; CRP, C-reactive
protein; ECG, electrocardiographic; HF, heart failure; LA, left atrial; LV, left ven-
tricular; LVH, left ventricular hypertrophy; MI, myocardial infarction; and VHD,
valvular heart disease.
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ment or elimination of the condition. Because long-term
follow-up data are not available in these clinical sce-
narios and AF may recur, these patients should receive
careful follow-up.
See Online Data Supplements 1 and 2 for additional data
on electrophysiological and pathophysiologicalmechanisms.3. CLINICAL EVALUATION: RECOMMENDATION
CLASS I
1. Electrocardiographic documentation is recommended to
establish the diagnosis of AF. (Level of Evidence: C)
The diagnosis of AF in a patient is based on the patient’s
clinical history and physical examination and is
conﬁrmed by ECG, ambulatory rhythm monitoring (e.g.,
telemetry, Holter monitor, event recorders), implanted
loop recorders, pacemakers or deﬁbrillators, or, in
rare cases, by electrophysiological study. The clinical
evaluations, including additional studies that may be
required, are summarized in Appendix 4.3.1. Basic Evaluation of the Patient With AF
3.1.1. Clinical History and Physical Examination
The initial evaluation of a patient with suspected
or proven AF involves characterizing the pattern of
the arrhythmia (paroxysmal, persistent, long-standing
persistent, or permanent), determining its cause,
deﬁning associated cardiac and extracardiac disease, and
assessing thromboembolic risk. Symptoms, prior treat-
ment, family history, and a review of associated condi-
tions and potentially reversible risk factors as outlined in
Table 5 should be recorded.
The physical examination suggests AF by the presence
of an irregular pulse, irregular jugular venous pulsations,
and variation in the intensity of the ﬁrst heart sound or
absence of a fourth sound previously heard during sinus
rhythm. Physical examination may also disclose associ-
ated valvular heart disease or myocardial abnormalities.
The pulse in atrial ﬂutter is often regular and rapid, and
venous oscillations may be visible in the jugular pulse.
3.1.2. Investigations
An ECG, or other electrocardiographic recording, is the
essential tool for conﬁrming AF. A chest radiograph
should be done if pulmonary disease or HF is suspected
and may also detect enlargement of the cardiac chambers.
As part of the initial evaluation, all patients with AF
should have a 2-dimensional transthoracic echocardio-
gram to detect underlying structural heart disease,
assess cardiac function, and evaluate atrial size. Addi-
tional laboratory evaluation should include assessment of
serum electrolytes and of thyroid, renal, and hepatic
function, and a blood count.
Transesophageal Echocardiography (TEE): TEE is the
most sensitive and speciﬁc technique to detect LA
thrombi as a potential source of systemic embolism in AF
and can be used to guide the timing of cardioversion or
catheter ablation procedures (Section 6.1.1). TEE can also
identify features associated with an increased risk of LA
thrombus formation, including reduced LAA ﬂow veloc-
ity, spontaneous LA contrast, and aortic atheroma. In 5%
to 15% of patients with AF, TEE before planned cardio-
version revealed an LA or LAA thrombus (164,165).
Electrophysiological Study: An electrophysiological
study can be helpful when initiation of AF is due to a
supraventricular tachycardia, such as AV node reentrant
tachycardia, AV reentry involving an accessory pathway,
or ectopic atrial tachycardia. Ablation of the supraven-
tricular tachycardia may prevent or reduce recurrences of
AF. Electrophysiological study is often warranted in
patients with a delta wave on the surface ECG indicating
pre-excitation. Some patients with AF also have atrial
ﬂutter that may beneﬁt from treatment with radio-
frequency catheter ablation. AF associated with rapid
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duction) may sometimes be mislabeled as ventricular
tachycardia, and an electrophysiological study can help
establish the correct diagnosis.
Additional Investigation of Selected Patients With AF:
Plasma levels of B-type natriuretic peptide or N-terminal
pro-B-type natriuretic peptide may be elevated in
patients with paroxysmal and persistent AF in the
absence of clinical HF, and levels decrease rapidly after
restoration of sinus rhythm. A sleep study may be useful
if sleep apnea is suspected (166).
3.1.3. Rhythm Monitoring and Stress Testing
Prolonged or frequent monitoring may be necessary to
reveal episodes of asymptomatic AF. Electrocardiography,TABLE 6 Summary of Recommendations for Risk-Based Antithr
Recommendations
Antithrombotic therapy based on shared decision making, discussion of risks of strok
patient’s preferences
Selection of antithrombotic therapy based on risk of thromboembolism
CHA2DS2-VASc score recommended to assess stroke risk
Warfarin recommended for mechanical heart valves and target INR intensity based on
of prosthesis
With prior stroke, TIA, or CHA2DS2-VASc score $2, oral anticoagulants recommended
Warfarin
Dabigatran, rivaroxaban, or apixaban
With warfarin, determine INR at least weekly during initiation of therapy and monthl
Direct thrombin or factor Xa inhibitor recommended if unable to maintain therapeuti
Reevaluate the need for anticoagulation at periodic intervals
Bridging therapy with UFH or LMWH recommended with a mechanical heart valve if
Bridging therapy should balance risks of stroke and bleeding
For patients without mechanical heart valves, bridging therapy decisions should bala
bleeding risks against duration of time patient will not be anticoagulated
Evaluate renal function before initiation of direct thrombin or factor Xa inhibitors, an
clinically indicated and at least annually
For atrial ﬂutter, antithrombotic therapy is recommended as for AF
With nonvalvular AF and CHA2DS2-VASc score of 0, it is reasonable to omit antithrom
With CHA2DS2-VASc score $2 and end-stage CKD (CrCl <15 mL/min) or on hemodial
to prescribe warfarin for oral anticoagulation
With nonvalvular AF and a CHA2DS2-VASc score of 1, no antithrombotic therapy or tr
anticoagulant or aspirin may be considered
With moderate-to-severe CKD and CHA2DS2-VASc scores $2, reduced doses of direct
Xa inhibitors may be considered
For PCI,* BMS may be considered to minimize duration of DAPT
After coronary revascularization in patients with CHA2DS2-VASc score $2, it may be
clopidogrel concurrently with oral anticoagulants but without aspirin
Direct thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended
and end-stage CKD or on dialysis because of a lack of evidence from clinical tri
balance of risks and beneﬁts
Direct thrombin inhibitor dabigatran should not be used with a mechanical heart valv
*See the 2011 PCI guideline for type of stent and duration of DAPT recommendations (12).
AF indicates atrial ﬁbrillation; BMS, bare-metal stent; CHA2DS2-VASc, Congestive heart fa
thromboembolism (doubled), Vascular disease, Age 65 to 74 years, Sex category; CKD, chron
antiplatelet therapy; INR, international normalized ratio; LMWH, low-molecular-weight hepar
TIA, transient ischemic attack; and UFH, unfractionated heparin.ambulatory rhythm monitoring (e.g., telemetry, Holter
monitor, and event recorders), and exercise testing can be
useful to judge the adequacy of rate control. Patient-
activated electrocardiographic event recorders can help
assess the relation to symptoms, whereas auto-triggered
event recorders may detect asymptomatic episodes.
These technologies may also provide valuable information
to guide drug dosage for rate control or rhythm
management.
4. PREVENTION OF THROMBOEMBOLISM
4.1. Risk-Based Antithrombotic Therapy: Recommendations
See Table 6 for a summary of recommendations from this
section.ombotic Therapy
COR LOE References
e and bleeding, and I C N/A
I B (167–170)
I B (171–173)
type and location I B (174–176)
. Options include:
I A (171–173)
I B (177–179)
y when stable I A (180–182)
c INR I C N/A
I C N/A
warfarin is interrupted. I C N/A
nce stroke and I C N/A
d reevaluate when I B (183–185)
I C N/A
botic therapy IIa B (183,184)
ysis, it is reasonable IIa B (185)
eatment with oral IIb C N/A
thrombin or factor IIb C N/A
IIb C N/A
reasonable to use IIb B (186)
in patients with AF
als regarding the
III: No Beneﬁt C (177–179,187–189)
e III: Harm B (190)
ilure, Hypertension, Age $75 years (doubled), Diabetes mellitus, Prior Stroke or TIA or
ic kidney disease; COR, Class of Recommendation; CrCl, creatinine clearance; DAPT, dual
in; LOE, Level of Evidence; N/A, not applicable; PCI, percutaneous coronary intervention;
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1. In patients with AF, antithrombotic therapy should
be individualized based on shared decision making after
discussion of the absolute risks and RRs of stroke and
bleeding and the patient’s values and preferences. (Level of
Evidence: C)
2. Selection of antithrombotic therapy should be based on the
risk of thromboembolism irrespective of whether the AF
pattern is paroxysmal, persistent, or permanent (167–170).
(Level of Evidence: B)
3. In patients with nonvalvular AF, the CHA2DS2-VASc* score
is recommended for assessment of stroke risk (171–173).
(Level of Evidence: B)
4. For patients with AF who have mechanical heart valves,
warfarin is recommended, and the target international
normalized ratio (INR) intensity (2.0 to 3.0 or 2.5 to 3.5)
should be based on the type and location of the prosthesis
(174–176). (Level of Evidence: B)
5. For patients with nonvalvular AF with prior stroke, tran-
sient ischemic attack (TIA), or a CHA2DS2-VASc score of 2 or
greater, oral anticoagulants are recommended. Options
include warfarin (INR 2.0 to 3.0) (171–173) (Level of
Evidence: A), dabigatran (177) (Level of Evidence: B),
rivaroxaban (178) (Level of Evidence: B), or apixaban (179).
(Level of Evidence: B)
6. Among patients treated with warfarin, the INR should
be determined at least weekly during initiation of
antithrombotic therapy and at least monthly when anti-
coagulation (INR in range) is stable (180–182). (Level of
Evidence: A)
7. For patients with nonvalvular AF unable to maintain a
therapeutic INR level with warfarin, use of a direct
thrombin or factor Xa inhibitor (dabigatran, rivaroxaban, or
apixaban) is recommended. (Level of Evidence: C)
8. Reevaluation of the need for and choice of antithrombotic
therapy at periodic intervals is recommended to reassess
stroke and bleeding risks. (Level of Evidence: C)
9. Bridging therapy with unfractionated heparin (UFH) or low-
molecular-weight heparin (LMWH) is recommended for
patients with AF and a mechanical heart valve undergoing
procedures that require interruption of warfarin. Decisions
on bridging therapy should balance the risks of stroke and
bleeding. (Level of Evidence: C)
10. For patients with AF without mechanical heart valves who
require interruption of warfarin or new anticoagulants for
procedures, decisions about bridging therapy (LMWH or
UFH) should balance the risks of stroke and bleeding and*CHA2DS2-VASc indicates Congestive heart failure, Hypertension, Age $75
years (doubled), Diabetes mellitus, Prior Stroke or TIA or thromboembolism
(doubled), Vascular disease, Age 65 to 74 years, Sex category.the duration of time a patient will not be anticoagulated.
(Level of Evidence: C)
11. Renal function should be evaluated before initiation of
direct thrombin or factor Xa inhibitors and should be
reevaluated when clinically indicated and at least annually
(183–185). (Level of Evidence: B)
12. For patients with atrial ﬂutter, antithrombotic therapy is
recommended according to the same risk proﬁle used for
AF. (Level of Evidence: C)
CLASS IIa
1. For patients with nonvalvular AF and a CHA2DS2-VASc score
of 0, it is reasonable to omit antithrombotic therapy
(183,184). (Level of Evidence: B)
2. For patients with nonvalvular AF with a CHA2DS2-VASc score
of 2 or greater and who have end-stage chronic kidney disease
(CKD) (creatinine clearance [CrCl] <15 mL/min) or are on he-
modialysis, it is reasonable to prescribe warfarin (INR 2.0 to
3.0) for oral anticoagulation (185). (Level of Evidence: B)
CLASS IIb
1. For patients with nonvalvular AF and a CHA2DS2-VASc score
of 1, no antithrombotic therapy or treatment with an oral
anticoagulant or aspirin may be considered. (Level of
Evidence: C)
2. For patients with nonvalvular AF and moderate-to-severe
CKD with CHA2DS2-VASc scores of 2 or greater, treatment
with reduced doses of direct thrombin or factor Xa inhibitors
may be considered (e.g., dabigatran, rivaroxaban, or apix-
aban), but safety and efﬁcacy have not been established.
(Level of Evidence: C)
3. In patients with AF undergoing percutaneous coronary
intervention,y bare-metal stents may be considered to
minimize the required duration of dual antiplatelet therapy.
Anticoagulation may be interrupted at the time of the pro-
cedure to reduce the risk of bleeding at the site of peripheral
arterial puncture. (Level of Evidence: C)
4. Following coronary revascularization (percutaneous or
surgical) in patients with AF and a CHA2DS2-VASc score of
2 or greater, it may be reasonable to use clopidogrel (75 mg
once daily) concurrently with oral anticoagulants but
without aspirin (186). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. The direct thrombin inhibitor dabigatran and the factor Xa
inhibitor rivaroxaban are not recommended in patients with
AF and end-stage CKD or on dialysis because of the lack of
evidence from clinical trials regarding the balance of risks
and beneﬁts (177–179,187–189). (Level of Evidence: C)ySee the 2011 percutaneous coronary intervention guideline for type of stent
and duration of dual antiplatelet therapy recommendations (12).
TABLE 7
Comparison of the CHADS2 and CHA2DS2-VASc
Risk Stratiﬁcation Scores for Subjects With
Nonvalvular AF
Stroke Risk Stratiﬁcation
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e17CLASS III: HARM
1. The direct thrombin inhibitor dabigatran should not be used
in patients with AF and a mechanical heart valve (190).
(Level of Evidence: B)
Deﬁnition and Scores for CHADS2
and CHA2DS2-VASc
With the CHADS2 and
CHA2DS2-VASc Scores
Score
Adjusted Stroke
Rate (% per y)
CHADS2 CHADS2*
Congestive HF 1 0 1.9
Hypertension 1 1 2.8
Age $75 y 1 2 4.0
Diabetes mellitus 1 3 5.9
Stroke/TIA/TE 2 4 8.5
Maximum score 6 5 12.5
6 18.2
CHA2DS2-VASc CHA2DS2-VASc†
Congestive HF 1 0 0
Hypertension 1 1 1.3
Age $75 y 2 2 2.2
Diabetes mellitus 1 3 3.2
Stroke/TIA/TE 2 4 4.0
Vascular disease (prior MI,
PAD, or aortic plaque)
1 5 6.7
Age 65–74 y 1 6 9.8
Sex category (i.e., female sex) 1 7 9.6
Maximum score 9 8 6.7
9 15.20
*These adjusted stroke rates are based on data for hospitalized patients with AF and
were published in 2001 (201). Because stroke rates are decreasing, actual stroke rates in
contemporary nonhospitalized cohorts might vary from these estimates.
†Adjusted stroke rate scores are based on data from Lip and colleagues
(15,30,171,202,203). Actual rates of stroke in contemporary cohorts might vary from
these estimates.
AF indicates atrialﬁbrillation; CHADS2, Congestive heart failure, Hypertension, Age$75
years, Diabetes mellitus, Prior Stroke or TIA or Thromboembolism (doubled); CHA2DS2-
VASc, Congestive heart failure, Hypertension, Age $75 years (doubled), Diabetes melli-
tus, Prior Stroke or TIA or thromboembolism (doubled), Vascular disease, Age 65 to
74 years, Sex category; HF, heart failure; MI, myocardial infarction; PAD, peripheral artery
disease; TE, thromboembolism; and TIA, transient ischemic attack (202,203).4.1.1. Selecting an Antithrombotic Regimen—Balancing Risks and
Beneﬁts
AF, whether paroxysmal, persistent, or permanent and
whether symptomatic or silent, signiﬁcantly increases the
risk of thromboembolic ischemic stroke (191–194). Non-
valvular AF increases the risk of stroke 5 times, and AF in
the setting of mitral stenosis increases the risk of stroke
20 times (195) over that of patients in sinus rhythm.
Thromboembolism occurring with AF is associated with a
greater risk of recurrent stroke, more severe disability,
and mortality (196). Silent AF is also associated with
ischemic stroke (191–194). The appropriate use of antith-
rombotic therapy and the control of other risk factors,
including hypertension and hypercholesterolemia, sub-
stantially reduce stroke risk.
Antithrombotic agents routinely used for the preven-
tion of thromboembolism in patients with nonvalvular AF
include anticoagulant drugs (UFH and LMWH, warfarin,
and direct thrombin and factor Xa inhibitors) and anti-
platelet drugs (aspirin and clopidogrel). Although anti-
coagulants have been effective in reducing ischemic
stroke in multiple randomized controlled trials (RCTs),
their use is associated with an increased risk of bleeding,
ranging from minor bleeding to fatal intracranial or
extracranial hemorrhage. Platelet inhibitors (alone or in
combination) are less effective than warfarin, are better
tolerated by some patients, and are associated with a
lower risk of intracerebral hemorrhage. However,
they have similar overall rates of major bleeding in
some studies (184,189,197–199). Careful consideration is
required to balance the beneﬁts and risks of bleeding in
each individual patient.
4.1.1.1. Risk Stratiﬁcation Schemes (CHADS2, CHA2DS2-VASc,
and HAS-BLED)
One meta-analysis has stratiﬁed ischemic stroke risk
among patients with nonvalvular AF using the following
point scoring systems: AF Investigators (200); CHADS2
(Congestive heart failure, Hypertension, Age $75 years,
Diabetes mellitus, Prior Stroke or TIA or Thromboembo-
lism [doubled]) (201), or CHA2DS2-VASc (Congestive heart
failure, Hypertension, Age $75 years [doubled], Diabetes
mellitus, Prior Stroke or TIA or thromboembolism
[doubled], Vascular disease, Age 65 to 74 years, Sex
category) (Table 7).
The CHADS2 score has been validated in multiple
nonvalvular AF cohorts, with ﬁndings indicating an
increase in stroke rate of approximately 2.0% for each1-point increase in CHADS2 score (from 1.9% with a score
of 0 to 18.2% with a score of 6) (201,204). A limitation of
the CHADS2 score is that a score of 1 is considered an
“intermediate” risk and those at lowest risk may not be
well identiﬁed. Furthermore, patients whose only risk
factor is a CHADS2 score of 2 due to prior stroke may have
a greater risk than a score of 2 would indicate.
When compared with the CHADS2 score, the CHA2DS2-
VASc score (15) for nonvalvular AF has a broader score
range (0 to 9) and includes a larger number of risk factors
(female sex, 65 to 74 years of age, and vascular disease)
(202,203). In this scheme, women cannot achieve a
CHA2DS2-VASc score of 0. In a nationwide Danish registry
from 1997 to 2008, the CHA2DS2-VASc index better
discriminated stroke risk among subjects with a baseline
CHADS2 score of 0 to 1 with an improved predictive
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CHA2DS2-VASc score more clearly deﬁned anticoagulation
recommendations than the CHADS2 score did (173). More
patients, particularly older women, were redistributed
from the low- to high-risk categories. In a study of
Swedish patients with nonvalvular AF, women again had
a moderately increased stroke risk compared with men;
however, women younger than 65 years of age and
without other AF risk factors had a low risk for stroke, and
it was concluded that anticoagulant treatment was not
required (205). However, the continued evolution of
AF-related thromboembolic risk evaluation is needed.
Bleeding risk scores to quantify hemorrhage risk
include HAS-BLED (Hypertension, Abnormal renal/liver
function, Stroke, Bleeding history or predisposition,
Labile INR, Elderly, Drugs/alcohol concomitantly), RIETE
(Computerized Registry of Patients With Venous Throm-
boembolism), HEMORR2HAGES (Hepatic or Renal Dis-
ease, Ethanol Abuse, Malignancy, Older Age, Reduced
Platelet Count or Function, Rebleeding, Hypertension,
Anemia, Genetic Factors, Excessive Fall Risk and Stroke),
and ATRIA (Anticoagulation and Risk Factors in Atrial
Fibrillation) (206–208). Although these scores may be
helpful in deﬁning patients at elevated bleeding risk,
their clinical utility is insufﬁcient for use as evidence for
the recommendations in this guideline. The RIETE score
was developed from a large venous thromboembolism
cohort and includes 2 points for recent bleeding, 1.5
points for abnormal creatinine levels or anemia, and
1 point for each of the following: >75 years of age, cancer,
or pulmonary embolism at baseline. The ATRIA score
assigns points to the following variables: anemia, 3;
severe renal disease, 3; >75 years of age, 2; prior hemor-
rhage, 1; and hypertension, 1.
HAS-BLED (14,30) is a score based on the presence of
hypertension (systolic blood pressure >160 mmHg),
abnormal liver or renal function, history of stroke or
bleeding, labile INRs, elderly age (>65 years), use of drugs
that promote bleeding, or alcohol excess (209). A score $3
indicates potentially “high risk” for bleeding and may
require closer observation of a patient for adverse risks,
closer monitoring of INRs, or differential dose selections
of oral anticoagulants or aspirin. HAS-BLED is better at
discriminating risk than the HEMORR2HAGES or ATRIA
scoring systems are, but all 3 scores had C indexes <0.70
in the receiver operating curves, indicating only modest
performance and poor predictive accuracy (210).
4.2. Antithrombotic Options
Antithrombotic medications prevent strokes and systemic
emboli among patients with AF in part by reducing the
formation of platelet-rich or thrombotic clots in the LA or
LAA, from which the clots can embolize through the
systemic circulation to the brain or other sites. Strokeprevention trials (Figure 3) compared warfarin or aspirin
with placebo and compared aspirin with warfarin or
clopidogrel and aspirin. Warfarin was also compared with
dual antiplatelet agents (clopidogrel and aspirin). Trials
have also compared direct thrombin inhibitors and factor
Xa inhibitors with warfarin and, in 1 case, with aspirin.
Both primary and secondary stroke prevention have been
evaluated. The selection of an antithrombotic agent
should be based on shared decision making that takes
into account risk factors, cost, tolerability, patient pref-
erence, potential for drug interactions, and other clinical
characteristics, including time in the INR therapeutic
range if the patient has been on warfarin, irrespective
of whether the AF pattern is paroxysmal, persistent, or
permanent.
Meta-analyses have summarized the effect of antith-
rombotic therapies for stroke prevention in nonvalvular
AF. The largest meta-analysis identiﬁed 29 RCTs from
1996 to 2007 that tested antithrombotic therapies of
>12 weeks’ duration among 28 044 patients (184). Nine
trials were double-blind designs with a mean follow-up of
1.5 years per patient. The average age of the subjects was
71 years, and 35% of the subjects were women. Among
12 of the trials, 3003 subjects were randomized to placebo
or control, with an average stroke rate of 4.1% per year
among the primary prevention studies and 13% per year
among those with prior stroke or TIA.
4.2.1. Antiplatelet Agents
No studies, with the exception of the SPAF (Stroke Pre-
vention in Atrial Fibrillation)-1 trial, show beneﬁt for
aspirin alone in preventing stroke among patients with AF
(183,184,211). Antiplatelet therapy was compared with
placebo or no treatment in 8 trials with a total of 4876
subjects (184) (Figure 3). Seven of these 8 trials compared
different doses of aspirin ranging from 25 mg twice a day
to 1300 mg once a day (184). For primary prevention,
aspirin was associated with a 19% reduction (95% CI: 1%
to 35%) in stroke incidence with an absolute risk reduc-
tion of 0.8% per year (number needed to treat: 125). The
95% CI encompassed 0, which includes the possibility
that aspirin has no real effect on stroke reduction. For
secondary prevention among those with TIA or strokes,
aspirin was associated with an absolute risk reduction of
2.5% per year and a corresponding number needed to
treat of 40. It is important to recognize that the 19%
reduction in stroke incidence observed in this meta-
analysis was driven by positive results from only 1 of
these RCTs—the SPAF-1 trial. In this trial, aspirin was
prescribed at 325 mg once daily, and the impact of aspirin
was very heterogeneous between groups. Aspirin was
ineffective in preventing strokes in those >75 years of age
and did not prevent severe strokes. Moreover, aspirin has
not been studied in a population at low risk of AF.
FIGURE 3 Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular AF (Meta-Analysis)
ACTIVE-W indicates Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events-W; AF, atrial ﬁbrillation; AFASAK, Atrial Fibrillation,
Aspirin and Anticoagulant Therapy Study; ATAFS, Antithrombotic Therapy in Atrial Fibrillation Study; BAATAF, Boston Area Anticoagulation Trial for
Atrial Fibrillation; CAFA, Canadian Atrial Fibrillation Anticoagulation; CI, conﬁdence interval; EAFT, European Atrial Fibrillation Trial; ESPS, European Stroke
Prevention Study; JAST, Japan AF Stroke Prevention Trial; LASAF, Low-Dose Aspirin, Stroke, Atrial Fibrillation; NASPEAF, National Study for Prevention of
Embolism in Atrial Fibrillation; PATAF, Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation; SAFT, Swedish Atrial Fibrillation
Trial; SIFA, Studio Italiano Fibrillazione Atriale; SPAF, Stroke Prevention in Atrial Fibrillation Study; SPINAF, Stroke Prevention in Atrial Fibrillation; and
UK-TIA, United KingdomTransient Ischemic Attack.
Adapted with permission from Hart et al. (184).
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prevention in the ACTIVE (Atrial Fibrillation Clopidogrel
Trial With Irbesartan for Prevention of Vascular
Events)-W trial (198). This trial was terminated early
(before planned follow-up was completed) on the
recommendation of the Data Safety and Monitoring Board
because the combination of antiplatelet agents, clopi-
dogrel (75 mg once daily) plus aspirin (75 mg to 100 mg
once daily), proved inferior to warfarin (target INR 2.0 to
3.0) in patients with a mean CHADS2 score of 2. ACTIVE-W
found a 40% RR reduction (95% CI: 18% to 56%; p<0.001)
for stroke with warfarin compared with the dual
antiplatelet regimen. ACTIVE-A compared clopidogrelcombined with aspirin versus aspirin alone in patients
with AF who were unsuitable candidates for oral anti-
coagulation and who had $1 additional stroke risk
factor (199). The combination of clopidogrel and aspirin
resulted in a 28% RR reduction (95% CI: 17% to 38%;
p<0.0002) in all strokes compared with aspirin alone.
Major bleeding was signiﬁcantly greater with the combi-
nation and increased by 57% (95% CI: 29% to 92%;
p<0.001). The absolute differences between the treat-
ment arms were small, with major vascular events
decreased by 0.8% per year and major hemorrhages
increased by 0.7% per year. The results of ACTIVE-W and
ACTIVE-A demonstrate that adjusted-dose warfarin for
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e20stroke prevention is signiﬁcantly better than clopidogrel
plus aspirin, and clopidogrel plus aspirin is superior to
aspirin alone. The latter beneﬁts are dampened by the
signiﬁcant increase in major bleeding events. No direct
comparisons have been made between clopidogrel and
aspirin and the new oral anticoagulants that have lower
bleeding risks than warfarin. However, there is a direct
comparison between aspirin and the factor Xa inhibitor
apixaban in the AVERROES (Apixaban Versus Acetylsali-
cylic Acid to Prevent Strokes) study, a double-blind
study of 5599 patients deemed unsuitable for warfarin
therapy (189). Subjects were randomized to apixaban 5 mg
twice daily (2.5 mg twice daily for those who had 2 of the
following 3 factors: age $80 years, weight #60 kg, serum
creatinine $1.5 mg/dL) or to aspirin 81 mg or 325 mg once
daily. The primary outcome of the study was the occur-
rence of a stroke or systemic embolism. After a mean
follow-up of 1.1 years, the study was prematurely termi-
nated owing to the superiority of apixaban over aspirin
for preventing the primary outcome. Major bleeding risk
between the 2 treatments was similar.Intrinsic Pathway
(Contact Activation)
VKAs
XII
XI
IX
VIII
X
V
II
Fibrinogen
FIGURE 4 Coagulation Cascade
AT indicates antithrombin and VKAs, vitamin K antagonists.
Adapted with permission from Nutescu et al. (213).4.2.2. Oral Anticoagulants
See Online Data Supplement 3 for additional data and
evidence tables on warfarin versus aspirin and the new oral
anticoagulants.
4.2.2.1. Warfarin
Warfarin is a vitamin K antagonist in use since the 1950s
as an oral anticoagulant for stroke prevention in patients
with AF. Its multiple sites of action in the coagulation
cascade are shown in Figure 4. Among 6 RCTs of 2900
subjects in which adjusted-dose warfarin was compared
with placebo or no treatment, the mean INR ranged from
2.0 to 2.9 (184,212). Adjusted-dose warfarin resulted in a
64% RR reduction (95% CI: 49% to 74%) for ischemic and
hemorrhagic stroke compared with placebo. The absolute
risk reduction was 2.7% per year, which yielded a number
needed to treat of 37 for 1 year to prevent 1 stroke and
12 for patients with prior stroke or TIA (184).
A Cochrane Collaboration review of warfarin versus
placebo among subjects without prior cerebral events
found that warfarin was associated with a signiﬁcant riskTissue
Factor
Extrinsic Pathway
(Tissue Factor)
VII
Direct Thrombin Inhibitors
Dabigatran
Factor Xa Inhibitors (-AT)
Apixaban and Rivaroxaban
Fibrin Clot
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e21reduction in all strokes, ischemic stroke, and the combined
endpoint of stroke, MI, or vascular death (214). With an
ischemic stroke rate of 4% per year in the control group,
the absolute risk reduction was about 2.6% per year for
those with no prior stroke or TIA, or about 25 ischemic
strokes prevented in 1 year per 1000 subjects treated with
warfarin. The RR reductions were consistent across the
trials. Intracranial hemorrhage was not signiﬁcantly
increased among the subjects randomized to warfarin, but
the patient numbers were small and the CI wide.
For nonvalvular AF, 2 separate Cochrane Collaboration
reviews evaluated the efﬁcacy and safety of oral antico-
agulants compared with antiplatelet agents (215,216). One
review included those with no history of stroke or TIA and
the other those with a history of stroke or TIA. Among
9598 subjects with AF, the majority (90%) of whom had
no prior stroke or TIA, oral anticoagulants were associated
with a signiﬁcant reduction in all strokes and ischemic
strokes compared with antiplatelet agents. Assuming an
absolute stroke risk of 4% per year with antiplatelet
agents, approximately 19 strokes could be prevented per
year for every 1000 patients with AF treated with oral
anticoagulants. The risk of intracranial hemorrhage was
signiﬁcantly increased among those treated with oral
anticoagulants, but major extracranial hemorrhages were
not signiﬁcantly different. After excluding the ACTIVE-W
trial, which used clopidogrel and aspirin as the anti-
platelet agent comparison, oral anticoagulants were
signiﬁcantly associated with an increased risk of bleeding
(OR: 1.90; 95% CI: 1.07 to 3.39) (215). Similarly, amongFIGURE 5 Pooled Estimates of Stroke or Systemic Embolism in Patients Wi
ACTIVE W indicates Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevent
of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fib
Birmingham Atrial Fibrillation Treatment of the Aged Study; CI, conﬁdence inter
ROCKET AF, Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation; and SP
Adapted with permission from Agarwal et al. (224).patients with a prior history of stroke or TIA, oral anti-
coagulants compared with antiplatelet agents were asso-
ciated with signiﬁcant reductions in all major vascular
events and recurrent stroke. Bleeding risks—including for
any intracranial bleeds and major extracranial bleeds—
were increased with oral anticoagulants.
The BAFTA (Birmingham Atrial Fibrillation Treatment of
the Aged) study also evaluated the efﬁcacy of warfarin
among higher-risk elderly subjects >75 years of age (197).
BAFTA was designed to compare warfarin with aspirin for
the prevention of fatal and nonfatal stroke, intracranial
hemorrhage, and other clinically signiﬁcant arterial embo-
lism in a primary care population of patients $75 years of
age who had AF.Warfarin was superior in preventing stroke
or systemic embolism without a signiﬁcant increase in
bleeding risk. The annual risk of extracranial hemorrhage
was 1.4% in thewarfarin group and 1.6% in the aspirin group.
Despite strong evidence for the efﬁcacy of warfarin,
several limitations have led to it being underused (217–221).
The narrow therapeutic window and increased risk of
bleeding, including in the brain, have hindered broader
use, especially among the elderly. Interactions with other
drugs, effects of alterations in diet, and the requirement for
close monitoring with frequent blood tests have also made
the dosing of warfarin challenging for clinicians and
patients. Even in well-conducted clinical trials, the time in
therapeutic range (TTR) of those taking warfarin was
reported as 55% to 66% (177–179), whereas in some com-
munity settings, TTR has been reported as approximately
50% (222,223). Despite underutilization of warfarin amongth AF Treated With Warfarin
ion of Vascular Events-W; AF, atrial ﬁbrillation; Amadeus, Evaluating the Use
rillation; ARISTOTLE, Apixaban Versus Warfarin in Patients With AF; BAFTA,
val; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy;
ORTIF, Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation.
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meta-analysis of contemporary studies found risk of stroke
or systemic embolism estimated to be at 1.66% per year
for warfarin in patients with AF (224) (Figure 5).
See Online Data Supplements 4 and 5 for additional data
on warfarin and antiplatelet therapy.
4.2.2.2. New Target-speciﬁc Oral Anticoagulants
Dabigatran is the ﬁrst new oral anticoagulant approved by
the U.S. Food and Drug Administration (FDA) to reduce the
risk of stroke and systemic embolism in patients with
nonvalvular AF and is a direct thrombin inhibitor. Its site of
action in the coagulation cascade is shown in Figure 4.
Dabigatran was compared with warfarin in the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation
Therapy) trial, which was an open-label randomized com-
parison of dabigatran (110 mg or 150 mg twice daily in a
blinded fashion) with adjusted-dose warfarin in 18 113 pa-
tients over a median follow-up period of 2 years (177). The
mean CHADS2 score was 2.1 and the primary outcome was
stroke (of any type) and systemic embolism, with any major
hemorrhage being the primary safety outcome. Half of the
patients were naïve to oral anticoagulants. The mean TTR
for those randomized to warfarin was 64%. The primary
outcome was assessed ﬁrst for noninferiority followed by
superiority. For the primary outcomes, dabigatran 150 mg
twice daily was superior to warfarin, and dabigatran 110 mg
twice daily was noninferior to warfarin. When dabigatran
was compared with warfarin, the risk of hemorrhagic
strokes was also signiﬁcantly lower (74% lower) with both
the 110 mg and 150 mg doses. Major bleeding was signiﬁ-
cantly decreased with the 110 mg dose but not with the 150
mg dose. Both doses had lower rates of intracranial
bleeding and life-threatening bleeding, whereas gastroin-
testinal bleeding was higher in the 150 mg dose (1.6%
versus 1.0% per year) group. Dyspepsia was more frequent
for both doses. For secondary prevention of stroke, the
results were similar to the primary analysis but statistically
weaker because of smaller sample size (225).
Dabigatran is renally excreted, and patients with a CrCl
of <30 mL/min were excluded from the RE-LY trial. CKD
is associated with increased bleeding risk during both
dabigatran therapy and warfarin therapy (226). The FDA
approved the higher dose of 150 mg twice daily but not
the lower dose of 110 mg twice daily. The FDA also
approved a dose of 75 mg twice daily for those with low
CrCl (15 mL/min to 30 mL/min) based on pharmacological
modeling, but that dose was never clinically studied.
The RE-LY trial included subjects distributed equally
across stroke risk strata (CHADS2 score 0 to 1 in 31.8% of
subjects, 2 in 35.6%, and >2 in 32.5%). For the primary
efﬁcacy endpoint and intracranial bleeding, there was
similar efﬁcacy across the range of CHADS2 scores (177). In
patients <75 years of age, both doses of dabigatran wereassociated with less intracranial and extracranial bleeding
than warfarin; in patients $75 years of age, both doses
reduced intracranial bleeding. However, extracranial
bleeding was similar or more frequent compared with
warfarin (227). Higher CHADS2 scores were associated
with increased risks for stroke or systemic embolism,
bleeding, and death in patients with AF receiving oral
anticoagulants (228). The beneﬁts of dabigatran compared
with warfarin in terms of efﬁcacy and safety were similar
in patient groups with paroxysmal, persistent, and per-
manent AF (169). An FDA postmarket analysis of gas-
trointestinal and intracranial bleeding of dabigatran
compared with warfarin indicates that bleeding rates do
not appear to be higher for dabigatran (229).
A post hoc analysis of 1989 electrical cardioversions
found a very low rate of stroke within 30 days after the
procedure (0.6% for warfarin, 0.3% for dabigatran 150 mg
twice daily, and 0.8% for dabigatran 110 mg twice daily)
(230). Most subjects were treated with their assigned
medication for $3 weeks before cardioversion. TEE was
performed in 25% of subjects. There was no signiﬁcant
difference in the incidence of LAA thrombus (1.1% for
warfarin; and for dabigatran, 1.2% for 150 mg twice daily
and 1.8% for 110 mg twice daily) (230).
In the RE-LY trial, there appeared to be an imbalance of
MIs: 0.8%, 0.8%, and 0.6% per year for patients ran-
domized to dabigatran 150 mg twice daily, dabigatran 110
mg twice daily, or warfarin, respectively (P¼0.09) (72).
Absolute events were low in a population in which 31% of
randomized patients had objective evidence of CAD. A
meta-analysis of a dabigatran RCT found a statistically
signiﬁcant increase in risk of MI and acute coronary syn-
dromes (ACSs) in patients randomized to dabigatran (231).
Interpretation of these results should be made with
caution, given the multiple limitations of this type of
analysis, which include the use of different controls and
different patient populations.
Rivaroxaban is the second new oral anticoagulant
approved by the FDA for reduction of risk of stroke and
systemic embolism in patients with nonvalvular AF and is
a direct factor Xa inhibitor (Figure 4). It should be
administered as a single daily dose with the evening meal
to ensure adequate absorption. It is predominantly
excreted by the kidneys. The evidence leading to approval
was based on the RCT ROCKET AF (Rivaroxaban Versus
Warfarin in Nonvalvular Atrial Fibrillation), which
compared rivaroxaban (20 mg once daily, 15 mg once daily
if CrCl was 30 mL/min to 49 mL/min) with warfarin among
14 264 patients (178). ROCKET AF differed from RE-LY in
that it selected higher-risk patients with AF ($2 risk fac-
tors for stroke compared with 1 risk factor). Patients in
ROCKET AF were older and had a greater mean CHADS2
score of 3.47. Similar to other AF trials, the primary
outcome was any stroke or systemic embolism, and
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e23the primary hypothesis was noninferiority. Although
the primary analysis was prespeciﬁed as a per-protocol
analysis, the intention-to-treat analysis was also pre-
sented. The main safety outcome was clinically relevant
bleeding events. This was a double-blind trial, and the
patients receiving warfarin had a lower mean TTR of 55%.
The trial demonstrated noninferiority for rivaroxaban
compared with warfarin; however, in the intention-to-
treat analysis, superiority was not achieved (P¼0.12).
Major bleeding was similar for rivaroxaban and warfarin,
but less fatal bleeding and less intracranial hemorrhage
were found for rivaroxaban. At the end of the trial,
patients transitioning to open-label therapy had more
strokes with rivaroxaban than with warfarin. However,
the risk of stroke or noncentral nervous system embolism
after elective temporary discontinuation of rivaroxaban
compared with warfarin in the ROCKET AF trial did not
differ signiﬁcantly in a post hoc analysis (232). The risk of
stroke was similar for patients assigned to rivaroxaban
and warfarin. In ROCKET AF, a decline in renal function
was an independent predictor of stroke risk.
Apixaban is the third new oral anticoagulant approved by
the FDA for reduction of risk of stroke and systemic embo-
lism with nonvalvular AF and is another direct factor Xa
inhibitor (Figure 4). It is predominantly eliminated hepati-
cally and is highly protein bound. It has been investigated in
2 clinical trials. In the ARISTOTLE (Apixaban Versus Warfarin
in Patients With Atrial Fibrillation) trial, apixaban (5 mg
twice daily) was compared with warfarin in a double-blind
RCT of 18 201 patients with AF and a mean CHADS2 score
of 2.1 (179). Apixaban 2.5 mg twice daily was used among
patients with $2 of the following conditions: $80 years of
age, weight #60 kg, or a serum creatinine level $1.5 mg/dL.
As with the other new anticoagulant trials, the primary
outcome was any stroke or systemic embolism and the pri-
mary safety outcome was major bleeding. Patients were
followed for a mean of 1.8 years, and the mean age was 70
years. For patients treated with warfarin, the TTR was 62%.
Apixaban was signiﬁcantly better than warfarin, with fewer
overall strokes (both ischemic and hemorrhagic), systemic
emboli, and major bleeding events. Patients treated with
apixaban had signiﬁcantly fewer intracranial bleeds, but
gastrointestinal bleeding complications were similar
between the 2 study groups. Patients treated with apixaban
had fewer deaths than those on warfarin. In ARISTOTLE, the
beneﬁt of apixaban was independent of type of AF, risk
proﬁle, CHADS2 or CHA2DS2-VASc score, and whether there
was a prior stroke.
Apixaban was also compared with aspirin in the AVER-
ROES study, a double-blind study of 5599 patients deemed
unsuitable for warfarin therapy (189) (Section 4.2). The mean
CHADS2 score was 2, and 36% of the subjects had a CHADS2
score of 0 to 1. After a mean follow-up of 1.1 years, the study
was prematurely terminated due to the superiority ofapixaban compared with aspirin for preventing the occur-
rence of any stroke or systemic embolism, whereas bleeding
risk between the 2 treatments was similar.
Patients with severe and end-stage CKD (serum creat-
inine >2.5 mg/dL or CrCl <25 mL/min) were excluded
from the ARISTOTLE and AVERROES trials (179,189). On
the basis of new pharmacokinetic proﬁles in a limited data
set (233), prescribing recommendations for apixaban were
revised for use in patients with end-stage CKD who were
maintained on stable hemodialysis with the recom-
mended dose of 5 mg twice daily with a reduction in dose
to 2.5 mg twice daily for either age $80 years or body
weight #60 kg. For patients with severe or end-stage
CKD not on dialysis, a dose recommendation was not
provided. There are no published data for the use of
apixaban in these clinical settings.
Other factor Xa inhibitors, including edoxaban (234)
and betrixaban (235), are under evaluation but not yet
approved by the FDA.
4.2.2.3. Considerations in Selecting Anticoagulants
Selection of agents for antithrombotic therapy depends
on a large number of variables, including clinical factors,
clinician and patient preference, and, in some circum-
stances, cost. The new agents are currently considerably
more expensive than warfarin. However, dietary limita-
tions and the need for repeated INR testing are eliminated
with the new agents. If patients are stable, their condition
is easily controlled, and they are satisﬁed with warfarin
therapy, it is not necessary to change to a new agent.
However, it is important to discuss this option with
patients who are candidates for the new agents.
All 3 new oral anticoagulants represent important
advances over warfarin because they have more pre-
dictable pharmacological proﬁles, fewer drug–drug
interactions, an absence of major dietary effects, and less
risk of intracranial bleeding than warfarin. They have
rapid onset and offset of action so that bridging with
parenteral anticoagulant therapy is not needed during
initiation, and bridging may not be needed in patients on
chronic therapy requiring brief interruption of anti-
coagulation for invasive procedures. However, strict
compliance with these new oral anticoagulants is critical.
Missing even 1 dose could result in a period without
protection from thromboembolism. As a result, the FDA
issued black box warnings that discontinuation of these
new agents can increase the risk of thromboembolism and
that coverage with another anticoagulant may be needed.
In addition, reversal agents, while in development, are
not available, although the short half-lives lessen the
need for an antidote. Although dose adjustments may be
warranted for those with CKD or body weight extremes,
these new agents do not require regular monitoring of INR
or activated partial thromboplastin time.
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or hemodynamically signiﬁcant mitral stenosis were
excluded from all 3 major trials (RE-LY, ROCKET AF, and
ARISTOTLE) (80,89,90); therefore, these patients should
be managed with warfarin. Patients with aortic stenosis or
aortic insufﬁciency who, in the estimation of the local RCT
principal investigator, would not need a surgical proce-
dure before the conclusion of the trial were included. The
RE-ALIGN (Randomized, Phase II Study to Evaluate the
Safety and Pharmacokinetics of Oral Dabigatran Etexilate
in Patients After Heart Valve Replacement) trial, a phase 2
dose-range study of the use of dabigatran compared with
warfarin in patients with mechanical heart valves, was
stopped because dabigatran users were more likely
to experience strokes, MI, and thrombus forming on
the mechanical heart valves than were warfarin users
(190,236,237). There was also more bleeding after valve
surgery in the dabigatran users than in the warfarin users;
thus, dabigatran is contraindicated for use in patients with
mechanical heart valves. Similar drug safety and efﬁcacy
information is lacking for rivaroxaban and apixaban and
mechanical heart valves. Bioprosthetic heart valves have
not been studied with any of the new anticoagulants.
None of the 3 major trials included pregnant or lactating
women, children, patients with reversible causes of AF, or
patients with severe hypertension (systolic blood pressure
>180 mmHg or diastolic blood pressure >100 mmHg).
Patients with a recent stroke (within 7 to 14 days), patients
with signiﬁcant liver disease, and complex patients with
multiple chronic conditions were excluded from all trials.TABLE 8
Dose Selection of Oral Anticoagulant Options for Pati
(Based on Prescribing Information for the United Stat
Renal Function Warfarin (238) Dabigatran† (1
Normal/mild impairment Dose adjusted for
INR 2.0–3.0
150 mg BID
(CrCl >30 mL/m
Moderate impairment Dose adjusted for
INR 2.0–3.0
150 mg BID
(CrCl >30 mL/m
Severe impairment Dose adjusted for
INR 2.0–3.0§
75 mg BIDk
(CrCl 15–30 mL/m
End-stage CKD not on dialysis Dose adjusted for
INR 2.0–3.0§
Not recommend
(CrCl <15 mL/m
End-stage CKD on dialysis Dose adjusted for
INR 2.0–3.0§
Not recommend
(CrCl <15 mL/m
*Renal function should be evaluated before initiation of direct thrombin or factor Xa inhibitors
measured using the Cockcroft-Gault method.
†The concomitant use of P-glycoprotein inducers or inhibitors with dabigatran or the concom
rivaroxaban or apixaban, particularly in the setting of CKD, may require dosing adjustment or a
gov/drugsatfda_docs/label/2014/202155s002lbl.pdf, Section 8.6).
‡Use apixaban 2.5 mg BID if any 2 patient characteristics are present: Cr $1.5 mg/dL, $80 y o
hepatic impairment.
§Dose-adjusted warfarin has been used, but observational data on safety and efﬁcacy are co
kModeling studies suggest that dabigatran 75 mg BID might be safe for patients with CrCl 1
outside the United States use 110 mg BID (177).
¶No published studies support a dose for this level of renal function.
#In patients with end-stage CKD on stable hemodialysis, prescribing information indicates the
or body weight is #60 kg.
AF indicates atrial ﬁbrillation; BID, twice daily; CKD, chronic kidney disease; Cr, creatini
normalized ratio; and QD, once daily.For patients with CKD, dose modiﬁcations of the new
agents are available (Table 8); however, for those with
severe or end-stage CKD, warfarin remains the anticoag-
ulant of choice, as there are no or very limited data for
these patients. Among patients on hemodialysis, warfarin
has been used with acceptable risks of hemorrhage (185).
The price of an effective anticoagulant is the risk of
bleeding, which, if extracranial, is usually not life-
threatening. Although INR and activated partial thrombo-
plastin time increase with dabigatran, this is not in a
linear fashion and cannot be used to monitor the level
of anticoagulation. The Hemoclot (HYPHEN BioMed,
Neuville-sur-Oise, France) thrombin clotting time is a more
accurate measure of anticoagulation levels, but the test is
not approved in the United States and is not widely
available elsewhere (94). If bleeding or overdose occurs,
the anticoagulant agent should be discontinued. The use of
activated charcoal to reduce absorption may be consid-
ered. Dabigatran is dialyzable, but apixaban and rivarox-
aban are not, and both are highly plasma protein bound.
Dabigatran, rivaroxaban, and apixaban are substrates
for the efﬂux transporter P-glycoprotein. P-glycoprotein
inhibitors, such as ketoconazole, verapamil, amiodarone,
dronedarone, quinidine, and clarithromycin, may in-
crease plasma concentrations. In addition, P-glycoprotein
inducers (such as phenytoin, carbamazepine, rifampin,
and St. John’s wort) can decrease levels of these drugs to
subtherapeutic blood levels, and coadministration should
be avoided. Absorbed dabigatran etexilate is “pumped”
back into the intestinal tract. Dabigatran also can causeents With Nonvalvular AF and CKD
es)*
77) Rivaroxaban† (178) Apixaban† (179)
in)
20 mg QD with the evening meal
(CrCl >50 mL/min)
5.0 or 2.5 mg BID‡
in)
15 mg QD with the evening meal
(CrCl 30–50 mL/min)
5.0 or 2.5 mg BID‡
in)
15 mg QD with the evening meal
(CrCl 15–30 mL/min)
No recommendation.
See Section 4.2.2.2¶
ed¶
in)
Not recommended¶
(CrCl <15 mL/min)
No recommendation.
See Section 4.2.2.2¶
ed¶
in)
Not recommended¶
(CrCl <15 mL/min)
No recommendation.
See Section 4.2.2.2¶#
and should be reevaluated when clinically indicated and at least annually. CrCl should be
itant use of dual P-glycoprotein and strong CYP3A4 inducers or inhibitors with either
voidance of concomitant drug use (see the FDA drug label at http://www.accessdata.fda.
f age, body weight #60 kg (179). Apixaban is not recommended in patients with severe
nﬂicting.
5–30 mL/min, but this has not been validated in a prospective cohort. Some countries
use of apixaban 5 mg BID with dose reduction to 2.5 mg BID if the patient is$80 y of age
ne; CrCl, creatinine clearance; FDA, Food and Drug Administration; INR, international
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e25dyspepsia. Coprescription with a proton pump inhibitor
can mildly reduce dabigatran peak concentrations; how-
ever, dose adjustment is not warranted (239). Rivarox-
aban and apixaban are contraindicated with drugs that are
combined P-glycoprotein and strong P450 3A4 (CYP3A4)
inducers.
Although the new oral anticoagulant trials were similar
in design and inclusion/exclusion criteria, it is difﬁcult to
make comparisons between the agents to judge differen-
tial efﬁcacy in the absence of direct comparisons.
4.2.2.4. Silent AF and Stroke
Clinically unrecognized and asymptomatic AF is a poten-
tially important cause of stroke, supporting efforts for early
detection of AF in at-risk individuals. Episodes of asymp-
tomatic AF are potentially detectable from implantable
arrhythmia management devices (pacemakers or deﬁbri-
llators) that have an atrial lead and can be programmed to
record the number, duration, and frequency of atrial rates
that exceed a certain threshold and, in some cases, also
provide stored electrograms for analysis. These devices
typically report “atrial high-rate events.”Whether the high-
rate event is AF, atrial ﬂutter, or an atrial tachycardia is not
necessarily discernible. Patients receiving arrhythmia
management devices often have risk factors for AF. Atrial
high-rate episodes have been observed in 10% to 28% of
patients who have no prior history of AF (61,191).
The ASSERT (Asymptomatic Atrial Fibrillation and
Stroke Evaluation in Pacemaker Patients and the Atrial
Fibrillation Reduction Atrial Pacing Trial) trial enrolled
2580 patients $65 years of age with hypertension and no
history of AF in whom a pacemaker or deﬁbrillator was
recently implanted. During the ﬁrst 3 months, 10% of
subjects had atrial high-rate episodes of >190 bpm
for >6 minutes (61). These high-rate episodes were asso-
ciated with a >5-fold increase in subsequent diagnosis of
atrial arrhythmia on ECG and a 1.60% per year rate of
stroke or systemic embolism compared with a 0.69% per
year rate for those without high-rate episodes during the
ﬁrst 3 months. In a subgroup analysis of the MOST (Mode
Selection Trial in Sinus Node Dysfunction) trial, patients
with atrial high-rate episodes (rate >220 bpm for >10
beats detected by a pacemaker) were more than 2 times as
likely to die or have a stroke and 6 times as likely to be
subsequently diagnosed with AF as similar patients
without atrial high-rate events (193). In a prospective
study of 2486 patients receiving arrhythmia management
devices who had $1 AF risk factor for stroke—20% of
whom had a history of AF—patients with atrial tachy-
cardia/AF burden (deﬁned as the longest total atrial
tachycardia/AF duration on any given day during the prior
30-day period) >5.5 hours had a thromboembolism rate of
2.4% per year compared with 1.1% per year for those with
less or no atrial tachycardia/AF burden (194). In a study of560 patients with HF, the recording of atrial high-rate
events lasting >3.8 hours in 1 day was associated with a
9-fold increased thromboembolic event rate (240).
Additional studies are needed to further clarify the rela-
tionship between stroke risk and atrial high-rate episodes
detected by implanted devices and to deﬁne key char-
acteristics of atrial high-rate episodes in patients who war-
rant further investigation or potentially therapy (192,194).
4.3. Interruption and Bridging Anticoagulation
Interruption of anticoagulation is often considered for
patients with AF who have episodes of bleeding or require
surgical or interventional procedures associated with a
bleeding risk. There is sparse evidence on which to base
speciﬁc recommendations on bridging oral anticoagulants
among patients with nonvalvular AF with adjusted-dose
heparin or LMWH (241); however, additional studies (e.g.,
BRIDGE [Bridging Anticoagulation in Patients who Require
Temporary Interruption of Warfarin Therapy for an Elec-
tive Invasive Procedure or Surgery]) are ongoing (242). The
duration of interruption and timing of resumption of
anticoagulation after the procedure are guided by indi-
vidualized consideration of the risk of thrombotic events
and the severity of the operative and perioperative
bleeding risk. For patients who are treated with warfarin
and who are at low risk of thromboemboli or those who are
back in normal sinus rhythm and are undergoing surgical
or diagnostic procedures that carry a risk of bleeding,
stopping warfarin for up to 1 week and allowing the INR to
normalize without substituting UFH is a recognized
approach. Warfarin is then resumed after adequate he-
mostasis has been achieved. For patients at higher risk
of thromboembolism (mechanical valves, prior stroke,
CHA2DS2-VASc score $2), bridging with UFH or LMWH is a
common practice, although data for LMWH are limited
(22). An increasingly common approach, especially for
pacemaker or implantable cardioverter-deﬁbrillator im-
plantation, catheter ablation, coronary angiography, and
other vascular interventions, is to perform the pro-
cedure without interrupting warfarin (241,243–247). Radi-
ofrequency catheter ablation of AF performed with a
therapeutic INR does not increase bleeding risk and re-
duces the risk of emboli (243,244). Pacemaker or deﬁbril-
lator implantation with a therapeutic INR has a lower risk
of postoperative bleeding than discontinuing warfarin and
initiating bridging anticoagulation with UFH or LMWH and
may be considered in those patients requiring device im-
plantation who also have a moderate-to-high thrombo-
embolic risk (241,245–250).
For oral factor Xa inhibitors and direct thrombin in-
hibitors, there is limited experience with drug withdrawal
before surgical procedures (244). In the ROCKET AF trial,
rivaroxaban was held for 2 days before elective surgery or
invasive procedure and for 24 hours before semiurgent
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weighed carefully against the urgency of surgery or an
invasive procedure. Interruption of anticoagulation
should be guided by the pharmacological properties of the
drug. The timing of resumption should take into account
the fact that anticoagulation, in contrast to warfarin, is
achieved promptly and that reversal agents are not yet
available for these agents, which complicates manage-
ment if bleeding occurs. For elective surgery, holding
these agents for 1 day (2 doses for dabigatran and apix-
aban; 1 dose for rivaroxaban) before the procedure is
generally sufﬁcient for patients with normal renal func-
tion (239). Also, for patients with normal renal function,
the need for complete hemostasis (e.g., for spinal punc-
ture, spinal/epidural catheter, or major surgery) will
require discontinuation for $48 hours. An activated par-
tial thromboplastin time for dabigatran and prothrombin
time for apixaban and rivaroxaban may provide useful
information; a level close to control suggests a low serum
concentration of these agents. For patients undergoing
catheter ablation or any procedure in which perforation of
the heart chamber is possible, these new agents must be
used with caution because of the lack of approved anti-
dotes in the event of cardiac tamponade. In some cases,
activated prothrombin complex concentrate and recom-
binant factor VIIa have been used to reverse the antico-
agulant effects of these new agents. Speciﬁc reversal
agents are not currently available but are in development.
Whether hemostasis will be easier and safer for coronary
interventions done by a radial artery approach rather than
a femoral approach is not known. The use of bare-metal
stents or coronary artery bypass surgery in preference to
drug-eluting stents where concomitant long-term use of
dual antiplatelet agents is anticipated and might increase
bleeding risk is a reasonable consideration when long-
term therapy with these anticoagulants is desired.
In patients undergoing percutaneous coronary inter-
vention, dual antiplatelet therapy with aspirin and
clopidogrel is indicated to prevent stent thrombosis. The
combination of oral anticoagulants and antiplatelet ther-
apy (“triple therapy”) is associated with a high annual risk
of fatal and nonfatal bleeding episodes (251–254). Recently,
in patients taking oral anticoagulants undergoing percu-
taneous coronary intervention, the efﬁcacy and safety of
antiplatelet therapy with aspirin and clopidogrel versus
clopidogrel alone were studied (186). The use of clopi-
dogrel without aspirin was associated with a reduction in
bleeding and no increase in the rate of thrombotic events.
4.4. Nonpharmacological Stroke Prevention
4.4.1. Percutaneous Approaches to Occlude the LAA
The LAA is the primary source for thromboembolism in AF
(255). Exclusion of the LAA, both surgically and with
devices, has been attempted with the goal of reducingthromboembolism in patients with AF. There are 2 general
approaches to occlude the LAA using percutaneous strate-
gies. The ﬁrst involves implantable devices that are inserted
percutaneously into the LAA with the goal of occluding or
plugging the LAA. Devices for LAA occlusion include the
WATCHMAN device (Boston Scientiﬁc, Natick, MA) and the
Amplatzer cardiac plug (St. Jude Medical, Plymouth, MN).
The WATCHMAN device is deployed percutaneously via
transseptal puncture and has a polyethylene membrane
that covers a self-expanding nitinol cage with barbs to an-
chor the device in the LAA (256). The early ﬁndings for the
WATCHMAN device suggest noninferiority to warfarin for
the composite endpoint of stroke, systemic embolism, and
cardiovascular death; however, early adverse events occur
in approximately 10% of patients, including pericardial
bleeding. Longer-term follow-up of the WATCHMAN device
at 1588 patient-years suggests noninferiority of this device
to warfarin (256). A subsequent registry study demonstrated
that the WATCHMAN device achieved noninferiority in
patients who could not receive warfarin (257). Lastly, data
from subsequent experience with the WATCHMAN device
suggest that the earlier device-related complications were
mitigated with increasing operator experience (258).
The Amplatzer cardiac plug, which has Conformité
Européenne Mark approval, consists of a small proximal
disc, a central polyester patch, and a larger distal disc with
hooks to anchor the device in the LAA. It does not require
anticoagulation. A European-based trial found a 96%
success rate for deployment/implantation but with a 7%
incidence of serious complications (259). The second
strategy is to tie off the LAA using an epicardial snare,
referred to as the LARIAT device (SentreHEART, Redwood
City, CA). This device received FDA approval in 2009 for
facilitation of suture placement and knot tying for use
in surgical applications in which soft tissues are being
approximated. It has been adapted for use in AF and
combines a percutaneous epicardial and endocardial
approach. The initial experience with this device appeared
promising, with 97% acute obliteration of the LAA as
conﬁrmed by TEE and a favorable safety proﬁle (260). The
long-term outcomes of use of the LARIAT device, re-
quiring RCTs to study reduced stroke risk and safety, are
not yet deﬁned. The device requires subxiphoid pericar-
dial access that may not be achievable in the presence of
pericardial adhesions, it can provoke pericarditis that can
be severe, and it is not suitable for all LAA anatomies. It is
not yet clear if occluding the LAA with the LARIAT device
lowers stroke risk. Additional devices are in development.
4.4.2. Cardiac Surgery—LAA Occlusion/Excision:
Recommendation
CLASS IIb
1. Surgical excision of the LAA may be considered in patients
undergoing cardiac surgery. (Level of Evidence: C)
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surgery are controversial for several reasons. What should
seem technically simple and reproducible—removal of the
LAA—yields inconsistent results, and the anatomy of the LAA
is quite variable (261). The circumﬂex coronary artery lies
proximate to the base of the LAA, and epicardial and
endocardial-based surgical techniques to occlude the LAA
are often inadequate because of surgeons’ concern about
damage to the circumﬂex artery during a suture-based
closure of the appendage. Epicardial techniques include
simple suture ligation, oversewing the base without excision,
excising the appendage and oversewing the base, and
surgical stapling and excision (262). One device, the Gillinov-
Cosgrove clip LAA exclusion system, has FDA approval (263).
Endocardial techniques include inversion of the appendage,
amputation, and then oversewing the base from the endo-
cardial aspect (262).
The results of surgical occlusion of the LAA remain
suboptimal, with echocardiographic follow-up suggest-
ing incomplete occlusion in $50% of subjects. In the
largest study to examine the success of LAA ligation,
2546 patients undergoing TEE between 1993 and 2004
were retrospectively examined (264); 137 patients
underwent a surgical attempt at LAA occlusion. Of
these 137 patients, 52 underwent excision and 85
underwent exclusion (by either suture or stapling).
TEE-deﬁned unsuccessful closures were characterized
by either persistent ﬂow into the LAA, a remnant stump
of >1.0 cm of the LAA, or color Doppler ﬂow into the
LAA. Overall, 55 of 137 closures were successful (40%).
Success varied with the technique used: for excision,
the success rate was 73%; for suture exclusion, 23%;
and for stapling, 0%. Particularly noteworthy is that
thrombus was identiﬁed in $25% of patients with
unsuccessful LAA occlusion with suture exclusion or
stapled LAA remnants. This latter ﬁnding constitutes
important data guiding the continued need for anti-
coagulation in patients who have undergone surgical
LAA ligation.
It is unclear whether occlusion of the LAA at the time
of concomitant heart surgery contributes to the success
and efﬁcacy of occlusion in terms of stroke prevention.
The LAAOS (Left Atrial Appendage Occlusion Study)
randomized 77 patients with risk factors for stroke to LAA
closure or control at the time of coronary artery bypass
surgery (265). During this trial, suture-based or staple-
based occlusion was permitted; the success of LAA
closure in the suture group was 45% versus 72% in the
stapled group. Nine appendage tears occurred during the
trial (1 control and 8 treatments), but these tears did not
contribute to mortality or morbidity. There were 2
thromboembolic events in the occlusion group and none
in the control. The authors concluded that LAA occlusion
could be performed safely; however, larger randomizedstudies are needed to determine whether LAA occlusion
could reduce stroke risk in patients with risk factors for
AF who undergo non–AF-related cardiac surgery. In a
retrospective cohort of 205 patients with echocardiogra-
phy following mitral valve replacement, 58 patients un-
derwent LAA ligation as judged by transthoracic
echocardiogram. Of these 58 patients, 52 had a complete
ligation of the LAA, as deﬁned by lack of color Doppler
ﬂow from the body of the LA into the appendage, and 6
had persistent ﬂow. The principal ﬁnding was that lack of
and incomplete LAA occlusion were both strongly asso-
ciated with the occurrence of a thromboembolic event
(266).
In summary, the current data on LA occlusion at the
time of concomitant cardiac surgery reveal a lack of clear
consensus because of the inconsistency of techniques
used for surgical excision, the highly variable rates of
successful LAA occlusion, and the unknown impact of
LAA occlusion on future thromboembolic events.5. RATE CONTROL: RECOMMENDATIONS
See Table 9 for a summary of recommendations for this
section.
CLASS I
1. Control of the ventricular rate using a beta blocker or
nondihydropyridine calcium channel antagonist is recom-
mended for patients with paroxysmal, persistent, or per-
manent AF (267–269). (Level of Evidence: B)
2. Intravenous administration of a beta blocker or non-
dihydropyridine calcium channel blocker is recommended
to slow the ventricular heart rate in the acute setting
in patients without pre-excitation. In hemodynamically
unstable patients, electrical cardioversion is indicated
(270–273). (Level of Evidence: B)
3. In patients who experience AF-related symptoms during
activity, the adequacy of heart rate control should be
assessed during exertion, adjusting pharmacological treat-
ment as necessary to keep the ventricular rate within the
physiological range. (Level of Evidence: C)
CLASS IIa
1. A heart rate control (resting heart rate <80 bpm) strategy is
reasonable for symptomatic management of AF (269,274).
(Level of Evidence: B)
2. Intravenous amiodarone can be useful for rate control in
critically ill patients without pre-excitation (275–277). (Level
of Evidence: B)
3. AV nodal ablation with permanent ventricular pacing is
reasonable to control heart rate when pharmacological
therapy is inadequate and rhythm control is not achievable
(278–280). (Level of Evidence: B)
TABLE 9 Summary of Recommendations for Rate Control
Recommendations COR LOE References
Control ventricular rate using a beta blocker or nondihydropyridine calcium channel antagonist for paroxysmal, persistent,
or permanent AF
I B (267–269)
IV beta blocker or nondihydropyridine calcium channel blocker is recommended to slow ventricular heart rate in the acute
setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated
I B (270–273)
For AF, assess heart rate control during exertion, adjusting pharmacological treatment as necessary I C N/A
A heart rate control (resting heart rate <80 bpm) strategy is reasonable for symptomatic management of AF IIa B (269,274)
IV amiodarone can be useful for rate control in critically ill patients without pre-excitation IIa B (275–277)
AV nodal ablation with permanent ventricular pacing is reasonable when pharmacological therapy is inadequate and
rhythm control is not achievable
IIa B (278–280)
A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable when patients remain asymptomatic
and LV systolic function is preserved
IIb B (274)
Oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated IIb C N/A
AV nodal ablation should not be performed without prior attempts to achieve rate control with medications III: Harm C N/A
Nondihydropyridine calcium channel antagonists should not be used in decompensated HF III: Harm C N/A
With pre-excitation and AF, digoxin, nondihydropyridine calcium channel antagonists, or amiodarone should not be
administered
III: Harm B (281)
Dronedarone should not be used to control ventricular rate with permanent AF III: Harm B (282,283)
AF indicates atrial ﬁbrillation; AV, atrioventricular; bpm, beats per minute; COR, Class of Recommendation; HF, heart failure; IV, intravenous; LOE, Level of Evidence;
LV, left ventricular; and N/A, not applicable.
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1. A lenient rate-control strategy (resting heart rate <110 bpm)
may be reasonable as long as patients remain asymptomatic
and LV systolic function is preserved (274). (Level of
Evidence: B)
2. Oral amiodarone may be useful for ventricular rate control
when other measures are unsuccessful or contraindicated.
(Level of Evidence: C)
CLASS III: HARM
1. AV nodal ablation with permanent ventricular pacing should
not be performed to improve rate control without prior
attempts to achieve rate control with medications. (Level of
Evidence: C)
2. Nondihydropyridine calcium channel antagonists should not be
used in patients with decompensated HF as these may lead to
further hemodynamic compromise. (Level of Evidence: C)
3. In patients with pre-excitation and AF, digoxin, non-
dihydropyridine calcium channel antagonists, or intravenous
amiodarone should not be administered as they may increase
the ventricular response and may result in ventricular
ﬁbrillation (281). (Level of Evidence: B)
4. Dronedarone should not be used to control the ventricular
rate in patients with permanent AF as it increases the risk of
the combined endpoint of stroke, MI, systemic embolism, or
cardiovascular death (282,283). (Level of Evidence: B)
Rate control in AF is an important strategy. It impacts
quality of life, reduces morbidity, and decreases the
potential for developing tachycardia-induced cardiomy-
opathy. Multiple agents, including beta blockers, non-
dihydropyridine calcium channel blockers, digoxin, andcertain antiarrhythmic drugs, including amiodarone and
sotalol, have been evaluated with regard to efﬁcacy in
attaining rate control. This information is summarized in
Table 10. When considering which agent(s) to use, clini-
cians must consider the patient’s degree of symptoms,
hemodynamic status, presence or absence of HF, and
potential precipitants of AF. When evaluating the evi-
dence supporting different agents, clinicians must
recognize that most clinical trials were performed in the
1980s and 1990s and have study design limitations that
include variable endpoints, small sample sizes, and
single-site study and observational trial designs. Issues to
consider include the acuity of attaining rate control,
which agent(s) to administer, and the degree of rate
control required. Over the last 40 years, several themes
have emerged. In general, beta blockers are the most
common agents used for rate control, followed by non-
dihydropyridine calcium channel blockers, digoxin, and
amiodarone. Patient comorbidities must be understood to
avoid medications that may precipitate adverse events
such as decompensation of HF, exacerbation of chronic
obstructive pulmonary disease, or acceleration of con-
duction in patients with pre-excitation.
When rapid control of ventricular rate during AF is
required, intravenous medications or electrical cardiover-
sion may be used. Electrical cardioversion is preferred in
patients with decompensated HF, ongoing myocardial
ischemia, or hypotension, although this may carry an in-
creased thromboembolic risk in patients with inadequate
anticoagulation or for whom AF is of uncertain duration.
In hemodynamically stable patients with a rapid ventric-
ular response, oral medications may be administered.
TABLE 10 Common Medication Dosage for Rate Control of AF
Intravenous Administration Usual Oral Maintenance Dose
Beta blockers
Metoprolol tartrate 2.5–5.0 mg IV bolus over 2 min; up to 3 doses 25–100 mg BID
Metoprolol XL (succinate) N/A 50–400 mg QD
Atenolol N/A 25–100 mg QD
Esmolol 500 mcg/kg IV bolus over 1 min, then 50–300 mcg/kg/min IV N/A
Propranolol 1 mg IV over 1 min, up to 3 doses at 2-min intervals 10–40 mg TID or QID
Nadolol N/A 10–240 mg QD
Carvedilol N/A 3.125–25 mg BID
Bisoprolol N/A 2.5–10 mg QD
Nondihydropyridine calcium channel antagonists
Verapamil 0.0750.15 mg/kg IV bolus over 2 min; may give an additional 10.0 mg
after 30 min if no response, then 0.005 mg/kg/min infusion
180–480 mg QD (ER)
Diltiazem 0.25 mg/kg IV bolus over 2 min, then 515 mg/h 120–360 mg QD (ER)
Digitalis glycosides
Digoxin 0.25 mg IV with repeat dosing to a maximum of 1.5 mg over 24 h 0.125–0.25 mg QD
Others
Amiodarone* 300 mg IV over 1 h, then 10–50 mg/h over 24 h 100–200 mg QD
*Multiple dosing schemes exist for the use of amiodarone.
AF indicates atrial ﬁbrillation; BID, twice daily; ER, extended release; IV, intravenous; N/A, not applicable; QD, once daily; QID, 4 times a day; and TID, 3 times a day.
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5.1.1. Beta-Adrenergic Receptor Blockers
By blocking sympathetic tone, beta blockers are useful for
ventricular rate control in patients with AF. Beta blockers,
including esmolol, propranolol, and metoprolol, are effec-
tive when administered intravenously in the setting of
acute AF (270,273,284). Orally administered beta blockers,
including atenolol, metoprolol, nadolol, propranolol, as
well as the antiarrhythmic drug sotalol, have all been
effectively used for ongoing ventricular rate control in pa-
tients with chronic AF. There is less published literature on
rate control of AF with additional beta blockers. In the
AFFIRM (Atrial Fibrillation Follow-Up Investigation of
Rhythm Management) study, beta blockers were the most
effective and commonly used drug class for rate control
(70% on beta blocker versus 54% on calcium channel
blocker) (269). In patients with HF, carvedilol had efﬁcacy
for heart rate control and, in combination with digoxin,
resulted in improved LV function (285). Combination ther-
apy of beta blockers with other agents, including digoxin, is
effective in ventricular rate control; however, drugs should
be titrated to avoid excessive bradycardia (267).
See Online Data Supplement 6 for additional data on
beta blockers.
5.1.2. Nondihydropyridine Calcium Channel Blockers
Diltiazem and verapamil have direct AV nodal effects,
blocking L-type calcium channels, and are used for ventric-
ular rate control in both acute and chronic AF. In the setting
of acute AF, intravenous administration of diltiazem wassafe and effective in controlling ventricular response in 83%
of patients (271). Intravenous verapamil is also effective in
establishing acute ventricular rate control (273,286,287).
Unless immediate rate control is required or an enteral route
of administration is not available, oral administration is
appropriate. Both verapamil and diltiazem reduce resting
and exercise heart rate and can improve exercise tolerance
(288). These nondihydropyridine calcium channel blockers
should not be used in patients with LV systolic dysfunction
and decompensated HF because of their negative inotropic
effects, but they may be used in patients with HF with pre-
served LV systolic function. In addition, these agents should
not be used in patients with pre-excitation and AF due to the
potential for shortening bypass tract refractoriness, which
may accelerate the ventricular rate to precipitate hypoten-
sion or ventricular ﬁbrillation (281,289) (Section 7.8).
See Online Data Supplement 7 for additional data on
nondihydropyridine calcium channel blockers.
5.1.3. Digoxin
Digoxin is not usually ﬁrst-line therapy for ventricular rate
control in patients with AF, despite its common use.
Although intravenous digoxin does slow the ventricular
response, onset of action requires>1 hour and the effect does
not peak until approximately 6 hours after initial adminis-
tration. Therefore, it is not an optimal agent when rapid rate
control is desired (290). During chronic oral therapy, digoxin
reduces the resting heart rate, but it is ineffective at con-
trolling the ventricular response during exercise (267).
Digoxin may be combined with beta blockers or
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ventricular rate control during exercise (267,291,292), and it
has been used in HF as 1 of the few rate control agents that
does not have negative inotropic effects. Adverse effects of
digoxin include AV block, ventricular arrhythmias, and,
infrequently, aggravation of sinus node dysfunction. Dose
adjustment is required in patients with renal dysfunction, the
elderly, and in the presence of drugs that reduce its excre-
tion, such as amiodarone, propafenone, or non-
dihydropyridine calcium channel blockers. Therefore,
periodic assessment of serum levels is warranted in many
patients. Studies ﬁnding an association between digoxin
therapy and mortality raise further concern about its use,
particularly long term (293,294). In the AFFIRM trial, digoxin
was associated with an increase in mortality, which in post
hoc analysis was irrespective of sex or HF (295). Arrhythmias,
which are dose related, are a potential source of mortality; in
the DIG (Digitalis Investigation Group) trial, serum levels
>0.9 ng/mL were associated with increased mortality (296).
However, in another AFFIRM subgroup propensity-matched
analysis with paroxysmal and persistent AF, there was no
increase in mortality or hospitalization in those taking
digoxin as baseline initial therapy (297). Because it can
shorten cardiac action potential duration, digoxin should not
be used as sole therapy in patients with pre-excitation.
See Online Data Supplement 8 for additional data
on digoxin).
5.1.4. Other Pharmacological Agents for Rate Control
Amiodarone exerts sympatholytic and calcium antago-
nistic properties that can depress AV nodal conduc-
tion. Although intravenous amiodarone can be used in
critically ill patients without pre-excitation to attain
ventricular rate control, it is less effective than non-
dihydropyridine calcium channel blockers (272,298) and
requires a longer time to achieve rate control (7 hours
versus 3 hours for diltiazem). There are limited data on
the efﬁcacy of chronic oral therapy with amiodarone for
rate control during persistent AF, but in 1 small trial it had
similar efﬁcacy to digoxin (299). Amiodarone is uniquely
lipid soluble. Its onset of action can be accelerated by a
high-dose amiodarone-loading regimen, but there is the
potential for worsening hemodynamics in patients with
recent decompensated HF or hypotension. Intravenous
amiodarone does not have the same electrophysiological
effects as oral amiodarone (300), and intravenous amio-
darone has the potential to accelerate the ventricular
response and precipitate fatal arrhythmias in patients
with AF and pre-excitation (301,302). Amiodarone has
many potential toxicities and drug interactions that limit
its long-term use for control of ventricular rate.
Dronedarone, which lacks iodine moieties of amiodar-
one, slows the resting rate in AF by an average of 12 bpm
and also improves exercise heart rate control (303);however, it should not be used for rate control in per-
manent AF, as it was found to increase rates of HF, stroke,
cardiovascular death, and unplanned hospitalization
(282). Furthermore, dronedarone should not be used for
ventricular rate control in patients with HF and LV
systolic dysfunction because it increases the likelihood of
the combined endpoint of stroke, MI, systemic embolism,
or cardiovascular death (282,283).
See Online Data Supplement 9 for additional data on
pharmacological agents for rate control.
5.2. AV Nodal Ablation
AV nodal ablation with permanent pacemaker implantation
effectively controls and regularizes ventricular heart rate
and, in selected patients, improves symptoms. Patients most
likely to beneﬁt include those with tachycardia-induced
cardiomyopathy with ventricular rate control refractory to
medical therapy (280,304–307). AV nodal ablation is usually
reserved for elderly patients, because it leads to pacemaker
dependency. Patients with symptoms refractory to medical
therapy who are treated with AV nodal ablation and per-
manent pacemaker implantation have an improvement in
cardiac symptoms, quality of life, and health care utilization.
With this approach, no rate-control medications are neces-
sary, but anticoagulation to prevent thromboembolism is
required, based on the patient’s stroke risk as assessed by the
CHA2DS2-VASc system. When this approach is under
consideration, the patient must receive counseling to un-
derstand that this is an irreversible measure that results in a
lifelong pacemaker dependency with its potential compli-
cations. Time permitting, pacemaker implantation may be
performed 4 to 6 weeks before the AV node ablation to
ensure proper pacemaker function, because malfunction due
to lead dislodgment can be catastrophic. Sudden death sec-
ondary to torsades de pointes or ventricular ﬁbrillation has
been reported after AV junction ablation. This outcome is
possibly related to increased dispersion of ventricular
refractoriness produced by sudden heart rate slowing and
ventricular pacing (308). After ablation, the ventricular pac-
ing rate is usually set between 90 bpm and 100 bpm and then
gradually tapered over several months (309,310). RV apical
pacing also creates a ventricular activation sequence that can
lead to depressed ventricular function. In patients with left
ventricular ejection fraction (LVEF) <35% and symptoms of
HF, implantation of a biventricular pacing system is recom-
mended. This procedure should also be considered for pa-
tients with less severe ventricular dysfunction (18). In the
BLOCK HF (Biventricular Versus Right Ventricular Pacing in
Heart Failure Patients With Atrioventricular Block) trial, pa-
tients with advanced AV block with LVEF <50% had
improved clinical outcomes when treated with a biven-
tricular pacemaker compared with RV apical pacing (311). An
upgrade to a biventricular pacing system should be consid-
ered for patients who have undergone AV nodal ablation
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to-severe LV systolic dysfunction (312).
See Online Data Supplement 10 for additional data on
AV junction ablation.
5.3. Selecting and Applying a Rate-Control Strategy
5.3.1. Broad Considerations in Rate Control
The optimal heart rate targets for rate control are
controversial. The target used in the AFFIRM trial was a
resting heart rate of either #80 bpm or averaging #100
bpm on ambulatory monitoring, without a rate >100% of
the maximum age-adjusted predicted exercise heart rate.
These conditions were achieved in 58% of patients during
initial drug therapy (269). One RCT, the RACE (Rate
Control Efﬁcacy in Permanent Atrial Fibrillation)-II trial,
assessed lenient versus strict rate control (274). In this
trial, 614 patients with permanent AF were randomized to
a lenient rate-control (resting heart rate <110 bpm) strat-
egy or a strict rate-control (resting heart rate <80 bpm)
strategy. At 3 years, the primary composite endpoint of
cardiovascular death, hospitalization for HF, stroke, em-
bolism, bleeding, or life-threatening arrhythmic events
was similar between the 2 groups (12.9% lenient rateAtrial Fib
No Other
CV Disease
Hypertension
or HFpEF
Beta blocker
Diltiazem
Verapamil
Beta blocker
Diltiazem
Verapamil
Amiodarone§
FIGURE 6 Approach to Selecting Drug Therapy for Ventricular Rate Contro
*Drugs are listed alphabetically.
†Beta blockers should be instituted following stabilization of patients with decom
the patient’s clinical condition.
‡Digoxin is not usually ﬁrst-line therapy. It may be combined with a beta blocker
control is insufﬁcient and may be useful in patients with HF.
§In part because of concern over its side-effect proﬁle, use of amiodarone for ch
respond to or are intolerant of beta blockers or nondihydropyridine calcium ant
COPD indicates chronic obstructive pulmonary disease; CV, cardiovascular; HF, he
ventricular.control versus 14.9% strict rate control); thus, a strict rate-
control strategy did not improve outcomes. Several con-
siderations warrant a cautious approach to extrapolating
these ﬁndings to the general AF population. The majority
of patients in the RACE-II trial had preserved LV systolic
function. RACE-II was a single noninferiority trial with a
90% CI for a composite endpoint. The resting heart rate
achieved in both groups only differed by 10 bpm, and 78%
of patients in the lenient control group had resting
rates <100 bpm. This single RCT does not provide sufﬁ-
cient evidence to assess deﬁnitive results of the impact on
all-cause mortality, HF symptoms, hospitalizations, or
quality of life. The degree of rate control, however,
remains an area of uncertainty and controversy that
requires further study.
See Online Data Supplement 11 for additional data on
rate control.
5.3.2. Individual Patient Considerations
Optimal ventricular rate control may differ and is impacted
by the degree of patient symptoms and comorbidities,
including the presence of valvular heart disease, LV
systolic dysfunction, HF, and presence of pre-excitation.rillation
LV
Dysfunction
or HF
COPD
Beta blocker
Diltiazem
Verapamil
Beta blocker†
Digoxin‡
l*
pensated HF. The choice of beta blocker (e.g., cardioselective) depends on
and/or a nondihydropyridine calcium channel blocker when ventricular rate
ronic control of ventricular rate should be reserved for patients who do not
agonists.
art failure; HFpEF, heart failure with preserved ejection fraction; and LV, left
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control in different patient populations.
6. RHYTHM CONTROL
Long-term AF management may attempt to restore and
maintain sinus rhythm, commonly referred to as “a
rhythm-control strategy,” using a combination of ap-
proaches, including cardioversion, antiarrhythmic drugs,
and radiofrequency catheter ablation in the setting of
appropriate anticoagulation and rate control. RCTs
comparing outcomes of a rhythm-control strategy using
antiarrhythmic drugs with a rate-control strategy in pa-
tients with AF failed to show a superiority of rhythm
control on mortality for either strategy (269,313).
Furthermore, when applied in patients who are candi-
dates for both treatment strategies (rhythm or rate con-
trol), a rhythm-control strategy results in more
hospitalizations. Therefore, the routine use of a rhythm-
control strategy is not warranted for some patients.
Catheter ablation has not been studied in this context.TABLE 11 Summary of Recommendations for Electrical and Phar
Recommendations
Prevention of thromboembolism
With AF or atrial ﬂutter for $48 h, or unknown duration, anticoagulate with warfa
and 4 wk after cardioversion
With AF or atrial ﬂutter for >48 h or unknown duration, requiring immediate cardi
soon as possible and continue for at least 4 wk
With AF or atrial ﬂutter <48 h and high stroke risk, IV heparin or LMWH, or factor
is recommended before or immediately after cardioversion, followed by long-
Following cardioversion of AF, long-term anticoagulation should be based on throm
With AF or atrial ﬂutter for $48 h or unknown duration and no anticoagulation for
to perform TEE before cardioversion and then cardiovert if no LA thrombus is
is achieved before TEE and maintained after cardioversion for at least 4 wk
With AF or atrial ﬂutter $48 h or unknown duration, anticoagulation with dabigatr
reasonable for $3 wk before and 4 wk after cardioversion
With AF or atrial ﬂutter <48 h and low thromboembolic risk, IV heparin, LMWH, a
antithrombotic may be considered for cardioversion
Direct-current cardioversion
Cardioversion is recommended for AF or atrial ﬂutter to restore sinus rhythm. If un
attempts may be repeated.
Cardioversion is recommended for AF or atrial ﬂutter with RVR, that does not resp
Cardioversion is recommended for AF or atrial ﬂutter and pre-excitation with hemo
It is reasonable to repeat cardioversion in persistent AF when sinus rhythm can be
meaningful time period between procedures
Pharmacological cardioversion
Flecainide, dofetilide, propafenone, and IV ibutilide are useful for cardioversion of
contraindications to the selected drug are absent
Amiodarone is reasonable for pharmacological cardioversion of AF
Propafenone or ﬂecainide (“pill-in-the-pocket”) to terminate AF out of hospital is r
safe in a monitored setting
Dofetilide should not be initiated out of hospital
AF indicates atrial ﬁbrillation; COR, Class of Recommendation; IV, intravenous; LA, left atria
RVR, rapid ventricular response; and TEE, transesophageal echocardiography.Although an initial rate-control strategy is reasonable
for many patients, several considerations favor pursuing a
rhythm-control strategy. Successful sinus rhythm main-
tenance is associated with improvements in symptoms
and quality of life for some patients (314,315). Persistent
symptoms associated with AF remain the most compelling
indication for a rhythm-control strategy. Other factors
that may favor attempts at rhythm control include difﬁ-
culty in achieving adequate rate control, younger patient
age, tachycardia-mediated cardiomyopathy, ﬁrst episode
of AF, AF precipitated by an acute illness, and patient
preference. AF progresses from paroxysmal to persistent
in many patients and subsequently results in electrical
and structural remodeling that becomes irreversible with
time (126,316). For this reason, acceptance of AF as per-
manent in a patient may render future rhythm-control
therapies less effective. This may be more relevant for a
younger patient who wishes to remain a candidate for
future developments in rhythm-control therapies. Early
intervention with a rhythm-control strategy to prevent
progression of AF may be beneﬁcial (317–319).macological Cardioversion of AF and Atrial Flutter
COR LOE References
rin for at least 3 wk before I (320–323)
oversion, anticoagulate as I C N/A
Xa or direct thrombin inhibitor,
term anticoagulation
I C N/A
boembolic risk I C N/A
preceding 3 wk, it is reasonable
identiﬁed, provided anticoagulation
IIa B (164)
an, rivaroxaban, or apixaban is IIa C (230,324,325)
new oral anticoagulant, or no IIb C (326)
successful, cardioversion I B (327)
ond to pharmacological therapies I C N/A
dynamic instability I C N/A
maintained for a clinically IIa C N/A
AF or atrial ﬂutter, provided I A (328–333)
IIa A (334,335)
easonable once observed to be IIa B (328)
III: Harm B (332,336)
l; LMWH, low-molecular-weight heparin; LOE, Level of Evidence; N/A, not applicable;
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e336.1. Electrical and Pharmacological Cardioversion of AF and
Atrial Flutter
See Table 11 for a summary of recommendations from this
section.
6.1.1. Prevention of Thromboembolism: Recommendations
CLASS I
1. For patients with AF or atrial ﬂutter of 48 hours’ duration or
longer, or when the duration of AF is unknown, anti-
coagulation with warfarin (INR 2.0 to 3.0) is recommended
for at least 3 weeks before and 4 weeks after cardioversion,
regardless of the CHA2DS2-VASc score and the method
(electrical or pharmacological) used to restore sinus rhythm
(320–323). (Level of Evidence: B)
2. For patients with AF or atrial ﬂutter of more than 48 hours’
duration or unknown duration that requires immediate car-
dioversion for hemodynamic instability, anticoagulation
should be initiated as soon as possible and continued for at
least 4 weeks after cardioversion unless contraindicated.
(Level of Evidence: C)
3. For patients with AF or atrial ﬂutter of less than 48 hours’
duration and with high risk of stroke, intravenous heparin or
LMWH, or administration of a factor Xa or direct thrombin
inhibitor, is recommended as soon as possible before or
immediately after cardioversion, followed by long-term
anticoagulation therapy. (Level of Evidence: C)
4. Following cardioversion for AF of any duration, the decision
about long-term anticoagulation therapy should be based
on the thromboembolic risk proﬁle (Section 4). (Level of
Evidence: C)
CLASS IIa
1. For patients with AF or atrial ﬂutter of 48 hours’ duration or
longer or of unknown duration who have not been anti-
coagulated for the preceding 3 weeks, it is reasonable to
perform TEE before cardioversion and proceed with cardio-
version if no LA thrombus is identiﬁed, including in the LAA,
provided that anticoagulation is achieved before TEE and
maintained after cardioversion for at least 4 weeks (164).
(Level of Evidence: B)
2. For patients with AF or atrial ﬂutter of 48 hours’ duration or
longer or when duration of AF is unknown, anticoagulation
with dabigatran, rivaroxaban, or apixaban is reasonable for
at least 3 weeks before and 4 weeks after cardioversion
(230,324,325). (Level of Evidence: C)
CLASS IIb
1. For patients with AF or atrial ﬂutter of less than 48 hours’
duration who are at low thromboembolic risk, anticoagulation
(intravenous heparin, LMWH, or a new oral anticoagulant)
or no antithrombotic therapy may be considered for cardio-
version, without the need for postcardioversion oral anti-
coagulation (326). (Level of Evidence: C)6.1.2. Direct-Current Cardioversion: Recommendations
CLASS I
1. In pursuing a rhythm-control strategy, cardioversion is rec-
ommended for patients with AF or atrial ﬂutter as a method
to restore sinus rhythm. If cardioversion is unsuccessful,
repeated attempts at direct-current cardioversion may be
made after adjusting the location of the electrodes, applying
pressure over the electrodes or following administration of
an antiarrhythmic medication (327). (Level of Evidence: B)
2. Cardioversion is recommended when a rapid ventricular
response to AF or atrial ﬂutter does not respond promptly
to pharmacological therapies and contributes to ongoing
myocardial ischemia, hypotension, or HF. (Level of Evidence: C)
3. Cardioversion is recommended for patients with AF or atrial
ﬂutter and pre-excitation when tachycardia is associated
with hemodynamic instability. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to perform repeated cardioversions in patients
with persistent AF, provided that sinus rhythm can be main-
tained for a clinically meaningful period between cardioversion
procedures. Severity of AF symptoms and patient preference
should be considered when embarking on a strategy requiring
serial cardioversion procedures. (Level of Evidence: C)
6.1.3. Pharmacological Cardioversion: Recommendations
CLASS I
1. Flecainide, dofetilide, propafenone, and intravenous ibutilide
are useful for pharmacological cardioversion of AF or atrial
ﬂutter, provided contraindications to the selected drug are
absent (328–333). (Level of Evidence: A)
CLASS IIa
1. Administration of oral amiodarone is a reasonable option for
pharmacological cardioversion of AF (334,335). (Level of
Evidence: A)
2. Propafenone or ﬂecainide (“pill-in-the-pocket”) in addition to
a beta blocker or nondihydropyridine calcium channel antag-
onist is reasonable to terminate AF outside the hospital once
this treatment has been observed to be safe in a monitored
setting for selected patients (328). (Level of Evidence: B)
CLASS III: HARM
1. Dofetilide therapy should not be initiated out of hospital
because of the risk of excessive QT prolongation that can
cause torsades de pointes (332,336). (Level of Evidence: B)
Direct-current cardioversion involves the delivery of
an electrical shock synchronized with the QRS complex
to avoid inducing ventricular ﬁbrillation that can occur
when a shock is delivered during ventricular repolari-
zation on the T wave. It is clinically relevant to differ-
entiate between a cardioversion in which sinus rhythm
was not restored, even transiently, and a cardioversion
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In the former scenario, approaches that improve energy
delivery and may allow for successful cardioversion
include increasing shock strength, delivering a biphasic
rather than monophasic waveform, changing the shock
vector by altering the electrode pad position, improving
energy transfer via pressure on the anterior electrode pad,
or using a drug such as ibutilide to lower the deﬁbrillation
threshold. In the latter scenario, when sinus rhythm is
restored but AF returns, pretreatment with selected anti-
arrhythmic drugs may increase the likelihood of mainte-
nance of sinus rhythm (327,337).
A number of technical factors inﬂuence cardioversion
efﬁcacy, including energy, waveform, and electrode
placement (7a,7b). A biphasic waveform is more effective
than a monophasic waveform (338). Anteroposterior elec-
trode placement is superior to anterolateral placement in
some but not all studies (7a,7b,339). If an attempt at car-
dioversion using 1 electrode placement fails, another
attempt using the alternative placement is recommended.
The initial use of a higher-energy shock is more effective
and may minimize the number of shocks required as well
as the duration of sedation (340). Risks associated with
cardioversion include thromboembolism, sedation-related
complications, ventricular tachycardia and ﬁbrillation,
bradyarrhythmias, skin burn or irritation from electrodes,
muscle soreness, and reprogramming or altering implan-
ted cardiac device function. Elective cardioversion should
not be performed in patients with evidence of digoxin
toxicity, severe hypokalemia, or other electrolyte imbal-
ances until these factors are corrected.
Appropriate anticoagulation management around the
time of cardioversion is essential for reducing thromboem-
bolic risk. Results of observational studies suggest that
thromboembolic risk after cardioversion is highest in the
ﬁrst 72 hours and that the majority of events occur within 10
days (341,342). Thromboembolism after cardioversion can be
due to migration of thrombi present at the time of cardio-
version or to the formation and subsequent migration of de
novo thrombi that form while atrial function is still
depressed in the postcardioversion period. In this guideline,
the Class I recommendation for anticoagulation with
warfarin for $3 weeks before and continuing for $4 weeks
after cardioversion is based on pathophysiological and
observational data (322,323). For new oral anticoagulants,
available data supporting similar use at cardioversion consist
of subgroup analyses of dabigatran from RE-LY, rivaroxaban
from ROCKET AF, and apixaban from ARISTOTLE in patients
who were receiving long-term anticoagulation (>3 weeks)
around the time of cardioversion (230,324,325).
TEE guidance is an alternative to 3 weeks of anti-
coagulation before cardioversion (164,343). Therapeutic
anticoagulation is achieved and followed by TEE; if no
thrombus is seen (including in the LAA), cardioversion isperformed and anticoagulation is continued for $4 weeks.
The absence of LA thrombus on TEE does not preclude the
need for anticoagulation during and after cardioversion. In
the ACUTE (Assessment of Cardioversion Using Trans-
esophageal Echocardiography) trial, hospitalized patients
were typically started on intravenous heparin before car-
dioversion, whereas outpatients were typically started on
warfarin 5 days before cardioversion and anticoagulation
status was veriﬁed at the time of cardioversion (164).
Alternative strategies for achieving rapid anticoagulation
include administration of LMWH (344) or a new oral anti-
coagulant. If a thrombus is identiﬁed on TEE, the cardio-
version should be postponed, followed by $3 to 4 weeks of
anticoagulation. Repeat TEE to ensure thrombus resolution
is an option before another cardioversion attempt (322). If a
thrombus remains on repeat TEE, an alternative strategy
such as rate control in conjunction with appropriate anti-
coagulation may be considered.
Data on cardioversion risks for atrial ﬂutter are limited.
Atrial ﬂutter, however, can be associated with thrombi
and episodes of AF. Therefore, it is recommended that the
anticoagulation management strategy for cardioversion of
atrial ﬂutter be the same as for AF.
In patients with AF clearly of <48 hours’ duration, it is
common practice to perform cardioversion without TEE
or antecedent anticoagulation (345). No RCTs comparing
anticoagulation strategies in patients with AF duration
of <48 hours exist (342). If high-risk features are present,
such as mitral stenosis or prior history of thromboembo-
lism, long-term anticoagulation should be considered.
Decisions about whether to initiate long-term systemic
anticoagulation at the time of cardioversion in a patient
with AF of <48 hours’ duration should be based on the
patient’s long-term risk of stroke using the CHA2DS2-VASc
risk score discussed in Section 4.1.
For patients with AF requiring emergency cardioversion
because of hemodynamic instability, initiation of anti-
coagulation should not delay interventions to stabilize the
patient. No RCTs have evaluated optimal anticoagulation
strategies in this patient population. It is reasonable to
administer heparin (intravenous bolus of UFH followed by
infusion, or LMWH) or new anticoagulant and to continue
this after cardioversionunless contraindicated. For patients
with AF or atrial ﬂutter of$48 hours’ duration or uncertain
duration, oral anticoagulation is recommended for $4
weeks after emergency cardioversion (similar to patients
undergoing elective cardioversion). If warfarin is used,
bridging with UFH or LMWH is indicated until the INR is
therapeutic. For patients with AF and thromboembolic risk
factors, oral long-term anticoagulation is recommended.
Antiarrhythmic drugs can be administered for attempted
conversion of AF to sinus rhythm or to facilitate electrical
cardioversion. Pharmacological cardioversion is most likely
effective when initiated within 7 days after onset of an
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drugs are speciﬁed in Table 12. In patients with recent-onset
AF, intravenous administration of ibutilide restored sinus
rhythm in about 50% of patients, with an average conversion
time of <30 minutes. The rates of successful termination
were higher in patients with atrial ﬂutter than in those with
AF (346). Pretreatment with ibutilide also improves the ef-
ﬁcacy of transthoracic electrical cardioversion of AF (327).
The major risk is excessive QT prolongation, which can
cause polymorphic ventricular tachycardia/torsades de
pointes. The latter occurs in up to 3% to 4% of patients.
Electrocardiographic monitoring should be continued for $4
hours after administration, and resuscitation equipment
must be immediately available. Ibutilide should be avoided
in patients with QT prolongation, marked hypokalemia, or a
very low ejection fraction (EF) (<30%) because of the risk of
ventricular proarrhythmia (327). Some experts administer
magnesium sulfate intravenously before administering ibu-
tilide in an attempt to lower this risk (331). Intravenous
amiodarone may facilitate slowing of the ventricular rate in
AF, but the effect to restore sinus rhythm is often delayed. In
1 study, oral amiodarone loaded over the course of several
weeks resulted in conversion of persistent AF to sinus
rhythm in about 25% of patients (314). An oral dose of ﬂe-
cainide or propafenone can be used as a “pill-in-the-pocket”
strategy to attempt to restore sinus rhythm shortly after the
onset of symptomatic AF (328,330). Because termination of
AF may be associated with bradycardia due to sinus node or
AV node dysfunction or a proarrhythmic response, an initialTABLE 12 Recommended Drug Doses for Pharmacological Cardio
Drug
Route of
Administration Dosage
Amiodarone* Oral 600–800 mg daily in divided doses to
a total load of up to 10 g, then
200 mg QD as maintenance
IV 150 mg over 10 min, then 1 mg/min for
6 h, then 0.5 mg/min for 18 h or
change to oral dosing
Dofetilide Oral CrCl (mL/min) Dose (mcg BID)
>60 500
40–60 250
20–40 125
<20 Not recommended
Flecainide Oral 200–300 mg  1†
Ibutilide IV 1 mg over 10 min; may repeat 1 mg
once if necessary (if weight <60 kg,
use 0.01 mg/kg)
Propafenone Oral 450–600 mg  1†
*Multiple dosing schemes exist for the use of amiodarone.
†Recommended given in conjunction with a beta blocker or nondihydropyridine calcium channe
IC agent (328).
AF indicates atrial ﬁbrillation; AV, atrioventricular; BID, twice a day; CAD, coronary artery di
IV, intravenous; and QD, once daily.
Adapted with permission from Fuster et al. (4).conversion trial in a monitored setting is recommended
before this approach is used in the unmonitored outpatient
setting. A beta blocker or nondihydropyridine calcium
channel antagonist should be administered $30 minutes
before administering the Vaughan Williams class IC agent to
prevent a rapid ventricular response due to 1:1 AV conduc-
tion during atrial ﬂutter (328).6.2. Pharmacological Agents for Preventing AF and
Maintaining Sinus Rhythm
6.2.1. Antiarrhythmic Drugs to Maintain Sinus Rhythm:
Recommendations
CLASS I
1. Before initiating antiarrhythmic drug therapy, treatment of
precipitating or reversible causes of AF is recommended.
(Level of Evidence: C)
2. The following antiarrhythmic drugs are recommended in
patients with AF to maintain sinus rhythm, depending on un-
derlying heart disease and comorbidities (Level of Evidence: A):
a. Amiodarone (314,347–349)
b. Dofetilide (332,336)
c. Dronedarone (350–352)
d. Flecainide (347,353)
e. Propafenone (347,354–357)
f. Sotalol (347,355,358)version of AF
Potential Adverse Effects References
Phlebitis (IV), hypotension, bradycardia,
QT prolongation, torsades de pointes
(rare), GI upset, constipation, increased INR
(334,335)
QT prolongation, torsades de pointes; adjust
dose for renal function, body size, and age
(332)
Hypotension, atrial ﬂutter with 1:1 AV conduction,
ventricular proarrhythmia; avoid in patients with CAD
and signiﬁcant structural heart disease
(328)
QT prolongation, torsades de pointes,
hypotension
(329,333,346)
Hypotension, atrial ﬂutter with 1:1 AV conduction,
ventricular proarrhythmia; avoid in patients
with CAD and signiﬁcant structural heart disease
(328,330)
l antagonist administered$30 minutes before administering the Vaughan Williams class
sease; CrCl, creatinine clearance; GI, gastrointestinal; INR, international normalized ratio;
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rhythmia, should be considered before initiating therapy
with each drug. (Level of Evidence: C)
4. Because of its potential toxicities, amiodarone should only
be used after consideration of risks and when other agents
have failed or are contraindicated (314,354,359–362). (Level
of Evidence: C)
CLASS IIa
1. A rhythm-control strategy with pharmacological therapy
can be useful in patients with AF for the treatment of
tachycardia-induced cardiomyopathy. (Level of Evidence: C)
CLASS IIb
1. It may be reasonable to continue current antiarrhythmic
drug therapy in the setting of infrequent, well-tolerated
recurrences of AF when the drug has reduced the fre-
quency or symptoms of AF. (Level of Evidence: C)
CLASS III: HARM
1. Antiarrhythmic drugs for rhythm control should not be
continued when AF becomes permanent (Level of Evidence: C),
including dronedarone (282). (Level of Evidence: B)
2. Dronedarone should not be used for treatment of AF in
patients with New York Heart Association (NYHA) class III
and IV HF or patients who have had an episode of de-
compensated HF in the past 4 weeks (283). (Level of
Evidence: B)
When a rhythm-control strategy is desired, antiar-
rhythmic drug therapy may be selected to reduce the
frequency and duration of AF and improve quality of life.
Before antiarrhythmic drug treatment is initiated,
reversible precipitants of AF should be identiﬁed and
corrected. After the ﬁrst episode of AF that resolves, it is
reasonable to address the underlying causes of AF and
need for anticoagulation, and to not initiate antiar-
rhythmic drug treatment until warranted by recurrences
of AF. Decisions about anticoagulation should be based on
the individual patient’s stroke risk proﬁle and not on the
response to antiarrhythmic drug therapy. Antiarrhythmic
drug efﬁcacy is modest, and asymptomatic AF re-
currences are common. Therefore, a rhythm-control
strategy should not result in cessation of antithrombotic
therapy, rate-control therapy, or treatment of underlying
heart disease.
Drug selection is guided to a greater extent by safety
concerns than by drug efﬁcacy. A common approach is to
identify available drug choices by ﬁrst eliminating, on the
basis of clinical parameters, drugs that have absolute or
relative contraindications. Patients with CAD, signiﬁcant
LV hypertrophy, and HF have more restricted options
than those with minimal or no structural heart disease.
Several other important factors must be considered,
including the risk for bradyarrhythmias, risk factors forexcessive QT prolongation and torsades de pointes (e.g.,
baseline QT prolongation, history of torsades de pointes
during therapy with a QT intervalprolonging drug,
potassium-wasting syndromes), and factors that inﬂuence
drug disposition, such as patient age and renal or hepatic
dysfunction. Because of its toxicity proﬁle, amiodarone
should only be used after consideration of risks and when
other agents have failed or are contraindicated.
Table 13 summarizes antiarrhythmic drugs useful in the
maintenance of sinus rhythm along with toxicity proﬁles.
In general, antiarrhythmic drugs have the potential to
precipitate or worsen bradycardia due to sinus node
dysfunction or abnormal AV conduction. A history of
syncope, sinus bradycardia, PR interval prolongation,
and bundle-branch block raise concerns for a risk of
bradyarrhythmia during antiarrhythmic drug therapy.
Depending on the speciﬁc agent selected, a pacemaker
may be required for patients with signiﬁcant
bradyarrhythmias.
In selecting a strategy of rhythm control with an
antiarrhythmic drug, providing for adequate rate control
in the event of AF recurrence should also be considered.
Once antiarrhythmic drug therapy is initiated, patient
symptoms may improve without complete AF suppres-
sion. The transition from frequent AF to infrequent,
well-tolerated recurrence of AF is a reasonable outcome
and does not necessarily indicate that the therapy
should be discontinued. However, if attempts at
rhythm control are abandoned (e.g., after AF has been
declared permanent), the antiarrhythmic drug should be
discontinued.
Several systematic reviews have summarized the data
on the efﬁcacy and safety of antiarrhythmic drugs for
treating AF (347,359,363,364). In a meta-analysis of 44
trials, antiarrhythmic drug therapy signiﬁcantly reduced
recurrence of AF (with a number needed to treat ranging
from 2 to 9). All drugs may require discontinuation of
therapy because of adverse effects (number needed to
harm ranging from 9 to 27), and all but amiodarone
and propafenone increased proarrhythmia in this
analysis (number needed to harm ranging from 17 to 119).
Vaughan Williams class IA drugs (quinidine and dis-
opyramide, pooled data) were associated with increased
mortality compared with controls, whereas no other
antiarrhythmic drug showed a signiﬁcant effect on
mortality (365). Most of the trials in this meta-analysis
had relatively short duration of follow-up and enrolled
relatively healthy patients; therefore, it is difﬁcult to
extrapolate these data to other patient populations.
Conclusions about other important clinical outcomes such
as stroke and HF were not analyzed, and dronedarone was
not included.
Antiarrhythmic drugs that prolong the QT interval,
notably sotalol, dofetilide, and disopyramide (all of which
TABLE 13 Dosage and Safety Considerations for Maintenance of Sinus Rhythm in AF
Drug Usual Doses
Exclude/Use With
Caution Major Pharmacokinetic Drug Interactions
Vaughan Williams class IA
Disopyramide  Immediate release: 100–200 mg
once every 6 h
 Extended release: 200–400 mg
once every 12 h
 HF
 Prolonged QT interval
 Prostatism, glaucoma
 Avoid other QT
intervalprolonging drugs
 Metabolized by CYP3A4: caution
with inhibitors (e.g., verapamil, diltiazem,
ketoconazole, macrolide antibiotics,
protease inhibitors, grapefruit juice)
and inducers (e.g., rifampin,
phenobarbital, phenytoin)
Quinidine  324–648 mg every 8 h  Prolonged QT interval
 Diarrhea
 Inhibits CYP2D6: [concentrations of
tricyclic antidepressants, metoprolol,
antipsychotics; Yefﬁcacy of codeine
 Inhibits P-glycoprotein: [digoxin
concentration
Vaughan Williams class IC
Flecainide  50–200 mg once every 12 h  Sinus or AV node dysfunction
 HF
 CAD
 Atrial ﬂutter
 Infranodal conduction disease
 Brugada syndrome
 Renal or liver disease
 Metabolized by CYP2D6 (inhibitors include
quinidine, ﬂuoxetine, tricyclics; also
genetically absent in 7%–10% of
population) and renal excretion
(dual impairment can [[plasma
concentration)
Propafenone  Immediate release: 150–300 mg
once every 8 h
 Extended release: 225–425 mg
once every 12 h
 Sinus or AV node dysfunction
 HF
 CAD
 Atrial ﬂutter
 Infranodal conduction disease
 Brugada syndrome
 Liver disease
 Asthma
 Metabolized by CYP2D6 (inhibitors
include quinidine, ﬂuoxetine, tricyclics;
also genetically absent in 7%–10%
of population)—poor metabolizers
have [beta blockade
 Inhibits P-glycoprotein: [digoxin
concentration
 Inhibits CYP2C9: [warfarin
concentration ([INR 25%)
Vaughan Williams class III
Amiodarone  Oral: 400–600 mg daily in divided doses
for 2–4 wk; maintenance typically
100200 mg QD
 IV: 150 mg over 10 min; then 1 mg/min
for 6 h; then 0.5 mg/min for 18 h or
change to oral dosing; after 24 h,
consider decreasing dose to 0.25 mg/min
 Sinus or AV node dysfunction
 Infranodal conduction disease
 Lung disease
 Prolonged QT interval
 Inhibits most CYPs to cause drug
interaction: [concentrations of
warfarin ([INR 0%–200%), statins,
many other drugs
 Inhibits P-glycoprotein: [digoxin
concentration
Dofetilide  125–500 mcg once every 12 h  Prolonged QT interval
 Renal disease
 Hypokalemia
 Hypomagnesemia
 Diuretic therapy
 Avoid other QT
intervalprolonging drugs
 Primary renal elimination involving
glomerular ﬁltration and active tubular
secretion: verapamil, HCTZ, cimetidine,
ketoconazole, trimethoprim,
prochlorperazine, and megestrol are
contraindicated; discontinue amiodarone
at least 3 mo before initiation
Dronedarone  400 mg once every 12 h  Bradycardia
 HF
 Long-standing persistent
AF/ﬂutter
 Liver disease
 Prolonged QT interval
 Metabolized by CYP3A: caution with
inhibitors (e.g., verapamil, diltiazem,
ketoconazole, macrolide antibiotics,
protease inhibitors, grapefruit juice)
and inducers (e.g., rifampin, phenobarbital,
phenytoin)
 Inhibits CYP3A, CYP2D6, P-glycoprotein:
[concentrations of some statins, sirolimus,
tacrolimus, beta blockers, digoxin
Sotalol  40–160 mg once every 12 h  Prolonged QT interval
 Renal disease
 Hypokalemia
 Hypomagnesemia
 Diuretic therapy
 Avoid other QT
intervalprolonging drugs
 Sinus or AV nodal dysfunction
 HF
 Asthma
 None (renal excretion)
AF indicates atrial ﬁbrillation; AV, atrioventricular; CAD, coronary artery disease; HCTZ, hydrochlorothiazide; HF, heart failure; INR, international normalized ratio; IV, intravenous;
and QD, once daily.
Adapted with permission from Roden et al. (369).
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current IKr), have a risk of causing torsades de pointes and
should be avoided in patients at increased risk of this
form of proarrhythmia. Amiodarone and dronedarone
have rarely been associated with prolongation of the QT
interval and torsades de pointes (366,367). General risk
factors associated with increased risk of torsades de
pointes include bradycardia, advanced age, hypokalemia,
hypomagnesemia, female sex, baseline prolonged QT
interval, congenital long-QT syndrome, concomitant use
of other QT-prolonging therapies, HF, and possibly LV
hypertrophy.
Structural heart disease has been associated with an
increased risk of drug-induced proarrhythmia that may
manifest as life-threatening ventricular arrhythmias.
Manifestations of heart disease sufﬁcient to warrant
consideration include prior MI, HF, and signiﬁcant LV
hypertrophy. Drugs that have prominent sodium channel–
blocking effects (e.g., ﬂecainide, Vaughan Williams
class IC drug) increase mortality in patients with MI
from CAD (368). This consideration has been inferred
for propafenone (Vaughan Williams class IC agents),
and these drugs should be avoided in patients with MI
from CAD.
6.2.1.1. Speciﬁc Drug Therapy
Amiodarone is an iodinated compound that, along with
its metabolites, blocks multiple ion channels (e.g., IKr,
INa, IKur, Ito, ICaL, IKAch, IKs). It is a noncompetitive beta-
adrenergic antagonist. It has a long half-life of weeks
and large volume of distribution into adipose tissue.
Although suppression of sinus and AV nodal function
can occur early within the ﬁrst few days of oral therapy,
the antiarrhythmic effect and QT prolongation can be
delayed for days or weeks. A loading phase accelerates
the onset of its antiarrhythmic activity, and adminis-
tration in divided doses and with food minimizes the
gastrointestinal symptoms associated with large doses
($600 mg) during the loading phase. Administration
with food also signiﬁcantly increases the rate and
extent of amiodarone absorption. Use of oral amiodar-
one for AF is associated with the added beneﬁt of
effective rate control, frequently eliminating the need
for other drugs to control the ventricular rate for AF
recurrences. Drug interactions and toxicities, however,
are sufﬁcient to preclude its routine use as a rate-
controlling agent.
Amiodarone is known to inhibit CYP3A, CYP2C9,
P-glycoprotein, and, consequently, the elimination of
multiple other medications. In patients also taking
warfarin or digoxin, dose reduction in these drugs may
be needed upon amiodarone initiation in anticipation
of a rise in INR (that can be variable) and serum digoxin
level. Doses of other medications for rate control shouldbe reduced when the rate slows after initiation of amio-
darone and stopped if the rate slows excessively.
Amiodarone is the most effective available antiar-
rhythmic drug for maintenance of sinus rhythm in
patients with paroxysmal or persistent AF. In direct
comparisons, it is more effective than dronedarone,
sotalol, or propafenone (314,360,362,370). A mixed treat-
ment comparison of amiodarone, dronedarone, ﬂecai-
nide, propafenone, and sotalol for the treatment of AF or
atrial ﬂutter found that amiodarone had the largest
reduction of AF recurrence (OR: 0.22; 95% CI: 0.16 to 0.29)
but was associated with the highest rate of patients
experiencing $1 serious adverse event (OR: 2.41; 95% CI:
0.96 to 6.06) and treatment withdrawals due to adverse
events (OR: 2.91; 95% CI: 1.66 to 5.11) (359). Trends
for increased mortality (OR: 2.17; 95% CI: 0.63 to 7.51)
were found that were stronger when small studies
randomizing <100 subjects per group were excluded from
the analysis. Amiodarone therapy was associated with an
increase in noncardiac mortality in patients with NYHA
class III HF in SCD-HeFT (Sudden Cardiac Death in Heart
Failure Trial) (371).
The major cardiovascular side effect of amiodarone is
bradycardia. Marked QT prolongation can occur, but it is
very rarely associated with torsades de pointes (366).
Extracardiac toxicities, including thyroid, liver, pulmo-
nary, and ocular and skin discoloration, are a major
problem with amiodarone, so it is not a ﬁrst-choice agent
(especially in younger patients) when other antiar-
rhythmic drugs are an option. The risk of many toxicities,
including pulmonary toxicity, is dose related and can be
fatal. Chronic oral doses of #200 mg daily may be effec-
tive and result in fewer side effects than higher-dose
regimens. In patients with LV hypertrophy, HF, CAD,
and/or previous MI, amiodarone is associated with a low
risk of proarrhythmia, making it an appropriate initial
choice to prevent recurrent AF in these clinical settings.
Appropriate surveillance for lung, liver, and thyroid
toxicity is warranted.
Flecainide and Propafenone are Vaughan Williams
class IC drugs that may be considered for rhythm control
in patients with AF without structural heart disease.
Flecainide, along with other potent sodium channel–
blocking drugs, increased mortality in patients with prior
MI and therefore should be avoided in patients with
ischemic heart disease (368). In addition, both drugs are
negative inotropes and should be avoided in patients with
LV dysfunction.
These medications can cause slowing of the atrial rate
in atrial ﬂutter, resulting in 1:1 AV conduction and an
increased ventricular rate; therefore, concomitant AV
nodal blocking medication is recommended. Drug-
induced, use-dependent increases in PR and QRS dura-
tions of up to 25% compared with baseline can also occur
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QRS duration may be a marker for proarrhythmia risk
(372). These agents should be used with caution in the
presence of signiﬁcant conduction system disease,
including intraventricular conduction delay or bundle-
branch block in the absence of a pacing system. Noncar-
diac side effects are uncommon and include dizziness and
visual disturbance, and propafenone can cause a metallic
taste. The parent compound has beta-blocker properties,
and its metabolites are electrophysiologically active with
weak beta-blocking activity. Propafenone is a substrate
for CYP2D6, which is genetically absent in approximately
7% of patients (poor metabolizers) and is inhibited by
quinidine, ﬂuoxetine, and tricyclic antidepressants,
among others. Thus, drug interactions and genetic sus-
ceptibility can cause abnormally increased plasma con-
centrations of propafenone, resulting in signiﬁcant beta
blockade.
Sotalol, an IKr inhibitor and beta blocker, is not effec-
tive for conversion of AF to sinus rhythm but may be used
to prevent recurrent AF. Much like with other antiar-
rhythmic drugs, with the exception of amiodarone, the
rates of maintaining sinus rhythm at 1 year for sotalol are
30% to 50% (347). Sotalol is renally cleared and should be
used with caution or avoided in patients with CKD or
unstable renal function. Sotalol causes drug-induced QT-
interval prolongation, so it should be administered with
caution or avoided when administered with other drugs
known to prolong the QT interval. During follow-up,
serum potassium and magnesium levels and renal func-
tion should be checked periodically. Trends toward
increased mortality for sotalol (OR: 3.44; 95% CI: 1.02 to
11.59) were observed in a comparison study (359), and it is
likely that proarrhythmia is a contributing mechanism.
Some experts initiate sotalol in hospital with electrocar-
diographic monitoring to observe for QT prolongation
and proarrhythmia in the absence of an implanted
cardioverter-deﬁbrillator.
Dofetilide is a potent and selective inhibitor of IKr that
may be considered for rhythm control in patients who are
at low risk for torsades de pointes induced by QT-interval
prolongation. Dofetilide has minimal noncardiac side
effects. In the SAFIRE-D (Symptomatic Atrial Fibrillation
Investigative Research on Dofetilide) trial, dofetilide (500
mcg twice daily) exhibited 58% efﬁcacy in maintaining
sinus rhythm at 1 year after cardioversion, compared with
only 25% in the placebo group (332). Torsades de pointes
occurred with an incidence of 0.8%. Dofetilide was dis-
continued because of excessive QT prolongation in 5% of
patients. In the DIAMOND (Danish Investigations of
Arrhythmia and Mortality On Dofetilide) study of patients
with reduced LV function, sinus rhythm was maintained
at 1 year in 79% of the dofetilide group compared with
42% of the placebo group (336). In the United States, forinitiation or dose escalation of therapy, inpatient elec-
trocardiographic monitoring is mandatory, as was the
case in clinical trials. Under these circumstances, dofeti-
lide does not increase mortality in HF and post-MI pop-
ulations (373). It is renally cleared, dosed according to
CrCl, and adjusted or discontinued depending on the
degree of QT prolongation. It should not be administered
concomitantly with multiple other drugs that inﬂuence
dofetilide disposition (Table 13) or can prolong the QT
interval.
Dronedarone may be considered for rhythm control in
patients who do not have HF. Dronedarone is a structural
analogue of amiodarone but lacks the iodine moieties of
amiodarone. It is associated with a lower incidence of
adverse events than amiodarone but is also less efﬁca-
cious (360). Its multiple electrophysiological actions
include sympatholytic effects as well as blocking of cal-
cium, sodium, and potassium currents. Dronedarone
reduced the combined endpoint of death and cardio-
vascular complications (largely by reducing hospi-
talizations for AF) in patients with paroxysmal or
persistent AF or atrial ﬂutter and risk factors for throm-
boembolism (350).
Dronedarone increases mortality in patients with
recently decompensated HF and depressed LV function
(283) and is contraindicated in patients with NYHA class
III or IV HF and in patients who have had an episode of
decompensated HF in the past 4 weeks, especially if they
have depressed LV function. In patients with permanent
AF, dronedarone increases the combined endpoint of
stroke, cardiovascular death, and hospitalization (282).
Therefore, dronedarone is contraindicated in patients
whose sinus rhythm is not restored.
The major cardiac adverse effects of dronedarone are
bradycardia and QT prolongation. Torsades de pointes is
rare but has been reported. Like amiodarone, dronedar-
one inhibits renal tubular secretion of creatinine, which
can increase plasma creatinine levels. However, there is
no reduction in the glomerular ﬁltration rate. Dronedar-
one is metabolized by CYP3A4 and is a moderate inhibitor
of CYP2D6 and P-glycoprotein. Consequently, it increases
levels of digoxin and dabigatran and should not be
administered with strong inhibitors of CYP3A4 (e.g., keto-
conazole and macrolide antibiotics), which may poten-
tiate its effects. Dronedarone can be administered with
verapamil or diltiazem, which are moderate CYP3A4 in-
hibitors, but low doses of these agents should be used
initially and titrated according to response and tolerance.
Dronedarone does not alter the INR when used with
warfarin. Dronedarone has been associated with rare
case reports of severe hepatotoxicity occurring within 6
months of initiation; therefore, hepatic serum enzymes
should be monitored, especially during the ﬁrst 6 months
of treatment.
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potent anticholinergic and negative inotropic effects that
can be considered for rhythm control in patients with AF.
Disopyramide can reduce recurrence of AF after direct-
current cardioversion (374). Because of its prominent
vagolytic pharmacological effects, disopyramide is useful
in AF that occurs in the setting of high vagal tone
(“vagally mediated AF”), such as sleep and in response to
stimuli that elicit a vagal response, but there is little
supporting evidence for this approach. Its negative
inotropic effects may be desirable in patients with HCM
associated with dynamic outﬂow tract obstruction (375).
Otherwise, it is avoided in structural heart disease. Dis-
opyramide can also prolong the QT interval.
Quinidine has a sodium channel–blocking effect at
rapid heart rates and a potassium channel–blocking effect
at slower heart rates, as well as vagolytic and alpha-
adrenergic receptorblocking effects, and was among
the ﬁrst antiarrhythmic drugs used to treat AF. It prolongs
the QT interval, can cause torsades de pointes, and is used
infrequently. Cumulative evidence from a systematic
review suggests that quinidine and disopyramide may
increase mortality slightly (365). Quinidine has no nega-
tive inotropic effects and can be used when there is
advanced renal dysfunction. Quinidine requires close
electrocardiographic monitoring at initiation and may be
an alternative treatment for AF when other, newer anti-
arrhythmic drugs cannot be used.
Beta blockers are usually not considered effective for
maintaining sinus rhythm in patients with AF. One
placebo-controlled study of 394 patients with persistent
AF found a lower risk of early recurrence after cardio-
version and slower ventricular response with sustained-
release metoprolol than with placebo (376). Combining
an antiarrhythmic drug with a beta blocker may be helpful
in some patients. These agents are useful to prevent AF in
patients following cardiac surgery and during a high
adrenergic state, such as exercise and thyrotoxicosis-
related AF. At least theoretically, they can aggravate
vagally mediated AF.
See Online Data Supplement 12 for additional data on
antiarrhythmic drug therapy.
6.2.1.2. Outpatient Initiation of Antiarrhythmic Drug Therapy
Drug-related proarrhythmia is most common during the
initiation phase of drug therapy. Serial ECGs are impor-
tant to detect excessive QT prolongation (such as with
dofetilide or sotalol), the appearance of “giant” U waves,
or QRS prolongation >25% (such as with ﬂecainide or
propafenone), and should be performed near the time of
peak drug concentration (377). Inpatient initiation or
dose escalation of dofetilide in an electrocardiographic-
monitored environment is required because of the risk
of untoward QT-interval prolongation and arrhythmiaprovocation (332,336). Sotalol also results in QT prolon-
gation and may cause proarrhythmia. Its initiation and
dose escalation during hospitalization with electrocar-
diographic monitoring should be considered; the package
insert has a corresponding black box warning. There is
considerable experience, however, initiating sotalol
in an outpatient setting. Some experts allow outpatient
initiation when sotalol is started with the patient in
sinus rhythm, provided that the QT interval and
serum potassium level are normal and no other QT
intervalprolonging medications are present, but require
inpatient hospitalization when sotalol is initiated while a
patient is in AF (316). Other experts always initiate sotalol
in an inpatient-monitored setting. Practice patterns vary
widely both in terms of which patients are hospitalized
for initiation of antiarrhythmic drug therapy and in length
of hospitalization. The decision about whether to initiate
other antiarrhythmic drugs in an inpatient or outpatient
setting should be carefully individualized (378). Data
supporting the outpatient initiation of antiarrhythmic
drug therapy are best established for amiodarone and
dronedarone (Table 13).
See Online Data Supplement 13 for additional data on
antiarrhythmic drug therapy.6.2.2. Upstream Therapy: Recommendations
CLASS IIa
1. An ACE inhibitor or angiotensin-receptor blocker (ARB) is
reasonable for primary prevention of new-onset AF in
patients with HF with reduced LVEF (130,379,380). (Level of
Evidence: B)
CLASS IIb
1. Therapy with an ACE inhibitor or ARB may be considered
for primary prevention of new-onset AF in the setting of
hypertension (381). (Level of Evidence: B)
2. Statin therapy may be reasonable for primary prevention of
new-onset AF after coronary artery surgery (136,382). (Level
of Evidence: A)
CLASS III: NO BENEFIT
1. Therapy with an ACE inhibitor, ARB, or statin is not beneﬁcial
for primary prevention of AF in patients without cardiovas-
cular disease (383). (Level of Evidence: B)
The goal of “upstream” therapy (i.e., ACE inhibitors,
ARBs, statins, and n-3 polyunsaturated fatty acids) is to
modify the atrial substrate to reduce susceptibility to, or
progression of, AF. Agents delivered as upstream drug
therapy might have the ability to halt or delay the cellular
processes leading to AF either before (primary prevention)
or after (secondary prevention) the development of AF.
A number of prospective trials investigating ARBs and
polyunsaturated fatty acids for prevention of recurrent
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stream therapies may be valuable strategies for primary
prevention of cardiac changes leading to AF in selected
patients, reversal of AF substrate has not been demon-
strated, and such therapy is not recommended for the
prevention of recurrence of AF in patients without
another indication. In retrospective studies and studies in
which AF was a prespeciﬁed secondary endpoint, ACE
inhibitors or ARBs slightly reduce the development of AF
in patients with HF and LV dysfunction and possibly
those with hypertension and LV hypertrophy (81). Several
systematic reviews of statin therapy to prevent AF have
been performed (136,384,389,390). The administration of
statins may reduce postoperative AF in patients under-
going coronary artery bypass graft surgery (136,382,391).
See Online Data Supplement 14 for additional data on
upstream therapy.
6.3. AF Catheter Ablation to Maintain Sinus Rhythm:
Recommendations
CLASS I
1. AF catheter ablation is useful for symptomatic paroxysmal
AF refractory or intolerant to at least 1 class I or III antiar-
rhythmic medication when a rhythm-control strategy is
desired (363,392–397). (Level of Evidence: A)
2. Before consideration of AF catheter ablation, assessment of
the procedural risks and outcomes relevant to the individual
patient is recommended. (Level of Evidence: C)
CLASS IIa
1. AF catheter ablation is reasonable for some patients with
symptomatic persistent AF refractory or intolerant to at least
1 class I or III antiarrhythmic medication (394,398–400).
(Level of Evidence: A)
2. In patients with recurrent symptomatic paroxysmal AF,
catheter ablation is a reasonable initial rhythm-control
strategy before therapeutic trials of antiarrhythmic drug
therapy, after weighing the risks and outcomes of drug and
ablation therapy (401–403). (Level of Evidence: B)
CLASS IIb
1. AF catheter ablation may be considered for symptomatic long-
standing (>12 months) persistent AF refractory or intolerant to
at least 1 class I or III antiarrhythmic medication when a rhythm-
control strategy is desired (363,404). (Level of Evidence: B)
2. AF catheter ablation may be considered before initiation
of antiarrhythmic drug therapy with a class I or III antiar-
rhythmic medication for symptomatic persistent AF when a
rhythm-control strategy is desired. (Level of Evidence: C)
CLASS III: HARM
1. AF catheter ablation should not be performed in patients
who cannot be treated with anticoagulant therapy during
and after the procedure. (Level of Evidence: C)2. AF catheter ablation to restore sinus rhythm should not be
performed with the sole intent of obviating the need for
anticoagulation. (Level of Evidence: C)
The role of catheter ablation in the management of AF
continues to evolve rapidly, with improvements in the efﬁ-
cacy and safety of the procedure (28). The efﬁcacy of radi-
ofrequency catheter ablation for maintaining sinus rhythm is
superior to current antiarrhythmic drug therapy for main-
tenance of sinus rhythm in selected patient populations. A
number of systematic reviews of the efﬁcacy of AF catheter
ablation versus antiarrhythmic drug therapy have been
performed (363,392–395,405,406). Cryoballoon ablation is an
alternative to point-by-point radiofrequency ablation to
achieve pulmonary vein isolation (407). The evidence sup-
porting the efﬁcacy of catheter ablation is strongest for
paroxysmal AF in younger patients with little to no struc-
tural heart disease (408) and in procedures performed in
highly experienced centers. Studies have demonstrated a
reduction of AF-related symptoms in these contexts (409).
Evidence is insufﬁcient to determine whether AF catheter
ablation reduces all-cause mortality, stroke, and HF (7a,7b).
Ongoing clinical trials (CABANA [Catheter Ablation Versus
Antiarrhythmic Drug Therapy for Atrial Fibrillation] and
EAST [Early Therapy of Atrial Fibrillation for Stroke Pre-
vention Trial]) should provide new information for assessing
whether AF catheter ablation is superior to standard therapy
with either rate- or rhythm-control drugs for reducing total
mortality and other secondary outcome measures and
whether early application of a rhythm-control therapy
involving ablation, antiarrhythmic drugs, or both can impact
endpoints of stroke, cardiovascular death, or HF compared
with usual care. These important trials will help address
whether catheter ablation provides beneﬁt beyond im-
provements in quality of life.
See Online Data Supplements 15 and 16 for additional data
on maintaining sinus rhythm and AF catheter ablation.6.3.1. Patient Selection
The decision whether to pursue catheter ablation depends
on a large number of variables, including the type of AF
(paroxysmal versus persistent versus long-standing
persistent), degree of symptoms, presence of structural
heart disease, candidacy for alternative options such as
rate control or antiarrhythmic drug therapy, likelihood
of complications, and patient preference (28). It is
important to recognize that most patients enrolled in
trials of AF catheter ablation have generally been
younger, healthy persons with symptomatic paroxysmal
AF refractory to 1 or more antiarrhythmic medications.
The safety and efﬁcacy of catheter ablation are less well
established for other populations of patients, especially
patients with long-standing persistent AF, very elderly
patients, and patients with signiﬁcant HF, including
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Figure 7 shows an approach to the integration of antiar-
rhythmic drugs and catheter ablation of AF in patients
without and with structural heart disease.
Two RCTs compared radiofrequency catheter ablation
with antiarrhythmic drug therapy as a ﬁrst-line rhythm-
control treatment. The RAAFT (Radiofrequency Ablation
Versus Antiarrhythmic Drugs for Atrial Fibrillation
Treatment)-2 trial compared the efﬁcacy of AF catheter
ablation with that of antiarrhythmic drug therapy as ﬁrst-line
therapy for rhythm control in 127 patients (88% with
paroxysmal AF) with a higher 1-year freedom from AF (45%
versus 28%; p¼0.02) (402). The MANTRA-PAF (Medical
Antiarrhythmic Treatment or Radiofrequency Ablation in
Paroxysmal Atrial Fibrillation) trial compared AF catheter
ablation with antiarrhythmic drug therapy as ﬁrst-line ther-
apy in 294 patients (410). At the 24-month follow-up, more
patients in the ablation group were free from any AF or
symptomatic AF, and quality of life was signiﬁcantly better
(403). However, total AF burden was not signiﬁcantly
different between the 2 groups, and major complications
requiring intervention were more common in the ablation
group. On the basis of these data, radiofrequency catheter
ablation may be considered as ﬁrst-line therapy in selectFIGURE 7 Strategies for Rhythm Control in Patients With Paroxysmal* and
*Catheter ablation is only recommended as ﬁrst-line therapy for patients with p
†Drugs are listed alphabetically.
‡Depending on patient preference when performed in experienced centers.
§Not recommended with severe LVH (wall thickness >1.5 cm).
kShould be used with caution in patients at risk for torsades de pointes ventricu
¶Should be combined with AV nodal blocking agents.
AF indicates atrial ﬁbrillation; AV, atrioventricular; CAD, coronary artery diseasepatients before a trial of antiarrhythmic drug therapy when a
rhythm-control strategy is desired.
6.3.2. Recurrence After Catheter Ablation
Recurrences of AF after catheter ablation are common
during the ﬁrst 3 months and do not preclude long-term
success, although they are associated with an increased
risk of procedural failure and rehospitalization. Therefore,
when AF occurs early after catheter ablation, a pharmaco-
logical rhythm-control approach rather than early repeat
ablation should be considered (28). Patients who have had
AF catheter ablation and develop persistent AF within the
3 months following ablation may require cardioversion.
Recurrent AF after 3 months is usually an indication of
recovery of pulmonary vein conduction and may respond
to repeat ablation or initiation of an antiarrhythmic
drug (411). A number of centers have reported late AF
recurrences >1 year after catheter ablation (78,412–415).
6.3.3. Anticoagulation Therapy Periablation
Because of the well-established risk of periprocedure
stroke or TIA associated with AF catheter ablation,
there is consensus that anticoagulation is indicated
to prevent thromboembolism around the time ofPersistent AF†
aroxysmal AF (Class IIa recommendation).
lar tachycardia.
; HF, heart failure; and LVH, left ventricular hypertrophy.
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tient’s baseline thromboembolic risk. Detailed consensus
recommendations have been published about the
approach to anticoagulation before, during, and after
catheter ablation (28). Both intraprocedural heparin and
oral anticoagulation are recommended for $2 months
postprocedure. AF catheter ablation should not be per-
formed in patients who cannot be treated with anticoag-
ulant therapy during and after the procedure.
Several reports indicate that AF catheter ablation may be
performed with fewer complications when oral warfarin
anticoagulation is continued as an alternative to a bridging
approach with UFH or LMWH (243,416–418). Several centers
reported their experience with the use of direct thrombin
and factor Xa inhibitors (mainly dabigatran) around the time
of AF catheter ablation (244,324,419–422). Typically, dabi-
gatran was held for 1 or 2 doses before the ablation proce-
dure, in part reﬂecting the lack of a reversal agent. These
reports suggest that the use of dabigatran is associated with a
similar risk of bleeding and thromboembolic complications
compared with uninterrupted warfarin; however, this is not
a uniform ﬁnding (244).
Continuation of anticoagulation >2 months after AF
catheter ablation, if the procedure is perceived as successful,
should be based on consideration of the patient’s thrombo-
embolic risk proﬁle (Section 4.1), bleeding risk, and patient
choice. Recurrence of AF after ablation is 3 to 7 times more
likely to be asymptomatic compared with before ablation
(423,424), and AF can recur late. Several large case series
have reported a low risk of stroke after AF ablation
(425–428). Although the stroke rate is low in these series, few
patients at high risk of stroke were monitored after
anticoagulation was stopped for a signiﬁcant period of time.
6.3.4. Catheter Ablation in HF
A number of smaller clinical trials have evaluated the role
of AF catheter ablation in selected patients with LV
dysfunction and HF and demonstrate a reasonable rate of
successful sinus rhythm maintenance with improvements
in LVEF and symptoms (47,307,429). The degree to which
LVEF improves varies according to patient characteristics
(430). In cases where LV dysfunction is thought to be due
to AF itself, AF catheter ablation and maintenance of si-
nus rhythm may result in a marked improvement. It may
be difﬁcult to determine in this population whether
symptoms are related to AF or the underlying HF and
whether AF itself has contributed to the decline in LVEF.
Improved rate control or cardioversion with antiar-
rhythmic drug therapy may help determine the causality.
Because of the extent of remodeling and underlying heart
disease, recurrence rates (431) and complication rates are
higher in this population. A meta-analysis reported that
the single-procedure efﬁcacy of AF catheter ablation was
lower in patients with systolic dysfunction, but a similarsuccess rate could be achieved among patients with and
without systolic dysfunction with repeat procedures
(432). Patient selection biases likely inﬂuence reported
outcomes. Taken as a whole, catheter ablation may be
reasonable to treat symptomatic AF in selected patients
with signiﬁcant LV dysfunction and HF.
6.3.5. Complications Following AF Catheter Ablation
AF catheter ablation is associated with important risks of
major complications. A 2010 international survey of
radiofrequency catheter ablation procedures reported a
4.5% incidence of major complications, including a 1.3%
rate of cardiac tamponade, a 0.94% rate of stroke or TIA, a
0.04% rate of atrial-esophageal ﬁstula, and a 0.15% rate of
death (433). A European observational multinational
registry reported a complication rate of 7.7%, of which
1.7% were major complications (434). A report from a
statewide inpatient database described a complication
rate of 5% with a 9% readmission rate (435). Much of the
data on rates of complications is derived from experi-
enced centers or voluntary registries.
Table 14 lists the complications associated with radio-
frequency catheter ablation for AF. A detailed summary of
deﬁnitions and prevention of speciﬁc complications is
covered elsewhere (28). Factors associated with compli-
cation rates include older age, female sex, and a CHADS2
score $2 (435–437). Also, LA catheter ablation results in a
small incidence of asymptomatic cerebral embolism
detectable on cranial magnetic resonance imaging. Most
of these lesions resolve or disappear over time. Further
research is needed to better deﬁne the relationship be-
tween ablation strategy and risk and to determine
methods to eliminate them (28,438,439).
6.4. Pacemakers and Implantable Cardioverter-Deﬁbrillators
for Prevention of AF
The primary role of pacemakers in the treatment of pa-
tients with AF is treatment of symptomatic bradycardia,
which is often related to underlying sick sinus syn-
drome. Antiarrhythmic therapy may exacerbate sick
sinus syndrome and require pacemaker implantation.
For patients with sick sinus syndrome who need pacing,
atrial or dual-chamber pacing signiﬁcantly decreases
the incidence of subsequent AF compared with RV pac-
ing (18). Attempts to prevent AF episodes by proprietary
overdrive atrial pacing algorithms that react to pre-
mature atrial complexes are inconsistent (18). Therefore,
permanent pacing is not indicated for the prevention
of AF in patients without other indications for pacemaker
implantation. Atrial deﬁbrillators to automatically cardiovert
AF do not have clinical value; most patients ﬁnd discharge
energies >1 J uncomfortable, and early recurrence of AF
following a shock is common. Implanted deﬁbrillators are
not indicated for rhythm control of AF.
TABLE 14 Complications of Radiofrequency Catheter Ablation for AF
Complication Symptoms/Signs Treatment
Air embolism Acute ischemia, cardiac arrest, AV block, hypotension Supplemental oxygen, ﬂuids, CPR, or pacing if indicated
Atrial-esophageal ﬁstula Usually 1–4 wk after ablation, dysphagia,
unexplained fever, chills, sepsis, neurological events
(septic emboli)
CT or MRI of esophagus, avoiding endoscopy, immediate
surgical correction
Cardiac tamponade/perforation Abrupt or gradual fall in BP Pericardiocentesis, emergent surgical drainage if
pericardiocentesis fails
Phrenic nerve injury resulting in
diaphragmatic paralysis
Shortness of breath, elevated hemidiaphragm None; usually resolves spontaneously
Iatrogenic atrial ﬂutter Tachycardia Cardioversion, antiarrhythmic drugs, or repeat ablation
Gastric motility disorder Nausea, vomiting, bloating, abdominal pain Depends on severity of symptoms
Mitral valve injury requiring surgery Entrapment of catheter Advance sheath with gentle catheter retraction,
surgical removal
MI Chest pain, ST changes, hypotension Standard therapy
Pericarditis Chest pain, typical quality NSAIDs, colchicine, steroids
Pulmonary vein stenosis Shortness of breath, cough, hemoptysis PV dilation/stent or no therapy
Radiation injury Pain and reddening at radiation site; can present late Treat as burn injury
Stroke or TIA Neurological deﬁcit Consider lysis therapy
Vascular access complications
 Femoral pseudoaneurysm Pain or pulsatile mass at groin Observation, compression, thrombin injection, possible surgery
 Arteriovenous ﬁstula Pain, bruit at groin site Observation, compression, possible surgery
 Hematoma Pain, swelling Compression
Death N/A N/A
AF indicates atrial ﬁbrillation; AV, atrioventricular; BP, blood pressure; CPR, cardiopulmonary resuscitation; CT, computed tomography; MI, myocardial infarction; MRI, magnetic
resonance imaging; N/A, not applicable; NSAIDs, nonsteroidal anti-inﬂammatory drugs; PV, pulmonary valve; and TIA, transient ischemic attack.
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CLASS IIa
1. An AF surgical ablation procedure is reasonable for selected
patients with AF undergoing cardiac surgery for other
indications. (Level of Evidence: C)
CLASS IIb
1. A stand-alone AF surgical ablation procedure may be
reasonable for selected patients with highly symptomatic AF
not well managed with other approaches (440). (Level of
Evidence: B)
The surgical maze procedure was introduced in 1987.
The initial 2 iterations were associated with high rates of
pacemaker implantation and are no longer performed.
The third version (Cox maze III) became the standard
surgical procedure to restore sinus rhythm in patients
with AF (441) but is not widely performed because of
surgeons’ reluctance to perform this complicated “cut and
sew” atrial lines of ablation operation approach in asso-
ciation with valve or coronary artery bypass procedures or
as a stand-alone procedure. The Cox maze intravenous
operation is less invasive, using radiofrequency or cry-
oablation to replicate surgical lines of ablation (442).
Data on long-term outcomes in patients undergoing
stand-alone AF surgery are limited. Of 282 patients pro-
spectively studied from 2002 to 2009 who underwent theCox maze IV procedure, 42% had paroxysmal AF and 58%
had either persistent or long-standing persistent AF (442).
Ninety-ﬁve of 282 patients (34%) had a stand-alone pro-
cedure, and 187 of 282 patients (66%) had a concomitant
AF procedure. Overall operative mortality was 2% (1% in
stand-alone maze procedures), and freedom from atrial
tachyarrhythmias was 89%, 93%, and 89% at 3, 6, and 12
months, respectively. Freedom from atrial tachyarrhyth-
mias off all antiarrhythmic drugs was 63%, 79%, and 78%
at 3, 6, and 12 months, respectively. In the period of the
study subsequent to 2006, 24-hour Holter monitoring or
pacemaker interrogation was performed in these patients.
In this cohort, 92% were free of atrial tachyarrhythmias,
and 78% were not taking antiarrhythmic drugs (442).
Nine RCTs comparing patients who undergo concomitant
AF surgery with patients who undergo mitral valve surgery
alone suggest greater freedom from AF in treated patients
(443–451); however, in the composite body of evidence,
there was no consistent surgical technique, patient pop-
ulations in the trial were quite varied, a consistent endpoint
deﬁning procedural success was lacking, and long-term
clinical endpoints were often missing as well.
The Society of Thoracic Surgeons Adult Cardiac Surgery
Database from 2005 to 2010 recorded 91 801 AF surgical
ablations, of which 4893 (5.3%) were stand-alone pro-
cedures (452). Propensity matching of 1708 patients
with and without cardiopulmonary bypass showed no
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bypass group” had fewer reoperations for bleeding,
shorter hospital stays, and less prolonged ventilation.
Minimally invasive stand-alone operations, bilateral pul-
monary vein isolation, intraoperative conﬁrmation of
mapping, ablation of ganglionic plexi, and exclusion of
the LAA procedures have been developed. Of 114 patients
undergoing bilateral minithoracotomy surgical ablation of
AF, 2 patients (1.8%) died within the perioperative period,
and the overall complication rate was 10% (453). At the
6-month follow-up (ECG, Holter monitor, event monitor,
or pacemaker interrogation), 52 of 60 patients (87%) with
paroxysmal AF were in sinus rhythm and 43 of 60 patients
(72%) were off antiarrhythmic drugs. In patients with
persistent or long-standing persistent AF, the success
rates of freedom from AF were lower, at 18 of 32 patients
(56%) and 11 of 22 patients (50%), respectively.
The FAST (Atrial Fibrillation Catheter Ablation Versus
Surgical Ablation Treatment) trial compared the outcomes
of catheter ablation and surgical ablation in a randomized
study design (440). Patients either had LA dilation and
hypertension (42 patients, 33%) or failed prior catheter
ablation (82 patients, 67%). Freedom from atrial arrhyth-
mias was greater after surgical ablation compared with
catheter ablation, but the complication rate after surgical
ablation was higher. Decisions about the choice of
catheter-based or surgical ablation must be made on the
basis of patient preference and institutional experience
and outcomes with each therapy (28).
7. SPECIFIC PATIENT GROUPS AND AF
See Table 15 for a summary of recommendations for this
section and Online Data Supplement 17 for additional data
on speciﬁc patient groups and AF.
7.1. Athletes
Paroxysmal or persistent AF is common in athletes and may
be autonomically mediated or triggered by other supraven-
tricular tachycardias (454). Contributing conditions such as
hypertension and CAD should be considered, particularly for
older athletes, and a transthoracic echocardiogram is helpful
to evaluate for structural heart disease. Evaluation of the rate
of ventricular response during an episode of AF is warranted
and may require ambulatory electrocardiographic moni-
toring and/or exercise testing to a level of exertion similar
to that of the intended sport. Other therapies such as
radiofrequency catheter ablation or a “pill-in-the-pocket”
approach can be considered in athletes. Speciﬁcs of these
therapies are considered in Section 6.1.3 (455).
7.2. Elderly
The prevalence of AF increases with age, and approxi-
mately 35% of patients with AF are $80 years of age(30,31). The elderly are a heterogeneous group with
potential for multiple comorbidities (Table 3). It is critical
to consider the implications of comorbidities to ensure
that the patient’s overall goals of care are factored into
management decisions. For the older patient with AF,
symptoms may be minimal and somewhat atypical. The
risk of stroke is increased in the elderly. For this reason,
the CHA2DS2-VASc risk scoring system identiﬁes 65 to 74
years of age as a minor risk factor for stroke and $75 years
of age as a major risk factor for stroke (Section 4.1).
Because AF is often associated with minimal or no
symptoms in this population and the clearance of
antiarrhythmic medications is diminished, sensitivity to
proarrhythmic effects, including bradyarrhythmias, is
often increased. Therefore, a rate-control strategy is often
preferred (30), and direct-current cardioversion is less
often warranted (456). Typically, rate control can be
achieved with beta blockers or nondihydropyridine cal-
cium channel antagonists. Care must be taken in these
patients because they are often more susceptible to
orthostatic hypotension or bradyarrhythmias and when
AF is paroxysmal and sinus node dysfunction is more
common. Comorbidities should also be considered.
Digoxin can be useful for rate control in the relatively
sedentary individual, but there are concerns about its
risks (Section 5.1.3).
7.3. Hypertrophic Cardiomyopathy: Recommendations
CLASS I
1. Anticoagulation is indicated in patients with HCM with AF
independent of the CHA2DS2-VASc score (50,457). (Level of
Evidence: B)
CLASS IIa
1. Antiarrhythmic medications can be useful to prevent recur-
rent AF in patients with HCM. Amiodarone or disopyramide
combined with a beta blocker or nondihydropyridine calcium
channel antagonists are reasonable for therapy. (Level of
Evidence: C)
2. AF catheter ablation can be beneﬁcial in patients with HCM
in whom a rhythm-control strategy is desired when antiar-
rhythmic drugs fail or are not tolerated (458–461). (Level of
Evidence: B)
CLASS IIb
1. Sotalol, dofetilide, and dronedarone may be considered for a
rhythm-control strategy in patients with HCM (11). (Level of
Evidence: C)
Patients with HCM are considered separately because
their unique pathology distinguishes them from other
patients with LV hypertrophy. HCM is deﬁned on the
basis of standard criteria such as the echocardiographic
identiﬁcation of a hypertrophied, nondilated LV in the
absence of another cardiac or systemic disease capable of
TABLE 15 Summary of Recommendations for Speciﬁc Patient Groups and AF
Recommendations COR LOE References
Hypertrophic cardiomyopathy
Anticoagulation is indicated in HCM with AF independent of the CHA2DS2-VASc score I B (50,457)
Antiarrhythmic drugs can be useful to prevent recurrent AF in HCM. Amiodarone or disopyramide combined
with a beta blocker or nondihydropyridine calcium channel antagonist are reasonable
IIa C N/A
AF catheter ablation can be beneﬁcial for HCM to facilitate a rhythm-control strategy when antiarrhythmics
fail or are not tolerated
IIa B (458–461)
Sotalol, dofetilide, and dronedarone may be considered for a rhythm-control strategy in HCM IIb C (11)
AF complicating ACS
Urgent cardioversion of new-onset AF in the setting of ACS is recommended for patients with hemodynamic
compromise, ongoing ischemia, or inadequate rate control
I C N/A
IV beta blockers are recommended to slow RVR with ACS and no HF, hemodynamic instability, bronchospasm I C N/A
With ACS and AF with CHA2DS2-VASc score $2, anticoagulation with warfarin is recommended unless contraindicated I C N/A
Amiodarone or digoxin may be considered to slow RVR with ACS and AF and severe LV dysfunction and HF
or hemodynamic instability
IIb C N/A
Nondihydropyridine calcium antagonists might be considered to slow RVR with ACS and AF only in the absence
of signiﬁcant HF or hemodynamic instability
IIb C N/A
Hyperthyroidism
Beta blockers are recommended to control ventricular rate with AF complicating thyrotoxicosis unless contraindicated I C N/A
When beta blockers cannot be used, a nondihydropyridine calcium channel antagonist is recommended to control
ventricular rate
I C N/A
Pulmonary diseases
A nondihydropyridine calcium channel antagonist is recommended to control ventricular rate with AF and COPD I C N/A
Cardioversion should be attempted for patients with pulmonary disease who become hemodynamically unstable
with new-onset AF
I C N/A
WPW and pre-excitation syndromes
Cardioversion is recommended for patients with AF, WPW syndrome, and RVR who are hemodynamically compromised I C (64)
IV procainamide or ibutilide to restore sinus rhythm or slow ventricular rate is recommended for patients with
pre-excited AF and RVR who are not hemodynamically compromised
I C (64)
Catheter ablation of the accessory pathway is recommended in symptomatic patients with pre-excited AF, especially
if the accessory pathway has a short refractory period
I C (64)
IV amiodarone, adenosine, digoxin, or nondihydropyridine calcium channel antagonists in patients with WPW syndrome
who have pre-excited AF is potentially harmful
III: Harm B (493–495)
Heart failure
A beta blocker or nondihydropyridine calcium channel antagonist is recommended for persistent or permanent AF
in patients with HFpEF
I B (269)
In the absence of preexcitation, an IV beta blocker (or a nondihydropyridine calcium channel antagonist with HFpEF)
is recommended to slow ventricular response to AF in the acute setting, with caution in patients with
overt congestion, hypotension, or HFrEF
I B (502–505)
In the absence of pre-excitation, IV digoxin or amiodarone is recommended to control heart rate acutely I B (277,503,506,507)
Assess heart rate during exercise and adjust pharmacological treatment in symptomatic patients during activity I C N/A
Digoxin is effective to control resting heart rate with HFrEF I C N/A
A combination of digoxin and beta blocker (or a nondihydropyridine calcium channel antagonist with HFpEF) is
reasonable to control resting and exercise heart rate with AF
IIa B (267,503)
It is reasonable to perform AV node ablation with ventricular pacing to control heart rate when pharmacological
therapy is insufﬁcient or not tolerated
IIa B (269,508,509)
IV amiodarone can be useful to control heart rate with AF when other measures are unsuccessful or contraindicated IIa C N/A
With AF and RVR causing or suspected of causing tachycardia-induced cardiomyopathy, it is reasonable to achieve
rate control by AV nodal blockade or a rhythm-control strategy
IIa B (51,307,510)
In patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is reasonable to use
a rhythm-control strategy
IIa C N/A
Amiodarone may be considered when resting and exercise heart rate cannot be controlled with a beta blocker
(or a nondihydropyridine calcium channel antagonist with HFpEF) or digoxin, alone or in combination
IIb C N/A
AV node ablation may be considered when rate cannot be controlled and tachycardia-mediated cardiomyopathy
is suspected
IIb C N/A
Continued on the next page
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TABLE 15 Continued
Recommendations COR LOE References
AV node ablation should not be performed without a pharmacological trial to control ventricular rate III: Harm C N/A
For rate control, IV nondihydropyridine calcium channel antagonists, IV beta blockers, and dronedarone should
not be given with decompensated HF
III: Harm C N/A
Familial (genetic) AF
For patients with AF and multigenerational family members with AF, referral to a tertiary care center for genetic
counseling and testing may be considered
IIb C N/A
Postoperative cardiac and thoracic surgery
A beta blocker is recommended to treat postoperative AF unless contraindicated I A (533–536)
A nondihydropyridine calcium channel blocker is recommended when a beta blocker is inadequate to achieve rate
control with postoperative AF
I B (537)
Preoperative amiodarone reduces AF with cardiac surgery and is reasonable as prophylactic therapy for patients
at high risk of postoperative AF
IIa A (538–540)
It is reasonable to restore sinus rhythm pharmacologically with ibutilide or direct-current cardioversion with
postoperative AF
IIa B (541)
It is reasonable to administer antiarrhythmic medications to maintain sinus rhythm with recurrent or refractory
postoperative AF
IIa B (537)
It is reasonable to administer antithrombotic medications for postoperative AF IIa B (542)
It is reasonable to manage new-onset postoperative AF with rate control and anticoagulation with cardioversion
if AF does not revert spontaneously to sinus rhythm during follow-up
IIa C N/A
Prophylactic sotalol may be considered for patients with AF risk after cardiac surgery IIb B (536,543)
Colchicine may be considered postoperatively to reduce AF after cardiac surgery IIb B (544)
ACS indicates acute coronary syndromes; AF, atrial ﬁbrillation; AV, atrioventricular; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age$75 years (doubled), Diabetes mellitus,
Prior Stroke or TIA or thromboembolism (doubled), Vascular disease, Age 65 to 74 years, Sex category; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation;
HCM, hypertrophic cardiomyopathy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LOE,
Level of Evidence; LV, left ventricular; N/A, not applicable; RVR, rapid ventricular response; and WPW, Wolff-Parkinson-White.
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AF is relatively common in HCM, increases with age, and
is often poorly tolerated symptomatically (50). The inci-
dence of AF is estimated at 2% per year in patients with
HCM, and approximately two thirds of patients with both
HCM and AF are paroxysmal (50). AF is associated with
increased mortality in patients with HCM (3% in patients
with AF versus 1% in sinus rhythm per year) (50,463) and
is primarily due to HF. The HF risk associated with AF in
patients with HCM is worse in patients with outﬂow
obstruction and those who develop AF before 50 years of
age (50).
There is an important risk of stroke and systemic
embolism in patients with HCM and AF (50,464,465). In a
study of 480 patients with HCM, the OR for stroke in
those with AF was 17.7 (50). Although no randomized
studies of anticoagulant therapy have been reported, the
incidence of thromboembolism in patients with HCM and
AF is high, and anticoagulation is indicated for these
patients independent of their CHA2DS2-VASc (or CHADS2)
scores. Anticoagulation with direct thrombin or factor Xa
inhibitors may represent another option to reduce the risk
of thromboembolic events, but data for patients with
HCM are not available (50,177,457).
Given the poor tolerance of AF in patients with HCM, a
rhythm-control strategy is preferred. However, for those
patients for whom a rate-control strategy is chosen, anondihydropyridine calcium channel blocker, a beta
blocker, or a combination of the 2 drugs is preferable.
Digoxin, a positive inotrope, may increase the outﬂow
gradient in HCM patients and should be avoided. There
have been no systematic studies of the treatment of AF in
patients with HCM, but various antiarrhythmic agents
have been used, including disopyramide, propafenone,
amiodarone, sotalol, dofetilide, and dronedarone. An
implantable cardioverter-deﬁbrillator may provide added
safety with QT intervalprolonging drugs. Amiodarone
or disopyramide in combination with ventricular rate-
controlling agents is generally preferred (11,466).
Success and complication rates for AF catheter ablation
appear to be similar for HCM and other forms of heart
disease, but reported outcomes are likely inﬂuenced by
selection bias (11,458,460). The surgical maze procedure
for AF shows some success (467); however, the role of a
surgical maze procedure for patients undergoing other
open chest surgical procedures (i.e., septal myectomy) is
unresolved (11,467).
7.4. AF Complicating ACS: Recommendations
CLASS I
1. Urgent direct-current cardioversion of new-onset AF in the
setting of ACS is recommended for patients with hemody-
namic compromise, ongoing ischemia, or inadequate rate
control. (Level of Evidence: C)
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ventricular response to AF in patients with ACS who do not
display HF, hemodynamic instability, or bronchospasm.
(Level of Evidence: C)
3. For patients with ACS and AF with a CHA2DS2-VASc score of
2 or greater, anticoagulation with warfarin is recommended
unless contraindicated. (Level of Evidence: C)
CLASS IIb
1. Administration of amiodarone or digoxin may be considered
to slow a rapid ventricular response in patients with ACS and
AF associated with severe LV dysfunction and HF or hemo-
dynamic instability. (Level of Evidence: C)
2. Administration of nondihydropyridine calcium antagonists
might be considered to slow a rapid ventricular response in
patients with ACS and AF only in the absence of signiﬁcant
HF or hemodynamic instability. (Level of Evidence: C)
The incidence of AF in patients with ACS ranges from 10% to
21% and increases with patient age and severity of MI
(138,468). In the Medicare population, AF is associated with
increased in-hospital mortality (25.3% with AF versus 16.0%
without AF), 30-day mortality (29.3% versus 19.1%), and
1-year mortality (48.3% versus 32.7%) (138). With multivar-
iate adjustment, AF remains an independent predictor of
mortality: in-hospital (OR: 1.21), 30-day (OR: 1.20), and 1-year
(OR: 1.34) (138). Patients who develop AF during hospitali-
zation have a worse prognosis than those with AF on
admission (138). Stroke rates are increased in patients with
MI and AF compared with rates in those without AF (3.1% for
those with AF versus 1.3% for those in normal sinus rhythm)
(468). Thus, AF is an independent predictor of poor long-
term outcome in patients with ACS (469,470). Speciﬁc rec-
ommendations for management of patients with AF in the
setting of ACS are based primarily on consensus because no
adequate trials have tested alternative strategies (20).
Patients treated for ACS normally require dual anti-
platelet therapy with aspirin plus other platelet in-
hibitors, such as clopidogrel, and may require the
addition of warfarin or a novel oral anticoagulant (“triple
therapy”) as treatment of AF (186) (Section 4.3). In pa-
tients with long-standing AF or a moderate-to-high
CHA2DS2-VASc score, efforts should be directed to mini-
mize duration of triple therapy, and decisions about stent
insertion should consider the potential requirement for
long-term anticoagulant therapy. For patients who
develop transient AF as a complication of ACS and who do
not have a prior history of AF, the need for anti-
coagulation and the duration of oral anticoagulation
should be based on the patient’s CHA2DS2-VASc score. Use
of dual antiplatelet therapy alone may be considered for
patients with ACS who have AF and a low CHA2DS2-VASc
score, with reconsideration of the indications for anti-
coagulation over time (199,323). An option is to considerthe use of oral anticoagulation plus clopidogrel with or
without aspirin (186). The novel oral anticoagulants have
not been evaluated in the context of AF and ACS, and thus
no recommendation for their use can be made.
Urgent direct-current cardioversion is appropriate in
patients with ACS presenting with new-onset AF and
intractable ischemia, hemodynamic instability, or inade-
quate rate control. Intravenous administration of a beta
blocker is indicated for rate control in patients with ACS
to reduce myocardial oxygen demands. Intravenous
amiodarone is an appropriate alternative for rate control
and may facilitate conversion to normal sinus rhythm.
Digoxin may be considered in those with severe LV
dysfunction and HF or hemodynamic instability. Systemic
anticoagulation is indicated in those with large anterior
infarcts and in survivors of ACS who develop persistent
AF. Treatment with ACE inhibitors appears to reduce the
incidence of AF in patients with LV dysfunction after ACS
(471,472).
7.5. Hyperthyroidism: Recommendations
CLASS I
1. Beta blockers are recommended to control ventricular rate in
patients with AF complicating thyrotoxicosis unless contra-
indicated. (Level of Evidence: C)
2. In circumstances in which a beta blocker cannot be used, a
nondihydropyridine calcium channel antagonist is recom-
mended to control the ventricular rate. (Level of Evidence: C)
AF is the most common arrhythmia in patients with hyper-
thyroidism (5% to 15% of patients) and is more frequent
among those >60 years of age (152,473,474). Complications
of AF in hyperthyroidism include HF and thromboembolism,
although the correlation with thromboembolic disease is
controversial (473–481). Treatment is directed primarily
toward restoring a euthyroid state, which is usually associ-
ated with a spontaneous reversion of AF to sinus rhythm.
Antiarrhythmic drugs and cardioversion often fail to achieve
sustained sinus rhythm while thyrotoxicosis persists (482);
therefore, efforts to restore normal sinus rhythm may be
deferred until the patient is euthyroid. Beta blockers are
effective in controlling the ventricular rate in this situation,
and treatment with beta blockers is particularly important in
cases of thyroid storm; nondihydropyridine calcium channel
antagonists are recommended for rate control (483).
Although several studies reported thromboembolism in pa-
tients with thyrotoxicosis and AF, evidence suggests that
embolic risk was not necessarily increased independent of
other stroke risk factors (484,485). Anticoagulation for the
patient with thyrotoxicosis and AF should be guided by
CHA2DS2-VASc risk factors (Sections 4.1 and 4.1.1).
Hyperthyroidism and thyrotoxicosis can infrequently
result from long-term amiodarone use. In the event
of iatrogenic hyperthyroidism during treatment with
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and beneﬁts of treating patients with AF with a known
history of thyroid disease with amiodarone should be
carefully weighed before initiation of therapy, and
patients should be monitored closely (486).
7.6. Acute Noncardiac Illness
A number of acute noncardiac conditions are associated
with AF (e.g., hypertension, postoperative state, pulmo-
nary embolism, viral infections). Management of the un-
derlying condition and correction of contributing factors
as ﬁrst-line treatment is common to all of these scenarios
(487), and for many of these patients AF will spontane-
ously terminate with correction of the underlying condi-
tion. However, during acute illness, patients may require
rate control with cardioversion, AV nodal blockers, and/or
antiarrhythmic drugs if AF is poorly tolerated or rate
control is not feasible. The speciﬁc rate- or rhythm-
control agent(s) will depend on the underlying medical
condition. Of note is that an elevated catecholamine state
is common to many of these clinical circumstances, and
unless contraindicated, a beta blocker is the preferred
initial drug. The role of anticoagulation is less clear and
likely disease speciﬁc and needs to be addressed on the
basis of risk proﬁle and duration of AF.
7.7. Pulmonary Disease: Recommendations
CLASS I
1. A nondihydropyridine calcium channel antagonist is re-
commended to control the ventricular rate in patients with
AF and chronic obstructive pulmonary disease. (Level of
Evidence: C)
2. Direct-current cardioversion should be attempted in patients
with pulmonary disease who become hemodynamically
unstable as a consequence of new-onset AF. (Level of
Evidence: C)
Supraventricular arrhythmias, including AF, are common
in patients with chronic obstructive pulmonary disease
(488–490). AF should be distinguished from multifocal atrial
tachycardia, which is unlikely to respond to electrical car-
dioversion but will often slow with treatment of the under-
lying disease and in response to nondihydropyridine calcium
channel blockers (491). Treatment of the underlying lung
disease and correction of hypoxia and acid-base imbalance
are of primary importance in this situation and represent
ﬁrst-line therapy. Antiarrhythmic drug therapy and cardio-
version may be ineffective against AF until respiratory
decompensation has been corrected. Theophylline and beta-
adrenergic agonists can precipitate AF and make control of
the ventricular response rate difﬁcult. Non–beta-1-selective
blockers, sotalol, propafenone, and adenosine are contra-
indicated in patients with bronchospasm. However, beta
blockers, sotalol, or propafenone may be considered inpatients with obstructive lung disease who develop AF and
do not have bronchospasm. Rate control can usually be
achieved safely with nondihydropyridine calcium channel
antagonists or possibly amiodarone (275). Digoxin can be
used with calcium channel blockers, particularly in those
with preserved LVEF (492). In patients refractory to drug
therapy, AV nodal ablation and ventricular pacing may be
necessary to control the ventricular rate. Anticoagulation,
although not speciﬁcally studied in patients with AF due to
pulmonary disease, is discussed in Section 4.2 for risk-based
antithrombotic therapy.
7.8. WPW and Pre-Excitation Syndromes: Recommendations
CLASS I
1. Prompt direct-current cardioversion is recommended for
patients with AF, WPW syndrome, and rapid ventricular
response who are hemodynamically compromised (64).
(Level of Evidence: C)
2. Intravenous procainamide or ibutilide to restore sinus
rhythm or slow the ventricular rate is recommended for
patients with pre-excited AF and rapid ventricular response
who are not hemodynamically compromised (64). (Level of
Evidence: C)
3. Catheter ablation of the accessory pathway is recommended
in symptomatic patients with pre-excited AF, especially if
the accessory pathway has a short refractory period
that allows rapid antegrade conduction (64). (Level of
Evidence: C)
CLASS III: HARM
1. Administration of intravenous amiodarone, adenosine,
digoxin (oral or intravenous), or nondihydropyridine calcium
channel antagonists (oral or intravenous) in patients with
WPW syndrome who have pre-excited AF is potentially
harmful because these drugs accelerate the ventricular rate
(493–495). (Level of Evidence: B)
AF is of speciﬁc concern in patients with WPW syndrome
because of the potential for degeneration to ventricular
ﬁbrillation related to rapidly conducting anterograde
accessory pathways. The risk of developing AF over 10
years in patients with WPW syndrome is estimated at 15%,
although the mechanism of increased AF risk is poorly
understood (496,497). Approximately 25% of patients with
WPW syndrome have accessory pathways with short
anterograde refractory periods (<250 msec), which are
associated with a risk of rapid ventricular rates and ven-
tricular ﬁbrillation (498,499). Patients with multiple
accessory pathways are also at greater risk of ventricular
ﬁbrillation (498). The safety and efﬁcacy of catheter abla-
tion of the accessory pathway is established (64); how-
ever, ablation of the accessory pathway does not always
prevent AF, especially in older patients, and additional
pharmacological or ablative therapy may be required. Once
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of selecting pharmacological therapy is the same as for
patients without pre-excitation.
Speciﬁcs of antiarrhythmic therapies are described in
Section 6. During AF, the ventricular rate is determined
by competing conduction over the AV node and the
accessory pathway(s). As with any unstable arrhythmia,
cardioversion is recommended for hemodynamic insta-
bility (64). Agents that slow AV nodal conduction
without prolonging accessory pathway refractoriness
can accelerate the ventricular rate and precipitate
hemodynamic collapse and ventricular ﬁbrillation in
high-risk patients. Intravenous administration of ibuti-
lide or procainamide may slow the rate of conduction
over the accessory pathway, slow the ventricular rate,
or may convert AF to sinus rhythm; it is recommended
for hemodynamically stable patients in the setting of AF
with conduction over an accessory pathway. Verapamil,
diltiazem, adenosine, digoxin (oral or intravenous), and
intravenous amiodarone can precipitate ventricular
ﬁbrillation and should not be used (493,495). Similarly,
use of lidocaine in pre-excited AF is considered poten-
tially harmful (500). Oral amiodarone can slow or
block accessory pathway conduction during chronic oral
therapy. Although beta blockers theoretically pose a
similar potential risk, the data are sparse regarding
administration of these agents in rapid AF in patients
with WPW syndrome; nevertheless, they should be used
with caution (494,501).
7.9. Heart Failure: Recommendations
CLASS I
1. Control of resting heart rate using either a beta blocker or
nondihydropyridine calcium channel antagonist is recom-
mended for patients with persistent or permanent AF and
compensated HF with preserved ejection fraction (HFpEF)
(269). (Level of Evidence: B)
2. In the absence of pre-excitation, intravenous beta-blocker
administration (or a nondihydropyridine calcium channel
antagonist in patients with HFpEF) is recommended to slow
the ventricular response to AF in the acute setting, with
caution needed in patients with overt congestion, hypo-
tension, or HF with reduced LVEF (502–505). (Level of
Evidence: B)
3. In the absence of pre-excitation, intravenous digoxin or
amiodarone is recommended to control heart rate acutely in
patients with HF (277,503,506,507). (Level of Evidence: B)
4. Assessment of heart rate control during exercise and
adjustment of pharmacological treatment to keep the rate in
the physiological range is useful in symptomatic patients
during activity. (Level of Evidence: C)
5. Digoxin is effective to control resting heart rate in patients
with HF with reduced EF. (Level of Evidence: C)CLASS IIa
1. A combination of digoxin and a beta blocker (or a non-
dihydropyridine calcium channel antagonist for patients with
HFpEF) is reasonable to control resting and exercise heart
rate in patients with AF (267,503). (Level of Evidence: B)
2. It is reasonable to perform AV node ablation with ventricular
pacing to control heart rate when pharmacological therapy
is insufﬁcient or not tolerated (269,508,509). (Level of
Evidence: B)
3. Intravenous amiodarone can be useful to control heart rate
in patients with AF when other measures are unsuccessful or
contraindicated. (Level of Evidence: C)
4. For patients with AF and rapid ventricular response causing
or suspected of causing tachycardia-induced cardiomyopa-
thy, it is reasonable to achieve rate control by either AV
nodal blockade or a rhythm-control strategy (51,307,510).
(Level of Evidence: B)
5. For patients with chronic HF who remain symptomatic from
AF despite a rate-control strategy, it is reasonable to use a
rhythm-control strategy. (Level of Evidence: C)
CLASS IIb
1. Oral amiodarone may be considered when resting and exer-
cise heart rate cannot be adequately controlled using a beta
blocker (or a nondihydropyridine calcium channel antagonist
in patients with HFpEF) or digoxin, alone or in combination.
(Level of Evidence: C)
2. AV node ablation may be considered when the rate cannot be
controlled and tachycardia-mediated cardiomyopathy is
suspected. (Level of Evidence: C)
CLASS III: HARM
1. AV node ablation should not be performed without a
pharmacological trial to achieve ventricular rate control.
(Level of Evidence: C)
2. For rate control, intravenous nondihydropyridine calcium
channel antagonists, intravenous beta blockers, and drone-
darone should not be administered to patients with
decompensated HF. (Level of Evidence: C)
Patients with HF are more likely than the general population
to develop AF (38), and there is a direct relationship between
the NYHA class and prevalence of AF in patients with HF,
progressing from 4% in those who are NYHA class I to 40% in
those who are NYHA class IV (511). AF is a strong indepen-
dent risk factor for subsequent development of HF as well
(38,512). In addition to those with HF and depressed EF,
patients with HF due to diastolic dysfunction with HFpEF are
also at greater risk for AF (513). HF and AF can interact to
perpetuate and exacerbate each other through mechanisms
such as rate-dependent worsening of cardiac function,
ﬁbrosis, and activation of neurohumoral vasoconstrictors. AF
can worsen symptoms in patients with HF and conversely,
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in AF.
As with other patient populations, the main goals of
therapy for those with AF and HF are prevention of
thromboembolism and control of symptoms. Most pa-
tients with AF and HF can be expected to be candidates
for systemic anticoagulation unless contraindicated
(Section 4). General principles of management include
correction of underlying causes of AF and HF as well as
optimization of HF management. As in other patient
populations, the issue of rate control versus rhythm
control has been investigated. For patients who develop
HF as a result of AF, a rhythm-control strategy should be
pursued. AF with a rapid ventricular response is one of
the few potentially reversible causes of HF. Therefore, a
patient who presents with newly detected HF in the
presence of AF with a rapid ventricular response should
be presumed to have a rate-related cardiomyopathy until
proved otherwise. In this situation, 2 strategies can be
considered. One is rate control of the patient’s AF to see if
HF and EF improve. The other is to attempt to restore and
maintain sinus rhythm. In this situation, it is common
practice to initiate amiodarone and then arrange for car-
dioversion a month later. Amiodarone has the advantage
of being both an effective rate-control medication and the
most effective antiarrhythmic medication with a low risk
of proarrhythmia.
In patients with HF who develop AF, a rhythm-control
strategy is not superior to a rate-control strategy (514). If
rhythm control is chosen, AF catheter ablation in patients
with HF may lead to an improvement in LV function and
quality of life but is less likely to be effective than in
patients with intact cardiac function (47,307).
Because of their favorable effect on morbidity and
mortality in patients with systolic HF, beta blockers are the
preferred agents for achieving rate control unless other-
wise contraindicated. Digoxin may be an effective adjunct
to a beta blocker. Nondihydropyridine calcium antago-
nists, such as diltiazem, should be used with caution
in those with depressed EF because of their negative
inotropic effect. For those with HF and preserved EF,
nondihydropyridine calcium antagonists can be effective
for achieving rate control but may be more effective when
used in combination with digoxin. For those patients for
whom a rate-control strategy is chosen, AV node ablation
and cardiac resynchronization therapy device placement
can be useful when rate control cannot be achieved either
because of drug inefﬁcacy or intolerance (515–520).
7.10. Familial (Genetic) AF: Recommendation
CLASS IIb
1. For patients with AF and multigenerational family members
with AF, referral to a tertiary care center for genetic coun-
seling and testing may be considered. (Level of Evidence: C)AF is heritable, and having an affected family member
is associated with a 40% increased risk of the arrhythmia
(155,521–524). Premature AF, deﬁned as a ﬁrst-degree
relative with onset of AF before the age of 66, is asso-
ciated with a doubling in risk of AF (155). Thus, it is
common, particularly among younger, healthier persons
with AF, to observe families with AF. In the last
10 years, many mutations have been identiﬁed in in-
dividuals and families with AF (525). The implicated
genes include a wide range of ion channels, signaling
molecules, and related proteins; however, the role of
these mutations in more common forms of AF appears
limited. Population-based or genomewide association
studies identiﬁed $9 distinct genetic loci for AF (156–
159). Furthermore, combinations of AF-associated sin-
gle nucleotide polymorphisms may identify individuals
at high risk for arrhythmia (526,527). However, the
role of these common genetic variants in risk stratiﬁca-
tion (155,528,529), assessment of disease progression,
and determination of clinical outcomes (157,530,531) is
limited. Routine genetic testing related to AF is not
indicated (532).7.11. Postoperative Cardiac and Thoracic Surgery:
Recommendations
CLASS I
1. Treating patients who develop AF after cardiac surgery
with a beta blocker is recommended unless contraindicated
(533–536). (Level of Evidence: A)
2. A nondihydropyridine calcium channel blocker is recom-
mended when a beta blocker is inadequate to achieve rate
control in patients with postoperative AF (537). (Level of
Evidence: B)
CLASS IIa
1. Preoperative administration of amiodarone reduces the
incidence of AF in patients undergoing cardiac surgery and is
reasonable as prophylactic therapy for patients at high risk
for postoperative AF (538–540). (Level of Evidence: A)
2. It is reasonable to restore sinus rhythm pharmacologically
with ibutilide or direct-current cardioversion in patients who
develop postoperative AF, as advised for nonsurgical
patients (541). (Level of Evidence: B)
3. It is reasonable to administer antiarrhythmic medications in an
attempt to maintain sinus rhythm in patients with recurrent or
refractory postoperative AF, as advised for other patients who
develop AF (537). (Level of Evidence: B)
4. It is reasonable to administer antithrombotic medication in
patients who develop postoperative AF, as advised for
nonsurgical patients (542). (Level of Evidence: B)
5. It is reasonable to manage well-tolerated, new-onset post-
operative AF with rate control and anticoagulation with
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rhythm during follow-up. (Level of Evidence: C)
CLASS IIb
1. Prophylactic administration of sotalol may be considered for
patients at risk of developing AF after cardiac surgery
(536,543). (Level of Evidence: B)
2. Administration of colchicine may be considered for patients
postoperatively to reduce AF after cardiac surgery (544).
(Level of Evidence: B)
Postoperative AF occurs in 25% to 50% of patients after open
heart surgery. Increased age is the most consistent risk factor
(545). With the projected increase in the number of elderly
patients undergoing cardiac operations, the incidence of
postoperative AF is likely to increase. Postoperative AF is
associated with stroke (546), increased cost (547), and mor-
tality (548). Beta blockers, nondihydropyridine calcium
channel blockers, and amiodarone are useful as treatments
in patients with postoperative AF and may be initiated pre-
operatively in some patients (391,544).
In a meta-analysis of patients undergoing coronary
revascularization, those who received preoperative statin
therapy had less AF than those not treated with statins
(391). No published data exist for patients undergoing
valvular or other heart surgery.
The COPPS (Colchicine for the Prevention of the
Postpericardiotomy Syndrome) substudy examined the efﬁ-
cacy and safety of colchicine for AF prevention (544). In this
multicenter trial, patients were randomized to colchicinewith
standard therapy or standard therapy alone. The primary
endpoint was incidence of AF at 1 month postoperatively.
Patients receiving colchicine had a reduced incidence of AF
(12% versus 22% at 30 days postoperatively). The colchicine
group also had a shorter length of hospital stay.
8. EVIDENCE GAPS AND
FUTURE RESEARCH DIRECTIONS
The past decade has seen substantial progress in the un-
derstanding of mechanisms of AF, clinical implementation
of ablation for maintaining sinus rhythm, and new drugs
for stroke prevention. Further studies are needed to better
inform clinicians about the risks and beneﬁts of thera-
peutic options for an individual patient. Continued
research is needed into the mechanisms that initiate and
sustain AF. It is hoped that better understanding of these
tissue and cellular mechanisms will lead to more deﬁnedapproaches to treating and abolishing AF. This includes
new methodological approaches for AF ablation that would
favorably impact survival, thromboembolism, and quality
of life across different patient proﬁles. New pharmacolog-
ical therapies are needed, including antiarrhythmic drugs
that have atrial selectivity and drugs that target ﬁbrosis,
which will hopefully reach clinical evaluation. The suc-
cessful introduction of new anticoagulants is encouraging,
and further investigations will better inform clinical prac-
tices for optimizing beneﬁcial applications and minimizing
the risks of these agents, particularly in the elderly, in
the presence of comorbidities and in the periprocedural
period. Further investigations must be performed to better
understand the links between the presence of AF, AF
burden, and stroke risk, and to better deﬁne the relation-
ship between AF and dementia. The roles of emerging
surgical and procedural therapies to reduce stroke will be
deﬁned. Great promise lies in prevention. Future strategies
for reversing the growing epidemic of AF will come from
basic science and genetic, epidemiological, and clinical
studies.
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e75APPENDIX 3. ABBREVIATIONSAC
AC
AF
AR
AV
bp
CA
CK
CrC
EC
EF
HC
HF
HF
INR
LA
LA
LM
LV
LV
RC
RV
TE
TIA
TT
UF
WPE ¼ angiotensin-converting enzyme
S ¼ acute coronary syndrome
¼ atrial ﬁbrillation
B ¼ angiotensin-receptor blocker
¼ atrioventricular
m ¼ beats per minute
D ¼ coronary artery disease
D ¼ chronic kidney disease
l ¼ creatinine clearance
G ¼ electrocardiogram/electrocardiographic
¼ ejection fraction
M ¼ hypertrophic cardiomyopathy
¼ heart failure
pEF ¼ heart failure with preserved ejection fraction¼ international normalized ratio
¼ left atrial/atrium
A ¼ left atrial appendage
WH ¼ low-molecular-weight heparin
¼ left ventricular
EF ¼ left ventricular ejection fraction
T ¼ randomized controlled trial
¼ right ventricular
E ¼ transesophageal echocardiography
¼ transient ischemic attack
R ¼ time in therapeutic range
H ¼ unfractionated heparin
W ¼ Wolff-Parkinson-White
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e76APPENDIX 4. INITIAL CLINICAL EVALUATION IN PATIENTS WITH AFMinimum Evaluation
1. History and physical examination, to deﬁne  Presence and nature of symptoms associated with AF
 Clinical type of AF (paroxysmal, persistent, or permanent)
 Onset of ﬁrst symptomatic attack or date of discovery of AF
 Frequency, duration, precipitating factors, and modes of initiation or
termination of AF
 Response to any pharmacological agents that have been administered
 Presence of any underlying heart disease or reversible conditions (e.g., hyperthyroidism
or alcohol consumption)
2. ECG, to identify  Rhythm (verify AF)
 LVH
 P-wave duration and morphology or ﬁbrillatory waves
 Pre-excitation
 Bundle-branch block
 Prior MI
 Other atrial arrhythmias
 To measure and follow R-R, QRS, and QT intervals in conjunction with antiarrhythmic
drug therapy
3. TTE, to identify  VHD
 LA and RA size
 LV and RV size and function
 Peak RV pressure (pulmonary hypertension)
 LV hypertrophy
 LA thrombus (low sensitivity)
 Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function  For a ﬁrst episode of AF
 When ventricular rate is difﬁcult to control
Additional Testing (1 or several tests may be necessary)
1. 6-min walk test  If adequacy of rate control is in question
2. Exercise testing  If adequacy of rate control is in question
 To reproduce exercise-induced AF
 To exclude ischemia before treatment of selected patients with a type IC*
antiarrhythmic drug
3. Holter or event monitoring  If diagnosis of type of arrhythmia is in question
 As a means of evaluating rate control
4. TEE  To identify LA thrombus (in LAA)
 To guide cardioversion
5. Electrophysiological study  To clarify the mechanism of wide-QRS-complex tachycardia
 To identify a predisposing arrhythmia such as atrial ﬂutter or paroxysmal
supraventricular tachycardia
 To seek sites for curative AF ablation or AV conduction block/modiﬁcation
6. Chest radiograph, to evaluate  Lung parenchyma, when clinical ﬁndings suggest an abnormality
 Pulmonary vasculature, when clinical ﬁndings suggest an abnormality
*Type IC refers to the Vaughan Williams classiﬁcation of antiarrhythmic drugs.
AF indicates atrial ﬁbrillation; AV, atrioventricular; ECG, electrocardiogram; LA, left atrial; LAA, left atrial appendage; LV, left ventricular; LVH, left ventricular hypertrophy; MI,
myocardial infarction; RA, right atrial; RV, right ventricular; TEE, transesophageal echocardiography; TTE, transthoracic echocardiogram; and VHD, valvular heart disease.
Adapted with permission from Fuster et al. (4).
